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Abstract 
Tigecycline is the first glycylcycline to enter clinical use and displays good in vitro 
activity against a broad range of Gram-positive and Gram-negative pathogens. It is 
often used as an agent of last resort for the treatment of infections caused by 
multidrug-resistant Gram-negative bacteria including some Enterobacteriaceae 
species and Acinetobacter baumannii. Therefore, the recent emergence of tigecycline 
resistance in some strains of these species is a serious public health concern. Efflux 
was investigated as a possible mechanism of tigecycline resistance using pre- and 
post-therapy pairs of clinical isolates and laboratory-selected, tigecycline-resistant 
mutants of A. baumannii and Enterobacter cloacae and a type strain, laboratory 
mutants, and a clinical isolate of Serratia marcescens. Minimum inhibitory 
concentrations (MICs) of tigecycline and other agents were determined by agar 
dilution. Pulsed-field gel electrophoresis was used to assign clones / determine isolate 
relatedness. Expression of efflux pump genes and genes thought to be implicated in 
their regulation was monitored by real-time reverse-transcriptase polymerase chain 
reaction and their role in tigecycline resistance was further investigated by knockout 
mutagenesis. There was an association between increased expression of specific 
resistance-nodulation-division (RND) efflux pump genes and elevated tigecycline 
MICs in all species studied. Insertional inactivation of RND efflux pump genes 
implicated the AdeABC, AcrAB and SdeXY-HasF systems of A. baumannii, E. 
cloacae and S. marcescens, respectively. The results of this study support the 
hypothesis that tigecycline resistance in clinical isolates of Gram-negative bacteria 
arises as a result of the up-regulated activity of intrinsic efflux systems of the RND 
family. 
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1. Introduction 
1.1. The problem of antimicrobial resistance 
Antimicrobial chemotherapy revolutionised 20th century healthcare and is one of the 
cornerstones of modem medicine. Antibiotics are used not just to treat acute bacterial 
infections but also as prophylactics, reducing the risks of infection for patients 
undergoing cancer chemotherapy, organ transplantation and other surgical procedures. 
Antimicrobial resistance is a serious public health problem worldwide. The 
complete loss of the antimicrobial arsenal would result in a human catastrophe of 
global proportions. In such a scenario, medical intervention would be problematic and 
many procedures that are currently considered routine would carry severe risks of 
infection. Antimicrobial resistance also increases the cost of healthcare delivery 
because it can mean patients are ill for longer periods, lengthening the course of 
therapy and hospital stays and thus potentially putting individuals and public health 
institutions under increased financial pressure. 
Fleming noted in 1929 that certain bacteria were innately resistant to penicillin 
whereas others were innately susceptible (85). He later recognised that organisms that 
were initially susceptible could develop resistance, especially when exposed to low 
doses of penicillin, and warned that careless use of the drug might promote resistance 
and compromise treatment. History has demonstrated that Fleming was right to be 
cautious as, since then, resistance has been reported to every class of antimicrobial 
compound to have entered clinical use. The real and unsettling prospect of a return to 
the pre-antibiotic era less than a century after the discovery of penicillin prompted the 
World Health Organisation (WHO) to declare antimicrobial resistance the subject of 
World Health Day 2011, highlighting it as one of most important issues adversely 
affecting human health (142). 
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Intense antibiotic selection pressure as a result of the widespread use of 
antibiotics in human and veterinary medicine has selected resistant organisms. This 
was evident in the 1950s when researchers reported a shift in the pattern of the type of 
organism causing serious nosocomial infection (between 1935 and 1957) after 
antibiotics were introduced into clinical practice from susceptible Gram-positive 
pathogens to penicillin-resistant Gram-negative species (83). Antibiotic pressure 
continues to select organisms that are resistant to newer agents, with multidrug 
resistant (MDR -i. e. resistant to three or more compound classes) Gram-negative 
species being of most concern in hospitals. Unfortunately, there are very few new 
drugs in the final stages of development which offer advantage over existing 
treatment options for MDR Gram-negative bacteria, such as the carbapenems (19). 
Antibiotic resistance can arise as a result of mutation or can be acquired by 
bacteria via mobile genetic elements. Some acquired resistance determinants can 
spread between different strains or, in some instances, between different species and 
genera. Diverse mechanisms of antimicrobial resistance have been described, 
including enzymatic modification of the drug or drug target, membrane permeability 
changes and active drug efflux, which is the topic of this thesis. 
1.2. Active efflux in Gram-negative bacteria 
The ability to extrude compounds, in an energy-dependent fashion, from the 
intracellular to the extracellular environment is a core biological function that appears 
to be a prerequisite for survival. Active transport systems have been described across 
all three domains of life, namely the Prokarya, Eukarya and the Archaea. 
In bacteria, efflux transporters can extrude toxins, including antimicrobial 
compounds, and have been classified into five families, namely, the major facilitator 
19 
superfamily (MFS), the small multidrug resistance (SMR) family, the multidrug and 
toxic compound extrusion (MATE) family, the ATP-binding cassette (ABC) 
superfamily and the resistance-nodulation-division (RND) superfamily. In Gram- 
negative bacteria these transporter proteins are associated with the cytoplasmic 
membrane although, as described below, some form part of multi-component 
complexes that span the entire cell envelope. 
1.2.1. MFS pumps 
The MFS represents the largest group of secondary transporters and are ubiquitous in 
nature (226). As opposed to primary transporters, which rely on the hydrolysis of ATP 
to provide the energy to extrude substrates against their concentration gradient, 
secondary transporters link to other physiological gradients and, in the cases of MFS 
systems, to the proton motive force. In bacteria, they mainly function as antiporters, 
where a molecule of substrate is exchanged for a hydrogen ion (Figure 1). Efflux 
pumps belonging to this family are a-helical cytoplasmic membrane proteins that 
contain 12 or 14 transmembrane segments (TMs). There are six MFS transporter 
families, though only the 12-TM drug/H+ antiporter 1 (DHA-1) family and the 14-TM 
DHA-2 family frequently occur in bacteria (226). Much of the knowledge of this 
efflux pump family has been acquired through the study of the archetypal MFS 
transporter, MdfA of Escherichia coli (74) which seems to function as a monomer 
(235). MFS pumps are known to export a wide range of structurally unrelated 
compounds. In Gram-negative bacteria, MFS pumps are of clinical importance since 
some members are able to efflux antibiotics, notably the tetracyclines (section 
1.2.2.1). 
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H+ 
Periplasm 
" 
Cytoplasm 
\/ 
/ý 
Substrate 
Figure 1. Principle of antiporter action. 
Membrane 
1.2.2. SMR pumps 
As suggested by the nomenclature, SMR efflux proteins are small molecules of 
approximately 110 amino acid residues. They too are cytoplasmic membrane proteins 
which contain just four TMs. They utilise the proton motive force and act as 
antiporters (Figure 2). Of all SMR-type pumps described in Gram-negative bacteria, 
EmrE of E. coli has been studied most extensively (229). EmrE extrudes a range of 
toxic cationic compounds, functions as a homodimer and displays an unusual anti- 
parallel (oppositely oriented) membrane topology (181). The substrate profiles of 
SMR transporters include dyes (e. g. ethidium bromide), antiseptics (e. g. acriflavine) 
and antimicrobials (147). 
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H+ 
Periplasm 
Cytoplasm 
\/ 
S11IR Membrane 
/\ Substrate 
Figure 2. Schematic of a SMR transporter. 
1.2.3. MATE pumps 
MATE family efflux proteins have been identified in all domains of life and share 
membrane topology characteristics with MFS proteins as they too contain 12 TMs 
(though no sequence homology). In contrast with MFS transporters, MATE-type 
pumps primarily use the Na+ gradient as an energy source (Figure 3). The archetypal 
pump of the MATE family is NorM which was initially described in Vibrio 
parahaemolyticus and was the first Na+ / drug antiporter multidrug efflux system to be 
characterised (176). The substrate profile of NorM includes cationic dyes and certain 
antibiotics, including some fluoroquinolones (177). 
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Figure 3. Schematic of a MATE transporter. 
1.2.4. ABC pumps 
Transporters of the ABC superfamily are multi-protein complexes that are driven by 
the hydrolysis of ATP and hence are primary transporters (Figure 4). ABC-type 
transporters of clinical importance in terms of multidrug resistance (MDR) have been 
described relatively rarely in Gram-negative bacteria; rather most prokaryotic efflux 
systems implicated in antibiotic extrusion are secondary transporters. Nevertheless, a 
few ABC-type pumps that efflux antibiotics have been described, of which the best 
studied is arguably the macrolide-specific transporter, MacB which has been 
identified in multiple species including E. coli and Neisseria gonorrhoeae (130; 218). 
Studies in E. coli show that it functions in concert with the periplasmic adapter 
protein, MacA and the promiscuous outer membrane channel ToIC (section 1.1.5), to 
form the functional complex MacAB-To1C (148; 279). 
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Figure 4. Schematic of an ABC transporter. 
1.2.5. RND transporters 
Efflux pumps of the resistance-nodulation-division (RND) family are ubiquitous in 
nature. In Gram-negative bacteria they are cytoplasmic membrane proteins that 
cooperate with a periplasmic adapter (otherwise known as membrane fusion) protein 
and an outer membrane channel. These tripartite complexes span the entire Gram- 
negative cell envelope and utilise the proton motive force to transport a broad range of 
structurally and chemically unrelated compounds to the extracellular environment, 
including bacterial derived products, dyes, detergents and antibiotics (Figure 5). 
It is increasingly recognised that RND efflux systems contribute significantly 
to MDR in Gram-negative bacteria (145). They have been implicated in resistance to 
multiple classes of clinically important antimicrobial agents that have diverse 
structures and modes of action. Extrusion of the antibiotic substrate, which may be 
captured from the periplasm or the cytoplasm, lowers the concentration of drug in the 
cellular environment (meaning fewer molecules of the drug reach their target) to a 
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sub-inhibitory level thus negating its toxic effect(s). In some instances, innate 
resistance to certain antimicrobials is due to the action of RND transporters which are 
expressed at normal physiological levels. For example, the innate resistance of 
Burkholderia cenocepacia to a number of agents is due to efflux by RND systems 
(21). However, in certain circumstances resistance occurs only when these systems 
become up-regulated as a result of genetic changes (e. g. via mutations in genes or in 
the motifs involved in the regulation of expression of pump genes). 
Figure 5. Schematic of the RND transporter AcrAB-To1C of E. coli. 
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1.2.5.1 Structure and function of RND transporters 
To date, crystal structures of two of the most intensively studied RND pumps have 
been solved. These are the closely-related MexB (multiple efflux) and AcrB 
(acriflavin resistance) proteins of Pseudomonas aeruginosa and E. coli, respectively 
(179; 232), which operate in situ as part of functional tripartite units in complex with 
the periplasmic adapter proteins MexA and AcrA and the outer membrane channels 
OprM and To1C, respectively, forming the functional MexAB-OprM and AcrAB- 
To1C transporters (88; 146; 159; 202). Data from crystallographic studies indicate that 
both MexA and AcrB function as asymmetric homotrimers, with each subunit 
containing 12 TMs and a relatively large periplasmic domain that consists of a central 
cavity with three passages into the periplasm and a funnel-like structure at the top 
which is connected to the cavity by a pore formed of three a-helices (Figure 6). Each 
protomer (structural unit of the oligomeric protein) exists in one of three possible 
conformations. Further crystallographic studies of AcrB both with and without 
substrates performed by Murakami et al. and Seeger et al. indicated that the three 
conformational states, designated L (loose), T (tight), and 0 (open) represent distinct 
stages in a transport cycle and both groups hypothesise that a novel peristaltic 
pumping (functional rotation) mechanism is responsible for substrate extrusion 
(178; 230). Direct evidence in support of this model of pump activity was presented by 
Takatsuka et al. using an innovative approach whereby three acrB sequences were 
linked together to form a `giant gene' which allowed for inactivation of individual 
protomers in the trimeric structure (243). Upon inactivation of a single protomeric 
unit, the entire complex was inactivated (243). Further evidence of the functional 
rotation mechanism of AcrB activity described by Seeger el al. was provided by site- 
directed disulphide cross-linking of AcrB subdomains (231). It was demonstrated that 
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such cross-linking had an adverse affect on pump function (231). Subsequently, 
normal pump activity was restored upon exposure to a reducing agent to split these 
cross links (231). 
Figure 6. Ribbon representation (side view) of the structure of AcrB (Murakami 
et al. 2002). 
The cytoplasmic membrane-associated RND proteins define the substrate 
specificity of the functional tripartite complex. The mechanics of substrate binding 
and substrate specificity of RND proteins have been studied intensively over the last 
decade. Most reports have focused on the archetypal RND proteins AcrB and MexB 
and a number of regions have been implicated within both the periplasmic and 
transmembrane domains. 
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In a study where hydroxylamine-mutagenized mexB was expressed in a 
AmexB strain, 19 single mutations were identified that adversely affected pump 
function (170). Most of these were located within the periplasmic loops between TMs 
1 and 2 and between TMs 7 and 8 (170) and lay in regions that were predicted to be 
involved in the interaction of MexB with MexA (the periplasmic adapter protein) or 
MexB trimer formation (170). Crystallographic and site-directed mutagenesis studies 
of AcrB bound with structurally diverse substrates by Yu et al. implicated both 
periplasmic and transmembrane domains in substrate recognition (282; 283). Bound 
substrate was observed not only in the central cavity but also within an external 
depression produced by the C-terminal periplasmic loop (282; 283). In addition, a 
single point mutation that was selected during levofloxacin exposure resulted in a 
Val-610-±Phe substitution in AcrB that had the effect of altering substrate specificity, 
thus providing further evidence of periplasmic domain involvement (28). In another 
study, chimeric constructs of AcrB and another E. coli RND protein, AcrD were 
produced in which portions of the periplasmic domain (specifically the loops between 
TMs 1 and 2 and between TMs 7 and 8) were replaced with those of the other protein 
(76). These constructs were expressed in a AacrB tacrD host strain and substrate 
specificity was investigated. It was observed that AcrB chimeras containing the AcrD 
periplasmic regions conferred resistance only to substrates of AcrD and vice versa, 
thus implicating the periplasmic loop domains in substrate specificity (76). Protomers 
of AcrB in the conformational state T (tight) were shown to form hydrophobic 
binding pockets that were rich in phenylalanine and other aromatic residues (230). It 
has been demonstrated that different substrates can interact with different residues 
within the binding pocket. For example, Murakami et al. reported that doxorubicin 
appeared to interact with Gln-176, Phe-615 and Phe-617 whereas minocycline seemed 
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to interact with Phe-78, Asn-274 and Phe-615 and hence proposed that the broad 
substrate profile of AcrB could perhaps be explained by the flexible nature of the 
interaction of different ligands primarily with hydrophobic and to a lesser extent polar 
residues within the binding pocket (178). A systematic site-directed mutagenesis 
study of phenylalanine residues within the binding pocket was carried out by Bohnert 
et al (29). They observed variable effects on the susceptibility to a number of 
substrates when different residues were mutated, but were able to identify Phe- 
610-+Ala as the mutation that had the most dramatic impact in terms of lowering 
substrate (e. g. macrolides) minimum inhibitory concentrations (MICs) (29). 
A number of crystallographic studies have shed light on the structure and 
function of the periplasmic adapter proteins, MexA of P. aeruginosa and AcrA of E. 
coli (4; 105; 171; 242). It was established in the 1990s that these proteins are essential 
for transporter function (159; 202). A detailed picture has since emerged of their 
functional role in stabilising the tripartite complex through interaction with both the 
RND and outer membrane components. It is clear that these proteins have four 
distinct subdomains: an a-helical hairpin, a lipoyl domain and a six-stranded ß-barrel 
domain, which is linked via a ß-ribbon to the recently modelled membrane proximal 
domain (242). The similarity of the (3-barrel and the membrane proximal domains is 
intriguing and it has been postulated that the overall structure of the protein arose as a 
result of domain duplication (242). The N-terminal cysteine residue has a lipid tail 
which acts as an anchor by inserting into the cytoplasmic membrane (Figure 7). A 
significant degree of conformational flexibility has been observed in the structures of 
both MexA and AcrA. This is due to the hinged nature of the linkers between the 
lipoyl domain and the (3-barrel and a-helical hairpin domains (171; 263). 
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Figure 7. Complete structure of MexA (Akama et al. 2004). 
The outer membrane channel proteins associate with both the RND proteins 
and the periplasmic adapter components to form the functional transporter and act as 
exit ducts for the substrates (Figure 5). X-ray crystallography has once again played a 
pivotal role in elucidating the structure and informing on the function of these 
important proteins. To date, the crystal structures of several of these proteins have 
been solved including ToIC of E. coli, OprM of P. aeruginosa, and VceC of V. 
cholerae all of which have a similar structure even though their sequence identity is 
low (3; 80; 134; 196). Of these, To1C has been the best studied and exists as a trimer, 
with each protomer consisting of a membrane-anchored ß-barrel and a long a-helical 
domain containing 12 coiled coils which extend into the periplasmic space (134). The 
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trimeric complex forms an outer membrane pore and a periplasmic tunnel which is 
closed at the proximal end by coiled a-helices (Figure 8) (134). Until relatively 
recently, these helices were thought to relax from a tightly packed state, in a iris-like 
fashion, thus allowing for To1C opening (8). However, molecular dynamic 
simulations of ToIC hint at a more complex mechanism whereby a peristaltic action of 
the periplasmic domain aids the transport of substrate through the tunnel (264). Site- 
specific crosslinking experiments suggested that the interaction of To1C with AcrA is 
most favourable when ToIC is an open conformation (242). Binding of AcrA to AcrB 
facilitates ToIC recruitment to the complex which in turn leads to ToIC opening. The 
interaction of AcrB and ToIC is stabilised by AcrA which prevents substrate leaking 
into the periplasmic space, thus allowing To1C to adopt a constitutively open 
conformation in the functional tripartite complex (242). 
Figure 8. Ribbon representation (side view) of the structure of ToIC (Koronakis 
et al. 2000). 
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There is also limited evidence of AcrB functioning in complex with another 
transmembrane protein, YajC which was reported to induce rotation of the 
periplasmic domain of AcrB (252). Data presented by the authors suggested that YajC 
binding was functionally significant, as a AyajC mutant E. coli strain displayed 
increased susceptibility to ampicillin (252). 
The stoichiometry of RND apparatus has been investigated using the 
archetypal pumps of E. coli and P. aeruginosa. In the case of AcrAB-ToIC, Symmons 
et al. proposed a stoichiometry of 3: 3: 3 (AcrA : AcrB : To1C) based upon 
modelling using the solved structures of all the components and crosslinking 
experiments performed at pH 7.5 (242). In contrast, a study of MexA / OprM 
interaction suggested a stoichiometry of 2: 1 at pH 7.5 and 6: 1 (MexA : OprM) at 
pH 5.5 (209). There are also descriptions in the literature of RND systems containing 
either two unique RND or periplasmic adapter proteins in which both are required for 
efflux activity (22; 174). 
1.2.5.2. Regulation of RND transporters 
Since the degree to which RND transporters confer resistance to antimicrobial agents 
has been linked to their levels of expression there has been much interest in the 
mechanisms of transcriptional regulation of efflux pump genes. Much of the 
knowledge about RND efflux gene regulation has come from studies in E. coli. It has 
become clear that the regulation of RND transporter genes is complex, involving both 
local and global regulatory elements. The pump genes are chromosomally encoded 
with the periplasmic adapter and RND components most often co-transcribed as an 
operon whereas the outer membrane channel gene may either be part of the same 
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structural operon or may be located elsewhere on the chromosome, as is the case for 
the AcrAB-To1C system of E. coli (88; 158). 
Expression of acrAB in E. coli is modulated at the local level by the 
divergently transcribed repressor gene acrR, which encodes a helix-turn-helix (HTH) 
DNA-binding domain-containing protein of the TetR family (157). AcrR negatively 
regulates acrAB as well as its own expression through binding to the regulatory region 
located between acrR and acrAB (Figure 9); however AcrR is not involved in up- 
regulating the pump in response to environmental stress, as demonstrated by elevated 
acrAB expression under stressed conditions (e. g. 4% ethanol, 0.5 M NaCl and entry 
into stationary phase) in the absence of functioning AcrR (157). This suggests that 
other regulatory elements are involved in acrAB induction under these conditions. It 
has been demonstrated that mutations in acrR can lead to increases in acrAB 
expression that are sufficient to contribute to fluoroquinolone resistance both in E. 
coli and Salmonella enterica serovar Typhimurium (190; 269). AcrAB and AcrEF, 
another E. coli RND system, have similar substrate profiles and a high degree of 
sequence homology. The acrS gene which encodes another repressor of the TetR 
family, AcrS and is the local regulator found upstream of the acrEF operon has also 
been shown to repress the expression of acrAB (109). 
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Figure 9. Regulation of acrAB and to1C by AcrR and MarA [adapted from 
Grkovic et al. 2002 (98)]. 
Bacteria are able to sense changes in environmental conditions and respond at 
the transcriptional level through the action of two-component signal transduction 
systems. These comprise of a sensor kinase and its cognate response regulator. When 
the membrane-associated sensor kinase protein binds a specific ligand it 
autophosphorylates at a conserved histidine residue. The phosphate group is then 
transferred to a conserved aspartic acid residue in the DNA-binding response 
regulator which then undergoes conformational change and modulates gene 
expression (38). A number of studies of E. coli have identified two-component 
systems that regulate the expression of RND transporters; these include the BaeSR 
and CpxAR regulatory systems which are activated by indole and which modulate 
transcription of the RND system mdtABC (18; 108; 187). 
AcrAB of E. coli is also regulated by SdiA, which is a transcriptional regulator 
of the LuxR family that is involved in regulating cell division in a manner which is 
ýr 
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dependent on cell density and hence quorum sensing (206). It was demonstrated that 
overexpression of sdiA resulted in increased fluoroquinolone MICs as a result of 
AcrAB activity and that a AsdiA mutant was more susceptible to fluoroquinolones and 
produced less AcrB than its wild-type parent (206). More recently, sdiA was found to 
be overexpressed in two mutants of E. coli selected in vitro; these were shown to have 
elevated levels of acrB and tolC transcript, and displayed decreased susceptibility to a 
number of antimicrobial agents (245). 
Expression of RND-type efflux pump genes in the Enterobacteriaceae is also 
controlled by global transcriptional regulators of the AraC family including MarA, 
SoxS, Rob and RamA, of which MarA of E. coli is the best studied. The mar 
(multiple antibiotic resistance) regulatory region comprises the marRAB operon; 
marC, which is divergently transcribed, and the marO operator/promoter region 
which is located between marRAB and marC (6). MarA activates transcription of a 
large number of genes including acrAB, tolC and marA itself by forming complexes 
with RNA polymerase which then bind to 20-bp DNA sequences known as marboxes 
that are located adjacent to the promoter regions of genes that are part of the MarA 
regulon, including within marO (6; 12; 165). Both marB and marC encode proteins of 
unknown function though studies by McDermott et al. indicate that MarC is not 
involved in MDR since neither inactivation or overexpression of marC led to changes 
in susceptibility to a number of antimicrobial agents (168). MarR is the repressor that 
restricts expression of marRAB by binding to marO at two sites located downstream 
from the marbox; the first is located between the -35 and -10 regions of the marRAB 
promoter and the second is further downstream at the ribosome binding site (166). 
Induction of the mar regulon occurs upon suppression of MarR activity. A 
number of compounds have been shown to induce marRAB expression through 
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interference with MarR / marO binding, including salicylate, plumbagin, menadione, 
2,4-dinitrophenol and the bacterial metabolite 2,4-dihydroxybenzoate (7; 47). 
Chloramphenicol and tetracycline have also been shown to induce the mar regulon 
(99). Hence, MarR is able to sense the presence of some toxic compounds and 
mediate derepression of marRAB, resulting in MarA-mediated activation of the mar 
regulon, which includes acrAB and tolC. More recent work suggested that, 
surprisingly, MarR may also interact with the unrelated bacterial proteins GyrA and 
TktA (transketolase A, involved in metabolism) and inhibit marRAB repression 
(70; 71) highlighting the fact that global regulation of RND transporters is highly 
complex and much of the detail remains obscure. 
1.2.5.2. Physiological role of RND transporters 
Over the last two decades, a large body of work has provided much evidence in 
support of the hypothesis that RND transporters play important roles in the biology of 
Gram-negative pathogens. One prominent example, with particular relevance to 
human infections, is their role in virulence. RND efflux systems have been implicated 
in the virulence of a number of species including P. aeruginosa, S. enterica, N. 
gonorrhoeae, Campylobacter jejuni, Francisella tularensis, Legionella pneumophila 
Borrelia burgdorferi, and Burkholderia pseudomallei 
(27; 36; 37; 39; 81; 107; 123; 149; 188). Gene knockout studies in S. enterica serovar 
Typhimurium indicated that DacrB and AtolC mutants were unable to invade mouse 
monocyte macrophages (36) while a strain lacking all multidrug efflux systems was 
reported to be avirulent in orally-inoculated mice (188). The virulence of a mutant F. 
tularensis strain that lacked functional AcrB was attenuated in a murine infection 
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model (27). In B. burgdorferi, the outer membrane protein BesC, a To1C homologue, 
forms part of the RND system BesABC and was shown to be essential for establishing 
infection in mice (37). The BpeAB-OprB efflux transporter of B. pseudomallei was 
shown to be important for virulence, as demonstrated by the attenuation of invasion of 
human lung epithelial and human macrophage cells by AbpeAB mutants as well as 
strains overexpressing a repressor of the bpeAB-oprB operon (39). The causative 
agent of legionnaire's disease, L. pneumophila, which is an intracellular parasite of 
amoeba, displayed attenuated virulence towards both human monocyte macrophages 
and amoebae upon inactivation of ToIC (81). 
RND efflux systems contribute to bacterial virulence at least in part because 
they appear to aid in the survival of bacterial cells within the often hostile host 
environment through their ability to extrude toxic host-derived products, including 
fatty acids, bile salts, and steroid hormones (73; 75; 159). It has been reported that 
expression of RND efflux genes can be induced by bile and other agents present in the 
human digestive tract, thus facilitating in vivo survival (108; 185; 186). Perhaps 
unsurprisingly, there is evidence to suggest that E. coli AcrAB has greater affinity for 
bile acids than for antimicrobials, which hints at the core biological function of these 
efflux systems in E. coli (285). There is also evidence that some RND efflux pumps 
confer resistance to mammalian antimicrobial peptides, pointing to a possible role in 
evading innate defence mechanisms (233; 272) although the E. coli AcrAB and P. 
aeruginosa MexAB pumps were not able to confer resistance to human antimicrobial 
peptides, even when overexpressed, suggesting this may not be a universal 
phenomenon (214). 
An interesting study that investigated the global impact of acrAB-tolC 
interruption in S. enterica by Webber et al. showed differential expression of genes 
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and proteins involved in pathogenesis in mutants lacking individual components of 
the transporter (274). Genes involved in chemotaxis, motility and type III secretion 
were shown to be expressed at lower levels in efflux-deficient strains, thus explaining 
how such mutants are attenuated, and demonstrating the importance of this transporter 
to the core biology of Gram-negative bacteria (274). 
In addition to promoting in vivo survival as described above, another 
important natural role of RND transporters appears to be cell-to-cell communication. 
As discussed in section 1.2.5.1, AcrAB of E. coli is positively regulated by the 
quorum sensing transcription factor SdiA (206). In further work it was demonstrated 
that AacrB and AtolC mutants grew to a higher cell density in stationary phase than 
wild-type strains despite having the same growth rate in exponential phase, whereas 
overexpression of acrAB had the effect of lowering cell density (280). The authors 
also present evidence that expression of rpoS, which encodes the stationary phase 
sigma factor, RpoS, is induced later in acrAB mutants and earlier in cells where 
acrAB was overexpressed (206; 280). These results, combined with observations that 
some quorum sensing molecules bear structural similarities to the fluoroquinolones 
(known substrates of E. coli RND systems), suggest that these transporters may have a 
role in the extrusion of quorum sensing signals (206; 280). 
Taken together, the evidence described above suggests that RND transporters 
perform multiple biological functions. It seems unlikely that the primary role of such 
efflux systems is the extrusion of antibiotics used in modem medicine since, for 
example, RND systems appear critical for bacterial survival in vivo. However, 
antimicrobial selection pressure has undoubtedly shaped bacterial evolution and will 
continue to do so. The widespread use of antibiotics over the last 70 years has selected 
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for Gram-negative bacteria which are better adapted to use these intrinsic efflux 
transporters as a defence mechanism against the chemotherapeutic offensive. 
1.2.5.3. Inhibitors of RND transporters 
Given their established role in MDR, there has been much interest in developing 
strategies for the disruption of RND pump activity. An ability to inhibit efflux is 
useful in order both to study pump function and to investigate the potential of 
therapeutic combinations of antibiotics and efflux pump inhibitors (EPIs) to restore 
antimicrobial activity (161; 192). Inhibition of RND transporter activity may be 
achieved using a number of approaches including blocking the outer membrane 
channel, inhibiting the assembly of the functional tripartite complex, collapsing 
proton motive force required for efflux activity, competing with the antimicrobial 
substrate or interfering with regulatory networks that control expression of pump 
genes. 
To date, no EPIs have entered clinical use since the experimental molecules 
often have toxic effects on eukaryotic cells, although the drug company Mpex 
Pharmaceuticals has a number of compounds in preclinical development (191). 
However, a number of EPIs are available to study the function of RND transporters 
including the peptidomimetic compound MC-207,110, Phe-Arg-ß-napthylamine 
(PAON), which competes with the antimicrobial substrates (155; 213). Another 
example of an EPI that is used to study RND systems is carbonyl cyanide m- 
chlorophenylhydrazone (CCCP) which acts an ionophore, collapsing the proton 
gradient; as such it disrupts active efflux by RND transporters (192). However, by 
their very nature, many of the effects of EPIs are non-specific and while they are a 
useful research tool the data obtained from them cannot be taken in isolation. 
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1.3. The tetracycline class of antimicrobials 
Tetracyclines were discovered over 60 years ago during investigations of the 
antimicrobial properties of the fermentation products of actinomycetes. The naturally 
occurring, first-generation tetracyclines, oxytetracycline, chlortetracycline and 6- 
demethylchlortetracycline were the products of actinomycetes' secondary metabolism 
and entered clinical and agricultural use soon after their discovery. They were the first 
naturally occurring agents with broad spectrum antimicrobial activity that included 
both Gram-positive and Gram-negative pathogens (45). Second-generation 
tetracyclines such as doxycycline and minocycline were developed two decades later 
in response to the emergence of resistance to the first-generation compounds. 
The pharmacophore of the tetracycline class includes a four-membered ring 
system, one of which is aromatic (Figure 10). Chemical modification of carbons 4,5, 
6 and 7 has resulted in the production of new molecules. These are semi-synthetic 
derivatives with improved spectrums of action and pharmacological profiles and 
include minocycline (45; 249) (Figure 10). 
Figure 10. Chemical structures of tetracycline (left hand side) and minocycline 
(right hand side) (PubChem). 
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1.3.1. Mode of action 
Antibiotics of the tetracycline class are bacteriostatic agents that exert their 
antimicrobial activity through binding to the 30S subunit of the prokaryotic ribosome 
and disrupting translation (5; 10; 34; 228). Specifically, tetracycline molecules, in 
complex with Mg, 2+ bind in the aminoacyl-tRNA acceptor site region (A site). This 
binding sterically prevents aminoacyl-tRNAs from entering the A site, and protein 
synthesis is arrested (34). To gain access to the target site on the ribosome, 
tetracycline preferentially crosses the outer membrane of E. coli cells in its Mgt+- 
chelated form via porin OmpF, as illustrated by a study that demonstrated a reduction 
in the intracellular accumulation of tetracycline in tetracycline-susceptible E. coli in 
the absence of this porin or when there was a low proportion of the Mg2+-bound 
versus free drug (251). Tetracycline most probably enters the cytoplasm by passive 
diffusion in its unbound form across the inner membrane (15). Thus, the ability of 
tetracycline to bind divalent cations is essential both for drug entry and target binding. 
1.3.2. Tetracycline resistance 
The widespread use of tetracyclines in human and veterinary medicine and agriculture 
over the last 60 years has created intense selection pressure for resistance. Since the 
1950s, resistance to this class of antimicrobials has rapidly increased in many species 
of both Gram-positive and Gram-negative bacteria, predominantly through horizontal 
transfer of tetracycline resistance (tet) and oxytetracycline resistance (otr) genes 
located on mobile genetic elements. Multiple mechanisms of tetracycline resistance 
have been described including active efflux, ribosomal protection, enzymatic 
inactivation and target modification/mutation. Of these mechanisms, active efflux and 
ribosomal protection are the most common (45). In 2001 a website was created in 
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order to collate information on acquired tet and otr genes (available at: 
http: //faculty. washington. edu/marilynr/). It is updated biannually and is curated by Dr 
Marilyn Roberts. An attempt to standardise the nomenclature for tetracycline 
resistance determinants based upon letters of the alphabet was proposed at the end of 
the 1980s (144). Subsequently, as more determinants were identified, Levy et al. 
suggested that future determinants be designated with Arabic numerals (143). 
1.3.2.1. Efflux 
The efflux pumps that confer acquired resistance to tetracyclines are the most 
intensively studied Tet determinants. The vast majority are members of the MFS of 
efflux transporters (section 1.2.1) and were initially divided into six groups a decade 
ago based upon protein sequence identity, although this number was subsequently 
increased to accommodate the multiple resistance determinants since identified 
(45; 216). Group 1 consists of members of the DHA-1 transporter family which are 
Tet(A), Tet(B), Tet(C), Tet(D), Tet(E), Tet(G), Tet(H), Tet(J), Tet(Y), Tet(Z), 
Tet(30), Tet(31), Tet(33), Tet(39), Tet(41) and Tet(42) (45; 249). Most of the Tet 
determinants belonging to group I are found only in Gram-negative bacteria; 
exceptions are Tet(Z), which was identified in the soil organism Corynebacterium 
glutamicum (244) and Tet(42), which was identified in various uncharacterised Gram- 
positive and Gram-negative bacteria recovered from deep terrestrial sediment (35). 
Group 2 contains Tet(L) and Tet(K) which are found mostly in Gram-positive species. 
Those of Streptomyces origin, namely Otr(B) and Tcr(3), have similar topology to 
group 2 and are classified as group 3 (45). The sole member of group 4, TetA(P) was 
identified in Clostridium perfringens and lacks conserved motifs characteristic of the 
MSF (236). Group 5 also has only a single member, namely Tet(V), which was 
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identified in Mycobacterium smegmatis (60). There are two members of group 6, 
namely, Tet(35) and Otr(C) (216; 247), and finally, Tet(38), which was identified in 
Staphylococcus aureus, and is most similar to Tet(K) (249; 254) so should be assigned 
to Group 2. 
The acquired tet genes that encode efflux transporters are common among 
Gram-negative bacteria, having been identified in 25 genera, and are generally found 
on transposons that have integrated into plasmids from diverse incompatibility groups 
(125; 216). Most confer resistance to tetracycline but not minocycline, though tet(B) 
confers resistance to both agents (44). The tet(B) gene is associated with the 
transposon Tn10, has been found on conjugative plasmids, and is the most widely 
disseminated acquired efflux pump gene among Gram-negative species (45; 216). 
Along with tet(A), tet(B) it is also one of the most common tet determinants 
among clinical isolates of Acinetobacter baumannii and is the predominant tet 
determinant associated with the internationally-disseminated European clone II 
(section 1.5) (118; 118). Mak et al. showed that 28 out of 32 A. baumannii isolates 
which were collected from multiple centres in Sydney, Australia were positive by 
PCR for tet(B) (162). 
1.3.2.2. Ribosomal protection 
Ribosomal protection proteins (RPPs) are cytoplasmic proteins of approximately 72.5 
kDa that protect the bacterial ribosome from the action of first- and second-generation 
tetracyclines. They have homology to the elongation factors EF-Tu and EF-G 
GTPases (246). RPPs interact with the ribosome in a manner that allosterically 
disrupts the primary tetracycline binding sites, resulting in the release of tetracycline 
from the ribosome (50). It has been proposed that RPPs evolved through divergence 
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of an ancient GTPase independent of the presence of tetracyclines, implying that these 
proteins have biological function(s) other than antimicrobial resistance (131). They 
are currently divided into three groups based upon protein sequence identity. Group 1 
consists of Tet(M), Tet(O), Tet(S), Tet(W), Tet(32) and Tet(36); group 2 contains 
TetB(P), Otr(A) and Tet; the two members of group 3 are Tet(Q) and Tet(T) (249). 
Tet(44), a novel RPP, has been recently described in the cattle pathogen 
Campylobacter fetus subsp. fetus associated with a transferable pathogenicity island 
and is most similar to Tet(O) and so should be assigned to group 1 (1). 
RPP genes have been detected in 42 genera including both Gram-positive and 
Gram-negative organisms as well as some members of the Mycoplasmataceae (216). 
Of all tet genes, tet(M) is the most widely disseminated. This can perhaps be 
explained by it often being found on integrative and conjugative elements of the 
Tn916-Tn1545 family which have a broad host range (48; 216). Surveillance studies 
of ribosomal protection mechanisms have been complicated by the discovery of 
mosaic RPP genes in the ruminant commensal Megasphaera elsdenii (240). 
Nucleotide sequencing of what was initially thought to be tet(O) from two isolates 
revealed that the genes were actually two different mosaics which comprised of tet(O) 
and tet(W) sequences that presumably arose through recombination events (240). A 
study of human faecal samples taken from individuals across Europe found that 46 % 
of resistance genes amplified directly from the samples using tet(O) primers were 
mosaics that included fragments of tet(O), tet(W) and tet(32) sequences, suggesting 
that such mosaic genes may be widespread (195). 
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1.3.2.3. Enzymatic inactivation of tetracyclines 
Enzymatic modification and inactivation of antimicrobial agents is a common 
mechanism of resistance to other compound classes such as the aminoglycosides and 
ß-lactams, but less so for the tetracyclines. To date, just three genes that encode 
tetracycline-modifying enzymes have been described (66; 189; 238). The first to be 
characterised, Tet(X), was originally identified in Bacteroides fragilis where it was 
non-functional (239). However, when the tet(X) gene was cloned and expressed in 
aerobically-growing E. coli it was shown to modify tetracycline and destroy its 
antimicrobial activity (238). Further characterisation of Tet(X) activity has shown that 
it is a flavin-dependent monooxygenase that hydroxylates tetracyclines at carbon 11 a 
(281). Another gene encoding an oxidoreductase enzyme with tetracycline-modifying 
activity was recovered from a cloned part of the human oral metagenome 
(encompassing all the genetic material present in the human mouth) and was 
designated tet(37) (66). Despite having similar properties, there is no homology 
between Tet(37) and Tet(X). The third gene encoding an enzyme that inactivates 
tetracycline, named tet(34), was identified in Vibrio sp. and is homologous to the 
xanthine-guanine phosphoribosyl transferase from V. cholerae (189). 
1.3.2.4. Target modification 
Modification of antimicrobial targets that arises through mutation is another common 
mechanism of drug resistance. Mutational changes to the bacterial ribosome that 
affect tetracycline activity have been documented in Gram-positive and Gram- 
negative species. The first report of tetracycline resistance mediated by this 
mechanism was that describing aG -+ C point mutation at position 1058 in 16S 
rRNA in clinical isolates of Propionibacterium acnes that were resistant to 
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tetracycline (217). When this mutation was engineered in E. coli by site-directed 
mutagenesis the resulting mutants were less susceptible to tetracycline than wild-type 
strains (217). 
Mutations in 16S rRNA located within the primary tetracycline binding site 
have also been implicated in tetracycline resistance in Helicobacter pylori (54; 96). 
Further work on this species showed that successive contiguous nucleotide 
substitutions have a cumulative effect on the level of tetracycline resistance with triple 
bp mutations conferring a higher level of resistance than single or double bp 
mutations (95). 
1.4. Glycylcydines and the development of tigecycline 
During a programme in the early 1990s at the pharmaceutical company American 
Cyanamid (which later became Wyeth after American Home Products acquired the 
company in 1994) to discover novel antibiotics with activity against MDR bacteria, it 
was observed that molecules with certain chemical modifications to the tetracycline 
scaffold at carbon 9 displayed better in vitro activity against organisms that possessed 
Tet efflux determinants (205). 
Further work led to the discovery of N, N-dimethylglycylamido (DMG) 
derivatives of minocycline (DMG-MINO) and 6-demethyl-6-deoxytetracycline 
(DMG-DMDOT). These compounds were the first semi-synthetic, third-generation 
tetracyclines, or so called glycylcyclines, that were shown to be active in vitro and in 
vivo versus Gram-positive and Gram-negative species that harboured tet genes 
encoding either efflux pumps or RPPs (248). However, concerns over the propensity 
for resistance to these novel agents to emerge through mutation of known tet genes 
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spurred the search for other glycylcyclines that had similarly potent or even greater 
activity but which did not possess such resistance liabilities (205). 
Tigecycline (initially known in the literature as TBG-MINO and GAR-936), is 
the 9-t-butylglyclamido derivative of minocycline (Figure 11). This broad-spectrum 
compound was more active than DMG-MINO and DMG-DMDOT (201; 241). An 
early study showed it to be active in vitro versus a range of aerobic and anaerobic 
Gram-positive and Gram-negative organisms, including those which possessed let 
genes encoding efflux pumps and RPPs (201). In particular, it displayed good in vitro 
activity versus clinical isolates of methicillin-resistant S. aureus (MRSA), 
vancomycin-resistant enterococci (VRE) and penicillin-resistant streptococci, with 
MIC90s (i. e. the MIC required to inhibit the growth of 90% of isolates) of < 0.5 mg/L 
while it was as active or more active than minocycline versus most Gram-negative 
species tested (201). It was demonstrated that tigecycline was also efficacious in vivo 
(murine model) against infections caused by E. coli and S. aureus (including MRSA) 
that harboured let genes (201). 
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Figure 11. Chemical structure of tigecycline (PubChem). 
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Further in vitro studies confirmed the findings of the initial report with MIC9, 
of <1 mg/L for all Gram-positive cocci and <2 mg/L for most Gram-negative species 
tested including Acinetobacter spp. (31; 91; 172; 211). Notably, some studies showed 
minocycline to be more active than tigecycline versus Acinetobacter spp. (91; 104). 
Tigecycline displayed only modest activity against Pseudomonas spp., Proteus spp., 
and Morganella morganii which generally had tigecycline MIC90s of >4 mg/L 
(31; 91; 172). Wild-type tigecycline MIC distributions are shown in Table 1. 
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The safety and clinical efficacy of tigecycline in the treatment of complicated 
skin and skin structure infections (cSSSI) and complicated intra-abdominal infections 
(cIAI) was assessed in a number of double-blind, phase III, multicentre clinical trials 
using a 100 mg loading dose followed by 50 mg intravenously every 12 hours for a 
duration of between 5 and 14 days (33; 77; 87; 225). These studies concluded that 
tigecycline monotherapy was efficacious in the treatment of cSSSI and cIAI as 
demonstrated by noninferiority to that of vancomycin plus aztreonam in the case of 
the former (33; 77; 225) and noninferiority to that of imipenem plus cilastatin in the 
case of the latter (87). In all studies, reports of adverse events were similar in the two 
groups with nausea and vomiting the most frequently reported events in the 
tigecycline group (33; 77; 87; 225). 
Further phase III trials evaluated the efficacy of tigecycline in the treatment of 
hospitalised patients with community-acquired pneumonia (CAP) (24; 57) and 
hospital-acquired pneumonia (HAP) (89). The CAP studies both concluded that 
tigecycline was safe and efficacious (noninferior to levofloxacin). However, data from 
the HAP trial demonstrated that tigecycline was inferior to imipenem in the ventilator- 
associated pneumonia (VAP) patient group (89). 
Tigecycline has only limited oral bioavailability and therefore is only available 
as an intravenous formulation. Pharmacokinetic analysis of phase I trial data on 
healthy volunteers indicated that tigecycline has a long terminal elimination half-life 
(ti/2) of approximately 40 hours and a large steady-state volume of distribution (V) of 
approximately 7- 10 L/kg, displaying widespread tissue penetration (169). While 
tigecycline rapidly and extensively penetrates body tissue, it displays relatively low 
maximum plasma concentrations (C,,. ), which for multiple-dose regimens is 
approximately 0.6 - 1.1 mg/L (169). Tigecycline is not extensively metabolised and 
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the primary route of elimination is through biliary / faecal excretion as unchanged 
drug (169). 
Tigecycline was licensed under the brand name Tygacil® for the treatment of 
cSSSI and clAI in adults by the Food and Drug Administration (FDA) in the United 
States (US) in 2005 and in Europe by the European Medicines Agency (EMA) in 
2006. In 2009, tigecycline was also approved by the FDA in the US for the treatment 
of CAP in adult patients. 
1.4.1. Mode of action 
Early studies showed that the glycylcyclines, DMG-MINO and DMG-DMDOT are 
bacteriostatic agents and that their mode of action is like that of the tetracyclines in 
that they bind to the bacterial ribosome and inhibit protein synthesis by preventing 
aminoacyl-tRNAs from entering the A site although more effectively than tetracycline 
or minocycline, suggesting a mechanism of evasion of RPP-mediated resistance 
(25; 208). Further work investigating the antibacterial activity of tigecycline found 
that, like tetracycline, tigecycline bound in the A site of the 30S subunit in complex 
with Mg2+ but in a manner that allowed tigecycline to escape ribosomal protection 
mechanisms (20). 
1.5. Gram-negative species studied 
Rates of tigecycline non-susceptibility among the Enterobacteriaceae (MIC, >1 
mg/L; EUCAST) remain low in the UK with the highest rates seen among Klebsiella 
spp. and Enterobacter spp. (17.7% and 6.8%, respectively; UK tigecycline survey, 
2007 data) (111). Despite Klebsiella spp. displaying the highest non-susceptibility 
rate, isolates of this genus were not studied here. This was because, unlike E. cloacae 
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and A. baumannii, no pre- and post-therapy pairs of Klebsiella spp. were available in 
the Antibiotic Resistance Monitoring and Reference Laboratory's (ARMRL's) isolate 
collection. More importantly, other researchers have previously published a number 
of manuscripts on tigecycline resistance mechanisms in K. pneumoniae both before 
and during the studentship (102; 220; 224). S. marcescens was selected for study 
because there were no reports describing the mechanisms of tigecycline resistance in 
the species. 
1.5.1. A. baumannii 
Over the past three decades the Gram-negative organism, A. baumannii has emerged 
as a major nosocomial pathogen (253). It poses a particular problem in intensive care 
units (ICUs) and other departments caring for debilitated patients who are vulnerable 
to infections (124). There have also been reports (although rarely in the UK) of severe 
community-acquired A. baumannii infections, including meningitis (156). The most 
common manifestations of hospital-acquired infection are: VAP; bacteraemia; and to 
a lesser extent, skin and soft tissue infection; wound infection (124). There are reports 
of high mortality rates in patients with A. baumannii VAP and secondary bacteraemia 
(79; 215). There is debate over the real clinical impact of A. baumannii infection, since 
this organism mostly affects individuals with severe underlying illness. It is therefore 
argued that the high mortality rates are actually due to the underlying disease rather 
than attributable directly to A. baumannii infection (68). Whatever the truth, this 
organism is certainly a serious public health concern, owing to its capacity to cause 
outbreaks of disruptive cross-infection in ICUs. 
A. baumannii is a highly adaptable organism. Both sporadic and outbreak 
strains persist in the nosocomial environment, at least in part, due to an ability to 
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survive desiccation (121). A. baumannii is intrinsically resistant to certain antibiotics 
but it also has the capacity to acquire resistance determinants via mobile genetic 
elements. Isolates of this species are commonly resistant to multiple antibiotic classes, 
thus compromising the clinician's ability to treat patients. Diverse mechanisms of 
resistance have been reported in A. baumannii (30; 78). These include antibiotic- 
modifying enzymes from AmpC-type cephalosporinases and other ß-lactamases 
including serine (OXA) and metallo-enzymes (IMP, VIM, SIM and NDM), to 
aminoglycoside-modifying enzymes (acetylating, nucleotidylating, and 
phosphorylating) (30; 78; 126). Antibiotic target modifications are also important 
mechanisms of resistance including gyrA and parC mutations that mediate quinolone 
resistance, and 16S rRNA methylases which confer aminoglycoside resistance 
(20; 59). Other mechanisms include alterations in membrane permeability through 
porin loss or down-regulation and active efflux (section 1.5.2) (30; 78; 126). 
Carbapenems are important agents for the treatment of A. baumannii infection (84). 
Therefore, the emergence and spread of carbapenem-resistant strains around the world 
is alarming (270; 278; 284). These mostly have OXA carbapenemases but a few have 
metallo types, including NDM-1. 
Molecular typing data on European isolates strongly indicate that A. 
baumannii is a clonal organism. Three distinct clusters have been identified which 
have caused wide-scale, nosocomial epidemics; these are designated European clones 
I, II and III (67; 265). More recent work looking at a large global collection of isolates 
identified eight so called world-wide (WW) clonal lineages, of which, WWI, WW2 
and WW3 contain representatives of European clones I, II, and III, respectively (106). 
In the UK, a number of PFGE-defined clones belonging to European clone II 
are of particular concern. One prominent example is the OXA-23 clone 1 lineage (49), 
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with over 60 centres affected to date, clustered mainly in London and the South East 
of England. Treatment options are severely limited since representatives of this clone 
are resistant to multiple antibiotic classes, including to carbapenems (due to 
production of OXA-23 carbapenemase). Indeed, OXA-23 clone 1 isolates are 
typically susceptible only to the polymyxins and tigecycline (49). 
Another widespread and problematic clone in the UK is known as the South 
East (SE) clone (259). First appearing in 2000, it has been detected in over 40 centres, 
again, particularly in London and South East England. Similarly to OXA-23 clone 1, 
the SE clone is MDR, although it displays variable resistance to the carbapenems 
(259). In the SE clone this resistance, where present, typically was mediated by up- 
regulation of the blaoxn-51-like gene by the insertion sequence, ISAbal (260), though 
an increasing proportion of isolates now also carry OXA-23 (257). 
There are currently no EUCAST species-specific MIC breakpoints for A. 
baumannii due to insufficient clinical evidence. Despite this, tigecycline is one of the 
few agents generally to remain active in vitro versus MDR lineages, although there is 
some variation in modal tigecycline MIC between distinct clones. For instance, OXA- 
23 clone 1 is intrinsically more susceptible to tigecycline than the SE clone; modal 
MICs are 0.5 and 2 mg/L, respectively (49; 259). This variation in modal tigecycline 
MIC between distinct clones is further exemplified by the ACB20 clone which has 
caused a multicity outbreak in the United States since 2005; it has OXA-40 
carbapenemase and a higher modal tigecycline MIC of 4 mg/L (154). The reasons for 
these differences in modal MIC are explored in this thesis. 
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1.5.1.1. Characterised RND transporters of A. baumannii 
The first RND system to be described in Acinetobacter spp. was AdeABC 
(Acinetobacter drug efflux) in 2001 (160). The authors used degenerate 
oligonucleotide primers with complementarity to conserved motifs of the RND 
protein family to PCR-amplify the adeB gene from the DNA of an isolate recovered 
from a patient with a urinary tract infection (160). The genes encoding the structural 
proteins adeA (periplasmic adapter), adeB (RND pump) and adeC (outer membrane 
channel) are co-transcribed as an operon that is regulated by a divergently co- 
transcribed two-component regulatory system, AdeRS (Figure 12) (164). This 
comprises of a sensor kinase, AdeS and its cognate response regulator, AdeR. 
AdeABC is stringently controlled by AdeRS and is therefore expressed at low levels 
in wild-type A. baumannii. Specific amino acid substitutions in both AdeS (Thrl 53 -> 
Met; G1y30 -º Asp) and AdeR (Pro 116 --+ Leu) have been linked with constitutive 
expression of this efflux system (51; 164). There is evidence that AdeABC contributes 
to antimicrobial resistance and its known antibiotic substrates include 
fluoroquinolones, aminoglycosides, chloramphenicol, trimethoprim, macrolides, ß- 
lactams (predominantly cephalosporins), and tetracyclines (32; 160). Some studies 
suggest a role for AdeABC in carbapenem resistance by demonstrating associations 
between increased MICs and adeABC overexpression (1 16; 139). Wong et al. reported 
that insertional inactivation of adeB in three clinical isolates resulted in four-fold 
decreases in meropenem MICs compared with the parent strains, whereas MICs of 
imipenem were unchanged (276). 
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Figure 12. Genetic organisation of the structural and regulatory operons and 
regulation of adeABC expression by AdeRS. AdeS autophosphorylates at a conserved 
histidine residue upon ligand binding. The phosphate group is then transferred to 
AdeR that then drives adeABC expression. 
It has been suggested that adeB sequence typing could be used to investigate 
the epidemiology of clinical A. baumannii strains (117). Since then, this approach has 
been used, in combination with other typing methods, for that purpose (110). 
However, studies have shown that a minority of isolates (approximately 30%) lack the 
adeB gene, which appears to be mostly associated with MDR strains (46; 117; 118). 
The next RND transporter to be described in A. baumannii was the AdeIJK 
system (56). AdeIJK was first identified in the same clinical isolate as AdeABC and, 
similarly, the structural genes are co-transcribed as an operon, which comprises of the 
periplasmic adapter gene, adel, the RND protein gene, adeJ and the gene encoding 
the outer membrane component, adeK (56). However, unlike with adeABC, no 
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regulatory genes have been found adjacent to adeIJK and so the mechanism(s) of 
transcriptional regulation remain obscure (56). The substrate profile of AdeIJK 
includes ß-lactams (cephalosporins and carboxypenicillins), chloramphenicol, 
tetracyclines, lincosamides and fluoroquinolones (56). The adeJ gene has a similar 
distribution to adeB, being present in the majority of MDR isolates (150). 
Recently, a third RND transporter, AdeFGH was described in the species (52). 
It was identified in laboratory-selected MDR mutants of a DadeABC DadeIJK strain 
by comparative microarray analysis (51; 52). Again, the pump genes are co- 
transcribed, and the authors present evidence that adeFGH expression is controlled by 
the divergently-transcribed LysR-type transcriptional regulator, adeL (52). The 
laboratory-selected mutants displayed overexpression of adeFGH and MICs of 
chloramphenicol, fluoroquinolones, tetracyclines, trimethoprim and clindamycin were 
elevated compared with their parent (52). The adeG gene was identified by PCR in 40 
out of 44 clinical isolates of A. baumannii (52). 
1.5.2. E. cloacae 
E. cloacae is a member of the Enterobacteriaceae family, is the most clinically 
important pathogen in the genus Enterobacter and is an important cause of 
nosocomial infection. Common sites of infection include the urinary and respiratory 
tracts, wounds, and the bloodstream. Like A. baumannii, E. cloacae bacteraemia is 
associated with high mortality rates in patients that have severe underlying disease 
(151). 
Increasing levels of antibiotic resistance in this species are of serious concern 
to the clinician because it compromises empiric regimens and, as such, contributes 
increased morbidity and mortality. Antibiotic- and target-modifying resistance 
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mechanisms have been described in E. cloacae. For example, a chromosomally- 
encoded AmpC ß-lactamase which, hyperproduced owing to mutation, confers 
resistance to penicillins, monobactams, and expanded-spectrum cephalosporins except 
cefepime and cefpirome (120). In addition, some isolates are extended-spectrum f- 
lactamase (ESBL) producers, with TEM, SHV and CTX-M-type enzymes (163). 
Resistance to the aminoglycoside class of antimicrobials in this species, although rare, 
can be mediated by aminoglycoside-modifying enzymes, many of which have been 
detected (266) and by the 16S rRNA methylases (43; 193). Mutations in gyrA and 
parC contribute to fluoroquinolone resistance (62). Resistance to the carbapenems can 
arise as a result of membrane permeability changes combined with AmpC or an ESBL 
(72), or via acquisition of IMP (234), VIM (122) and NDM (137) metallo-ß- 
lactamases or KPC enzyme production (114), and is worrying since these antibiotics 
are considered the treatment of choice for serious infections caused by MDR isolates 
of Enterobacteriaceae (194). 
1.5.2.1. Characterised RND transporters of E. cloacae 
An RND efflux system with a high level of similarity to the AcrAB-To1C transporter 
of E. coli and the closely-related species E. aerogenes was identified in a MDR 
clinical isolate of E. cloacae that was recovered from a patient admitted to an ICU 
(200). AcrAB-ToIC of E. cloacae is the only characterised RND pump described to 
date in the species. The genetic organisation of the structural genes resembles that of 
E. coli and the authors also identified a divergently-transcribed acrR-like gene (200). 
The substrate profile includes aminoglycosides, tetracyclines, fluoroquinolones, 
clindamycin and linezolid (200). The authors also report that acrA was present in six 
other unrelated E. cloacae isolates (200). 
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1.5.3. S. marcescens 
S. marcescens also belongs to the Enterobacteriaceae, and is an opportunistic 
pathogen that can cause serious problems for immunocompromised patients and those 
with underlying morbidities. It is especially associated with outbreaks in neonatal 
units (65; 100). 
The infections that it causes can be difficult to treat owing to the intrinsic and 
acquired resistance of S. marcescens to many antimicrobial agents. A variety of 
resistance mechanisms and determinants have been identified in this organism. 
Antibiotic-modifying enzymes including TEM and CTX-M-type ESBLs, 
carbapenemases, IMP, VIM and KPC, and chromosomally-encoded SME 
carbapenem-hydrolyzing enzymes also have been described (115; 138; 180; 255). S. 
marcescens also possesses an inducible, chromosomal AmpC ß-lactamase, which can 
be derepressed by mutation conferring cefotaxime resistance. Target modifications, 
mediated by both enzymatic and mutational mechanisms contribute to resistance to 
aminoglycosides and fluoroquinolones (69; 129). Other mechanisms of resistance 
include membrane permeability changes and active efflux (section 1.5.3.1) (219). 
1.5.3.1. Characterised RND transporters of S. marcescens 
Three RND transporters have been described to date in S. marcescens (22; 42; 135). 
The first to be characterised was the SdeXY system (Serratia drug efflux) which was 
identified through screening of a genomic library prepared from DNA obtained from a 
clinical isolate (42). The genetic organisation of the pump genes, sdeX (periplasmic 
adapter) and sdeY (RND) was typical of this type of transporter and suggested they 
are co-transcribed (42). Antibiotic substrates of SdeXY include tetracycline, 
erythromycin and norfloxacin (42). 
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The two other RND systems, SdeAB and SdeCDE were identified again 
through screening of a S. marcescens genomic library (135). The sdeAB locus consists 
of the periplasmic adapter gene, sdeA and the RND component gene, sdeB while the 
sdeCDE locus consists of the periplasmic adapter gene, sdeC and, unusually, two 
genes encoding RND proteins, sdeD and sdeE, both of which are required for activity 
(135). The SdeAB pump has been shown to function with the outer membrane 
channel, HasF, a To1C homologue, to form a functioning tripartite complex (23; 136). 
The substrate profile of SdeAB-HasF includes ciprofloxacin and other 
fluoroquinolones, whereas SdeCDE appears to have only limited substrate specificity 
(22). 
1.6. Tigecycline resistance 
Currently, the EUCAST defines tigecycline MIC breakpoints as follows: enterococci, 
> 0.5 mg/L resistant and < 0.25 mg/L susceptible; staphylococci, > 0.5 mg/L resistant 
and < 0.5 mg/L susceptible; Enterobacteriaceae, >2 mg/L resistant and <I mg/L 
susceptible; Acinetobacter spp., no MIC breakpoints 
(www. eucast. org/tileadmin/src/media/PDFs/EUCAST files/Disk test documents/EU 
CAST breakpoints v l. 3 pdf. pdf. last accessed 11/04/11). The US FDA defines 
tigecycline MIC breakpoints for the Enterobacteriaceae as, >8 mg/L resistant and <2 
mg/L susceptible, with other values identical to those of EUCAST and, again, with no 
values for Acinetobacter spp. The EUCAST Enterobacteriaceae breakpoints shall be 
used to define resistance when discussing all species, including A. baumannii. 
Tigecycline is not generally affected by the `classical' tetracycline resistance 
determinants including MSF efflux pumps and RPPs (86). Indeed, tigecycline 
resistance rates remain low in the UK (0.8% resistant for all species excluding 
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Proteus spp. and P. aeruginosa and 1.4% intermediate; UK tigecycline survey) (111), 
as elsewhere although rates are lower in countries using FDA breakpoints. Despite 
this, there have been reports of clinical resistance (MIC, >2 mg/L) emerging in a 
number of different species of Gram-negative bacteria, especially A. baumannii where 
there are reports of isolates with high-level resistance (MIC, > 256 mg/L) (119; 182) 
and instances of resistance emerging during tigecycline therapy (11; 199). Tigecycline 
resistance is very rare in Gram-positive organisms and, to date, there have only been 
two reports of resistance emerging in clinical isolates of E. faecalis and E. faecium 
where the mechanisms have been investigated (113; 275). 
1.6.1. Mechanisms of tigecydine resistance in Gram-positive bacteria 
1.6.1.1. Efflux 
Reduced susceptibility and resistance to tigecycline in Gram-positive organisms has 
been described only very rarely. McAleese et al. investigated the mechanisms of 
tigecycline resistance in S. aureus by exposing two tigecycline-susceptible clinical 
isolates of MRSA to tigecycline in vitro (167). Tigecycline MICs for the resulting 
final laboratory-selected mutants were 16- and 32-fold higher (4 and 16 mg/L, 
respectively) than those for their susceptible parents. Transcriptional profiling 
experiments revealed overexpression of a MATE-type efflux pump gene designated 
mepA. However, when this gene was overexpressed in the susceptible parent strains, 
only four-fold increases in tigecycline MICs were observed, suggesting that the 16- 
and 32-fold MIC rises for the laboratory mutants were the result of a combination of 
mepA overexpression and alterations in other unknown elements (167). 
The first report of tigecycline resistance in a Gram-positive species where the 
mechanisms were investigated was that of a clinical isolate of Enterococcus feacalis 
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with a tigecycline MIC of 2 mg/L (defined as resistant by current EUCAST criteria) 
that was isolated in Germany from the urine of a patient with a complicated clinical 
history who had received, among other antibiotics, a two week course of tigecycline 
to treat MDR S. maltophilia (275). The molecular basis of resistance was not 
established although the authors did not detect; tet(X) by PCR; mutations in 16S 
rDNA; potentiation by efflux pump inhibitors (275). Recently, the emergence of 
tigecycline resistance during tigecycline therapy in a vancomycin- and linezolid- 
resistant clinical isolate of E. faecium was described (tigecycline MIC, 8 mg/L) that 
was recovered from the bloodstream of a post-second liver transplant patient (113). 
Up-regulation of a MepA-like MATE efflux pump was observed in the resistant 
isolate compared with two tigecycline-susceptible, pre-therapy E. faecium isolates 
recovered from the same patient (113). 
1.6.2. Mechanisms of tigecydine resistance in Gram-negative bacteria 
1.6.2.1. Enzymatic modification 
There is evidence that tigecycline is a substrate for the tetracycline modification 
enzyme, Tet(X) (175). Tet(X) hydroxylates tigecycline at carbon 11a and the product, 
11 a-hydroxytigecycline is inherently unstable at physiological pH and thus antibiotic 
activity is abolished (175). To date, there have been no reports of clinical isolates that 
are resistant to tigecycline that harbour tet(X). A recent description of the crystal 
structure suggested that overcoming Tet(X)-mediated resistance by chemical 
modification would be problematic (268). These results, together with the finding that 
tet(X) has been found on transposons Tn4351 and Tn4400 (237) highlight the need to 
remain vigilant. 
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1.6.2.2. Tet(A)-mediated efflux 
Tuckman et al. (256) identified two veterinary isolates of Salmonella with reduced 
susceptibility to tigecycline (MIC, 2 mg/L) which were found to harbour a variant of 
the tet(A) gene, the sequence of which differed from that of the corresponding gene 
on transposon Tn1721 (273) by four nucleotides. Two of these were synonymous 
mutations while the two others led to a double frameshift of codons 201-203 that 
resulted in changes to the amino acid sequence in the interdomain loop (between TMs 
6 and 7) of the efflux pump protein from Ser-Phe-Val to Ala-Ser-Phe (256). When the 
tet(A) genes from both isolates were expressed in a laboratory strain of E. coli, 
tigecycline MICs were increased four- to eight-fold. The authors concluded that the 
double frameshift was responsible for the increases in tigecycline MIC. In one isolate, 
tet(A) was located on the chromosome, but it was plasmid-associated in the other. The 
authors expressed their concern that since this tet(A) variant was transposon- 
associated, it might quickly and easily move into organisms pathogenic to humans 
(256). 
More recently, a clinical isolate of S. enterica serovar Hadar with a tigecycline 
MIC of 16 mg/L was found with a Tn1721-associated tet(A) variant that contained the 
same double frameshift mutation described above as well as RamA-mediated AcrAB 
up-regulation (101). When this tet(A) gene alone was expressed in a laboratory strain 
of E. coli, a four-fold increase in tigecycline MIC was observed (101). 
1.6.2.3. RND transporter-mediated resistance 
There is evidence that tigecycline is a substrate for some members of the RND family 
of efflux transporters. 
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1.6.2.3.1. Enterobacteriaceae 
RND efflux systems have been implicated in reduced susceptibility and resistance to 
tigecycline in a number of Enterobacteriaceae species (127; 128; 222; 224; 267). 
Isolates of E. coli are usually susceptible to tigecycline and, with a modal MIC 
of 0.25 mg/L, it is the most susceptible Enterobacteriaceae species (EUCAST). 
However, two clinical isolates with reduced susceptibility to tigecycline (MIC, 2 
mg/L) were isolated from a single patient who had received the drug during Phase III 
clinical trials (128). Transcriptional profiling and real-time RT-PCR revealed 
overexpression of the RND efflux operon acrAB, its outer membrane component 
gene, tolC and transcriptional regulator, marA in these isolates compared with 
tigecycline-susceptible isolates recovered from the same patient (128). The 
involvement of AcrAB and MarA in reduced susceptibility to tigecycline in these 
isolates was confirmed by transposon mutagenesis (128). 
Transposon mutagenesis studies of a tigecycline-resistant clinical isolate of E. 
cloacae (MIC, 8 mg/L) yielded two tigecycline-susceptible mutant isolates with the 
transposon insertion mapped to acrA in one isolate and acrB in the other (127). When 
these isolates were trans-complemented with a plasmid carrying acrAB, tigecycline 
resistance was restored (127). Real-time RT-PCR and Northern blot analyses 
identified overexpression of acrAB and the transcriptional regulator gene ramA 
though not marA, suggesting the tigecycline-resistant phenotype was the result of 
RamA-mediated AcrAB up-regulation (127). More recently, an isolate of E. 
hormaechei (belonging to the E. cloacae complex) resistant to tigecycline that was 
recovered from a patient who had received the drug (among other antibiotics) was 
shown to overexpress acrAB compared with a susceptible isolate recovered from the 
same patient (58). 
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The majority of K. pneumoniae isolates are susceptible to tigecycline (modal 
tigecycline MIC, 0.5 mg/L; EUCAST) although in the UK 17.7% (111) are non- 
susceptible. Tigecycline resistance in this species has been associated with AcrAB up- 
regulation (102; 103; 224). In one study a clinical isolate with a tigecycline MIC of 4 
mg/L was subjected to transposon mutagenesis and a tigecycline-susceptible mutant 
was obtained where the transposon insertion mapped to ramA (224). The resistant 
phenotype was restored upon trans-complementation with a plasmid carrying ramA 
and the ramA gene and acrAB were shown to be overexpressed in the resistant isolate 
by Northern blot analysis compared with tigecycline-susceptible strains confirming 
the role of RamA and AcrAB in tigecycline resistance (224). In another more recent 
study, Hentschke et al. sequenced the ramR gene, the putative local repressor of 
ramA, in five K. pneumoniae isolates, each with a tigecycline MIC of 2 mg/L, and 
found various genetic lesions that were not present in 12 tigecycline-susceptible 
isolates (102). Trans-complementation of two of the mutants with wild-type ramR 
restored tigecycline susceptibility and repressed overexpression of both ramA and 
acrAB suggesting that non-functional RamR was responsible for RamA-mediated 
AcrAB up-regulation (102). 
Some members of the Enterobacteriaceae are intrinsically resistant or less 
susceptible to tigecycline as well as to other tetracyclines; these include P. mirabilis 
and M. morganii (modal MICs, 4 and I mg/L, respectively; EUCAST). Studies 
investigating tigecycline resistance mechanisms in clinical isolates of these two 
species also implicated the RND transporter, AcrAB (222; 267) 
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1.6.2.3.2. Non-fermenters 
Efflux by RND transporters has also been described as a mechanism of tigecycline 
resistance in non-fermenting species (61; 197; 207; 221; 223). 
Despite evidence of upward tigecycline MIC creep globally in recent years 
(271), the majority of A. baumannii isolates remain susceptible (modal MIC, 0.5 
mg/L; EUCAST). However, resistance has been described and in each case has been 
associated with efflux systems (197; 199; 221; 223). There is laboratory evidence that 
tigecycline is a substrate of the three characterised RND transporters of A. baumannii 
described to date, namely AdeABC, AdeIJK and AdeFGH (52; 56; 197; 223). However, 
where studies have focused on investigating resistance in clinical isolates, only the 
AdeABC transporter has been implicated (197; 221; 223). Ruzin et al. reported that 
adeABC was overexpressed in two clinical isolates of the A. calcoaceticus-A. 
baumannii complex recovered from the same patient which had tigecycline MICs of 4 
mg/L compared with susceptible isolates which were also recovered from the same 
patient (223). When the adeB gene of the resistant isolates was disrupted by a suicide 
plasmid, tigecycline MICs were reduced 8-fold (223). It was also demonstrated that 
the sensor kinase gene, adeS was disrupted by the insertion sequence, ISAbal in both 
resistant isolates which may have resulted in adeABC overexpression (223). In a 
separate study, two clinical isolates recovered from different patients who had both 
received tigecycline therapy were tigecycline non-susceptible (MIC, 2 mg/L) (197). 
Real-time RT-PCR revealed that adeABC was overexpressed in these isolates 
compared with another clinical isolate recovered from a different patient which was 
tigecycline-susceptible (197). In vitro exposure of this susceptible isolate to 
tigecycline selected for a tigecycline-resistant mutant which overexpressed adeABC in 
comparison with the susceptible parent (197). When the regulatory operon adeRS was 
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sequenced, no differences were found between the susceptible clinical isolate and it's 
in vitro-selected tigecycline-resistant mutant (197). 
P. aeruginosa is intrinsically resistant to tigecycline, (modal MIC, 16 mg/L; 
EUCAST). The mechanism of resistance was investigated using mutant derivatives of 
P. aeruginosa PAO1 that lacked functional MexAB or MexXY (61). The strain 
lacking MexXY was susceptible to tigecycline with an MIC of 0.5 mg/L whereas the 
tigecycline MIC of its parent and the strain lacking MexAB was 8 mg/L thus 
implicating MexXY (61). 
There is limited evidence that efflux transporters may also contribute to 
tigecycline resistance in clinical isolates of the B. cepacia complex (207). It was 
demonstrated by checkerboard titration that tigecycline MICs decreased with 
increasing concentrations of the EPI PA(3N (207), although further work will be 
required to positively identify the efflux system(s) responsible. 
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1.7. Aims 
Over the past five to six years the ARMRL at the HPA has received isolates of A. 
baumannii and of Enterobacteriaceae (mostly E. cloacae and K. pneumoniae but also 
a single isolate of S. marcescens) displaying reduced susceptibility (MIC, 2 mg/L) or 
resistance (MIC, >2 mg/L) to tigecycline, including pre- and post-treatment pairs of 
particular strains where resistance had emerged during therapy. 
In this work, these isolates were characterised, and the role of the RND efflux 
systems was investigated. Specific pumps investigated were AcrAB and AdeABC in 
the emergence of tigecycline resistance in pre- and post-therapy isolates of E. cloacae 
and A. baumannii, respectively. In addition, expression of adeABC was investigated in 
multiple isolates of three epidemic clones of A. baumannii in an attempt to explain 
observed differences in their modal tigecycline MICs. For S. marcescens, efflux by 
RND transporters was analysed as a possible mechanism of tigecycline resistance in a 
clinical isolate. 
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2. Materials and Methods 
2.1. Reagents and consumables 
All reagents and consumables were obtained from Sigma-Aldrich, Poole, UK and all 
restriction enzymes from Roche, Burgess Hill, UK, unless otherwise stated. 
2.2. Bacterial isolates and growth conditions 
All organisms were type strains, clinical isolates, laboratory-selected mutants or gene 
knockout mutants of A. baumannii, E. cloacae, or S. marcescens (Table 2) with the 
exception of the following strains that were used for cloning only: a-select E. coli 
(Bioline, London, UK) and pir+ E. coli (Cambio, Cambridge, UK). Isolates were 
propagated in Luria-Bertani (LB) or Iso-Sensitest (Thermo Fisher, Basingstoke, UK) 
media at 37°C unless otherwise stated. 
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2.3. Identification of bacteria 
2.3.1. Enterobacteriaceae 
Isolates were identified to species level by API20E (bioMerieux, Marcy 1'Etoile, 
France). 
2.3.2. A. baumannii 
Isolates were identified to genus level by API20NE (bioMerieux) and by A. 
baumannii-specific PCR for the blaoxA-51-like gene (261; 277). This PCR was 
undertaken as outlined in section 2.11.1 using primers OXA-51-likeF and OXA-51- 
likeR (Table 8), an annealing temperature of 60°C and an extension time of 30 
seconds, to amplify a 353-bp product. Single colonies from an overnight culture were 
suspended in 50 µl molecular biology grade water and incubated at 95°C for five 
minutes, cooled on ice and centrifuged at 12000 g for 30 seconds; 5 µl of the resulting 
supernatant (crude DNA extract) was used as template. A clinical isolate known to be 
positive for the blaoxA-5l-like gene was used as a positive control. 
2.4. Molecular typing of bacteria 
2.4.1. Pulsed-field gel electrophoresis (PFGE) 
Clinical isolates, laboratory-selected mutants and gene knockout mutants were 
profiled by PFGE in order to assign clones and/or determine isolate relatedness. 
After overnight culture on LB agar plates at 37°C, the organisms were 
suspended in SE buffer (75 mM NaCl, 25 mM EDTA, pH 7.5) to a turbidity of 
between 2.3 and 2.7 McFarland. This suspension was mixed with an equal volume of 
2% MacroSieve LM agarose (Flowgen Bioscience, Nottingham, UK) in SE buffer at 
56°C and dispensed into a plug mould, which was then kept at 4°C until set. 
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The plugs were transferred into bijoux bottles and 3 ml of FL buffer (6 mM 
Tris, 100 mM EDTA, 1M NaCl, 0.5% w/v Brij 58,0.2% w/v sodium deoxycholate, 
0.5% N-lauroyl sarcosine, 1 mM MgC12, pH 7.5) containing 0.5 mg/ml lysozyme was 
added. The bottles were then incubated with shaking (150 rpm) overnight at 37°C. 
After this incubation, the FL buffer was replaced with 3 ml of AL buffer (I% w/v N- 
lauroyl sarcosine, 0.5 M EDTA, pH 9.5) containing 60 . tg/ml proteinase K 
(Invitrogen, Paisley, UK) and the bottles were then incubated with shaking (150 rpm) 
overnight at 56°C. 
Buffer AL was removed, and the plugs were washed three times with 4 ml TE 
buffer (10 mM Tris, 10 mM EDTA, pH 7.5), each time for 30 minutes at 4°C. The 
plugs were cut to give a portion of the appropriate size (i. e. to fit in the wells of the 
running gel) which was washed in Apal (A. baumannii) or Xbal (Enterobacteriaceae) 
reaction buffer for 30 minutes at 4°C. The buffer was then replaced with fresh buffer 
and 20 U of Apal or Xbal and incubated overnight at 30°C or 37°C, respectively. For 
A. baumannii, a second incubation was then performed as above using fresh buffer 
and enzyme for a further 5 h. 
PFGE was performed using the CHEF-DR II system (Bio-Rad, Hemel 
Hempstead, UK). The running buffer was 0.5X TBE (44.5 mM Tris, 44.5 mM boric 
acid, 1 mM EDTA). Plugs and a phage ? ladder marker (New England Biolabs, 
Hitchin, UK) were loaded into a 1.2% molecular grade agarose (Bio-Rad) gel and the 
wells were sealed with molten agarose at 56°C. The CHEF parameters were as 
follows: 6 V/cm, 5 seconds initial and 35 seconds final switching time for 30 h at 
12°C. The gel was stained with 1 mg/L ethidium bromide for one hour and destained 
for one hour with distilled water. Bands were visualised and gels photographed using 
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a UV transilluminator and the GeneSnap image acquisition system version 6.03 
(Syngene, Cambridge, UK). 
2.5. Antimicrobial susceptibility testing 
MICs were determined by agar dilution on Iso-Sensitest agar and an inoculum of 104 
CFU according to BSAC guidelines (see Table 3 for control organisms) or by Etest 
(AB Biodisk, Solna, Sweden) on Iso-Sensitest agar. The concentrations of inhibitors 
used were as follows: clavulanic acid, 4 mg/L; cloxacillin, 100 mg/L; EDTA, 320 
mg/L. For the Etest methodology, several colonies from overnight cultures were 
suspended in 4 ml of Iso-Sensitest broth to the opacity of a 0.5 McFarland standard. 
This suspension was spread evenly on to Iso-Sensitest agar plates and allowed to dry. 
The Etest strip was then applied to the plate, which was incubated overnight at 37°C. 
The MIC was read after between 16 and 20 h incubation. MICs were interpreted using 
BSAC/EUCAST breakpoints (9). 
Table 3. MIC control organisms 
Organism 
E. cloacae 
E. coli 
E. coli 
E. coli 
E. coli 
P. aeruginosa 
P. aeruginosa 
P. aeruginosa 
K. pneumoniae 
Strain 
E684-con 
NCTC 10418 
NCTC 11560 
ATCC 25922 
ATCC 35218 
ATCC 27853 
PS 10586 
M2297 
ATCC 700603 
Purpose 
AmpC control 
susceptible control 
clavulanic acid control 
susceptible control 
clavulanic acid control 
susceptible control 
VIM control 
AmpC control 
ESBL control 
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2.6. Plasmid extraction 
Plasmids were isolated from all strains of E. coli using the PureYield Plasmid 
Miniprep System (Promega, Southampton, UK) and the manufacturer's protocol 
which is outlined below: 
The required volume of culture (to a maximum of 3 ml) was centrifuged at 
18000 xg for 30 seconds. The supernatant was discarded and the pellet re-suspended 
in 600 µl TE buffer (pH 8.0). Cell Lysis Buffer was added (100 . 
d) and mixed by 
inverting the tube. After mixing, 350 µl of cold (4°C) Neutralization Solution was 
added, mixed as above and then centrifuged at 18000 xg for three minutes. The 
supernatant was then transferred to a PureYield Minicolumn, which was centrifuged 
at 18000 xg for 30 seconds; the flow-through was discarded. 
The column was then washed by the addition of 200 µl of Endotoxin Removal 
Wash and centrifuged at 18000 xg for 15 seconds followed by the addition of 400 µl 
of Column Wash Solution and further centrifugation at 18000 xg for 30 seconds. The 
flow-through was discarded and the column transferred to a clean microcentrifuge 
tube. Plasmid DNA was then eluted by the addition of 30 . tl Elution Buffer and 
centrifugation at 18000 xg for 15 seconds. 
2.7. Genomic DNA purification 
Genomic DNA was purified from all organisms using the Wizard Genomic DNA 
Purification Kit (Promega) and the manufacturer's protocol, which is outlined below: 
Up to 1 ml of overnight culture was centrifuged at 18000 xg for two minutes 
and the supernatant discarded. The pellet was re-suspended in 600 . tl of Nuclei Lysis 
Solution, incubated at 80°C for five minutes and cooled to room temperature. After 
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cooling, 3 µl of RNase Solution was added, mixed by inversion and incubated at 37°C 
for 1 h. 
The lysate was cooled to room temperature and 200 gl of Protein Precipitation 
Solution was added, mixed by vortexing and incubated on ice for five minutes. The 
precipitated protein was pelleted by centrifugation at 18000 xg for three minutes. 
The supernatant was transferred to a clean microcentrifuge tube containing 
600 gl of isopropanol, mixed by inversion and centrifuged at 18000 xg for two 
minutes. The supernatant was discarded and the pellet was washed by the addition of 
600 gl of 70% ethanol followed by centrifugation at 18000 xg for two minutes. The 
ethanol was aspirated and the pellet air-dried for 15 minutes. The DNA was 
rehydrated by the addition of 100 µl of Rehydration Solution and incubation for one 
hour at 65°C. 
2.8. RNA extraction 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Crawley, UK) and the 
manufacturer's protocols which are outlined below: 
Isolates were grown overnight with shaking (225 rpm) in 10 ml of LB or Iso- 
Sensitest broth at 37°C. Those of A. baumannii and E. cloacae were used directly, 
whereas isolates of S. marcescens were sub-cultured to fresh LB broth and incubated 
at 37°C with shaking (225 rpm) until mid-log (OD600 = 0.5) phase before RNA 
extractions were performed. Two volumes (1 ml) of RNAprotect Bacteria Reagent 
(Qiagen) were added to one volume (500 µl) of culture in a microcentrifuge tube, 
mixed by vortexing and incubated for five minutes at room temperature. The mixture 
was centrifuged for 10 minutes at 5000 x g, the supernatant was discarded and the 
pellet was re-suspended in 100 µl TE buffer (pH 8.0) containing 1 mg/ml lysozyme 
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and incubated with shaking (150 rpm) for five minutes at room temperature. After 
incubation, 350 pl of buffer RLT containing 10 gl/ml ß-mercaptoethanol was added 
and mixed by vortexing. If particulate material was visible, it was pelleted by 
centrifugation and then the supernatant was transferred to another tube containing 250 
gl of 100% ethanol and mixed by pipetting. 
The lysate was transferred to an RNeasy Mini spin column and centrifuged at 
8000 xg for 15 seconds. The flow-through was discarded and the column washed 
with 350 µl of buffer RW1 (8000 xg for 15 seconds). On-column DNase digestion 
was then performed using the RNase-free DNase Set (Qiagen) by adding 70 µl of 
buffer RDD to 10 µl of DNase and incubating the reaction mixture on-column for 15 
minutes at room temperature. The column was washed with 350 µl of buffer RWI 
(8000 xg for 15 seconds) and the flow-through and collection tube were discarded. 
Two further washes were performed with 500 gl buffer RPE, the first at 8000 xg for 
15 seconds and the second at 8000 xg for two minutes. The column was transferred 
to an RNase-free microcentrifuge tube and RNA was then eluted by the addition of 50 
µ1 RNase-free water and centrifugation at 8000 xg for one minute. 
2.9. Quantification of nucleic acids 
Nucleic acids were quantified spectrophotometrically at 260 nm using a Nanodrop 
ND-1000 spectrophotometer (Thermo Scientific, Basingstoke, UK). 
2.10. DNA transformations 
Clinical isolates and laboratory-selected mutants were transformed by electroporation 
as outlined below unless otherwise stated. 
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2.10.1. Preparation of electrocompetent cells 
Isolates of all species except a-select E. coli and pir+ E. coli, were made 
electrocompetent as follows: 10 ml of modified LB broth (without NaCl) was seeded 
with 100 µl of an overnight LB broth culture of the relevant organism and incubated 
with shaking (225 rpm) at 37°C to mid-log phase (ODboo = 0.5). The culture was then 
centrifuged at 4°C at 4000 xg for 10 minutes, the supernatant removed and the pellet 
re-suspended in 40 ml of cold sterile water and re-centrifuged as before. The final 
pellet was suspended in 90 µl of 15% sterile glycerol. If necessary, competent cells 
were stored at -70°C for later use. 
2.10.2. Electroporation 
Competent cells (40 µl) were mixed with the DNA (in a maximum volume of 5 µl) by 
gentle pipetting and incubated on ice for one minute. Electroporation was performed 
with the Gene Pulser system (Bio-Rad) using cold 0.1 cm cuvettes (Bio-Rad) and the 
following conditions: 1.8 kV, 25 µF, 200 Q. Cell suspensions were made up to I ml 
with SOC medium (0.5% yeast extract, 2% tryptone, 10 mM NaCl, 2.5 mM KCI, 10 
mM MgC12,10 mM MgS04,20 mM glucose) and incubated at 37°C with shaking (225 
rpm) for one hour before being plated on to appropriate selective agar plates. 
2.11. PCR 
PCR was performed in 0.2-m1 PCR tubes with the following reaction components and 
cycling conditions unless otherwise stated. Master mixes (n+2) were prepared if 
multiple samples were to be analysed. 
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2.11.1. Taq DNA polymerase (Invitrogen) 
The components of a typical 50 µl reaction were as follows: 
Table 4. Components of a typical PCR reaction using Taq DNA polymerase 
Component 
Taq DNA polymerase 
l OX PCR Buffer 
MgC12 
Primers 
dNTP mix (Invitrogen) 
Template DNA (crude, genomic or plasmid extract) 
Molecular biology grade water (Invitrogen) 
Final concentration/volume 
2.5 U 
5 µl 
1.5 mM 
0.5 µM each 
250 µM of each 
variable 
upto50 A 
Thermocycling was performed using an Eppendorf Mastercycler (Eppendorf, 
Cambridge, UK) and the following conditions: initial denaturation at 94°C for three 
minutes, followed by 30 cycles of 94°C for 30 seconds, primer annealing at 50°C- 
60°C for 30 seconds, extension at 72°C for between 30 seconds and four minutes, and 
a final elongation step at 72°C for 10 minutes. Specific annealing temperatures and 
extension times are detailed subsequently. 
2.11.2. Expand High Fidelity (HiFi) Plus PCR System (Roche) 
The components of a typical 50 µl reaction were as follows: 
Table 5. Components of a typical PCR reaction using the Expand HiFi Plus 
PCR System 
Component 
Expand HiFi Plus Enzyme Blend 
5X Expand HiFi Plus Reaction Buffer with MgC12 
Primers 
dNTP mix 
Template DNA (crude, genomic or plasmid extract) 
Molecular biology grade water 
Final concentration/volume 
2.5 U 
10 µ1 
0.5 µM each 
200 µM of each 
variable 
up to 50 µl 
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Thermocycling was performed using an Eppendorf Mastercycler and the following 
conditions: initial denaturation at 94°C for two minutes, followed by 30 cycles of 
94°C for 30 seconds, primer annealing at 50°C-60°C for 30 seconds, extension at 72°C 
for between 30 seconds and four minutes, and a final elongation step at 72°C for 7 
minutes. 
2.11.3. Pfu DNA polymerase (Promega) 
The components of a typical 50 µl reaction were as follows: 
Table 6. Components of a typical PCR reaction using Pfu DNA polymerase 
Component Final concentration/volume 
Pfu DNA polymerase 1.25 U 
I OX Pfu DNA polymerase Buffer with MgSO4 5 . tl 
Primers 0.5 µM each 
dNTP mix 200 gM of each 
Template DNA (crude, genomic or plasmid extract) variable 
Molecular biology grade water up to 50 µl 
Thermocycling was performed using an Eppendorf Mastercycler and the following 
conditions: initial denaturation at 95°C for two minutes, followed by 30 cycles of 
95°C for 30 seconds, primer annealing at 50°C-60°C for 30 seconds, extension at 72°C 
for between two and four minutes, and a final elongation step at 72°C for 5 minutes. 
2.11.4. Visualisation of PCR products and estimation of amplicon size 
PCR products were separated using agarose gel electrophoresis (0.7 to 2%) and were 
visualised and photographed using a UV transilluminator and the GeneSnap image 
acquisition system version 6.03 after ethidium bromide staining (1 mg/L). Amplicon 
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size was estimated by comparison to either the 1 Kb DNA ladder (Invitrogen) or the 
123 bp DNA ladder (Invitrogen). 
2.12. Screening clinical isolates for the presence of tet(X) by PCR 
Tigecycline-resistant clinical isolates were screened for the presence of the tet(X) 
gene by PCR as outlined in section 2.11.1 using an annealing temperature of 58°C, an 
extension time of 30 seconds, primers tetXf and tetXr (Table 7) and 5 µl of a crude 
DNA extract (section 2.3.2) to amplify a 468 bp product. E. coli strain Em24 pBSJ 
was used a positive control (275). 
Table 7. 
Primer name 
M13 F 
Ml3 R 
MOD5 on F 
MOD5 on R 
tetXf 
tetXr 
Generic oligonucleotide primers used in this study 
Sequence (5' to 3') Tm Source 
GTAAAACGACGGCCAGT 59 this study 
CAGGAAACAGCTATGAC 51 this study 
CGATGAATT 17CTCGGGTGT 64 this study 
CCTGAAGCTCTTGTTGGCTA 62 this study 
CAATAATTGGTGGTGGACCC 64 (184) 
T"TCTTACCTTGGACATCCCG 64 (184) 
2.13. Purification of DNA from enzymatic reactions and agarose gels 
DNA was purified from enzymatic reactions and agarose gels using the Geneclean 
Turbo Kit (MP Biomedicals, Strasbourg, France) as described in the manufacturer's 
instructions which are outlined below: 
The appropriate band(s) was located under UV illumination and excised from 
the gel, placed into a microcentrifuge tube containing the appropriate volume of Salt 
Solution (100 µl per 100 mg gel), incubated at 55°C for five minutes and mixed by 
inversion. For purification of DNA from enzymatic reactions in solution, five 
volumes of the Salt Solution were added to the sample and mixed by inversion. 
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No more than 600 µl of the DNA/Salt Solution was transferred to the 
Geneclean Turbo column and pulsed in a microcentrifuge for five seconds. The 
supernatant was discarded and 500 µl of Wash Solution was added to the column, 
which was then centrifuged as above. The column was then centrifuged for a further 
four minutes at 12000 x g, the supernatant discarded, and the DNA eluted into a clean 
Catch Tube with 30 µl Elution Solution by centrifugation for one minute at 12000 x g. 
2.14. Nucleotide sequencing 
Sequencing was performed using the GenomeLab DTCS Quick Start Kit (Beckman 
Coulter, High Wycombe, UK) and the CEQ 8000 Genetic Analysis System automatic 
sequencer (Beckman Coulter). Samples were prepared as described in the 
manufacturer's instructions which are outlined below: 
2.14.1. Preparation of template DNA 
Template DNA was either a PCR product or a plasmid, both of which were purified as 
described in sections 2.11.3 and 2.6, respectively. The sequencing reaction was 
prepared by mixing the following components: 2 .d of primer 
(1.6 µM), 8 µl of DTCS 
Quick Start Master Mix, template DNA (between 50 and 100 ng), and molecular 
biology grade water to a final volume of 20 µl. The cycling conditions were as 
follows: 30 cycles of 96°C for 20 seconds, 50°C for 20 seconds, and 60°C for four 
minutes. 
2.14.2. Ethanol precipitation and sample loading 
The reaction mixture was transferred to clean 0.5 ml microcentrifuge tube containing 
5 gl of freshly prepared Stop Solution/Glycogen mixture [2 Al of 3M sodium acetate, 
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pH 5.2; 2 µl of 100 mM EDTA, pH 8.0; 1 µl of 20 mg/ml glycogen (Beckman 
Coulter)] and mixed by pipetting. Cold (-20°C) 95% ethanol was added (60 µl), mixed 
by vortexing and centrifuged at 18000 xg for 15 minutes. The supernatant was 
removed and the pellet washed by the addition of 200 Al of cold (-20°C) 70% ethanol 
and centrifugation at 18000 xg for three minutes. The supernatant was aspirated and 
the pellet air-dried for 30 minutes at 37°C, then re-suspended in 40 µl of Sample 
Loading Solution, transferred to the sample plate and overlaid with a single drop of 
mineral oil. The sample plate was then loaded on to the instrument and sequence was 
determined using dye-terminator chemistry. 
2.15. Gene expression studies 
Gene expression was monitored by real-time reverse transcriptase (RT)-PCR, 
performed on a LightCycler 2.0 Real-Time PCR System (Roche) using the QuantiFast 
SYBR Green RT-PCR Kit (Qiagen) and the manufacturer's protocols which are 
summarised below. 
2.15.1. Post-elution DNase treatment 
A post-elution DNase treatment step using molecular biology grade DNase I 
(Invitrogen) was performed on all RNA extracts (section 2.8) prior to RT-PCR. Up to 
1 gg of RNA in a maximum volume of 8 µl was transferred to a 0.2 ml PCR tube to 
which IU of DNase I and 1 µl of Reaction Buffer were added and mixed by 
inversion. The reaction mixture was centrifuged briefly and incubated at room 
temperature for 15 minutes before the addition of 1 gl of 25 mM EDTA, pH 8.0 
(Invitrogen). After mixing as above, the reaction was incubated for a further 10 
minutes at 65°C and cooled on ice. 
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2.15.2. Reaction setup and cycling conditions 
Reactions components were assembled on ice and consisted of the following: 10 Al of 
2X QuantiFast SYBR Green RT-PCR Master Mix, primer mix (final concentration of 
each primer =1 µM), 0.2 gl of QuantiFast RT Mix, 10 ng of template RNA, and 
RNase-free water to a final volume of 20 µl. Master mixes (n+2) were prepared if 
multiple samples were to be analysed. Template-free negative controls were included 
for each target. RT-negative controls were included for each sample/target 
combination. Each isolate was assayed in triplicate using template from separate RNA 
extractions. 
All reactions were performed using the following parameters: RT step at 50°C 
for 10 minutes, followed by an initial activation step at 95°C for five minutes and then 
35 cycles of denaturation at 95°C for 10 seconds and combined annealing/extension at 
60°C for 30 seconds. Fluorescence data acquisition was performed during the 
combined annealing/extension step. 
2.15.3. Data analysis 
RT-PCR data were analysed on the 530 nm channel. Threshold cycles (CT) were 
calculated using the LightCycler software version 4. Normalized expression of the 
target gene was then calculated relative to a housekeeping gene (rpoB) using the 2- 
°°CF method (152), where OOCT = CT of the target gene - CT of the housekeeping 
gene. 
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2.16. Cloning into pCR2.1 (Invitrogen) and pCR-Blunt (Invitrogen) 
PCR products were cloned into the TA cloning vector pCR2.1 or pCR-Blunt 
according to the manufacturer's guidelines (with some modifications), which are 
outlined below: 
The amplicon to be cloned into pCR2.1 was prepared using Taq polymerise, 
whereas that to be cloned into pCR-Blunt was prepared by Pfu polymerase (see 
individual sections for details of reaction conditions and components). PCR products 
were then analysed by agarose gel electrophoresis, cleaned (section 2.13) and 
quantified (section 2.9). 
The ligation reaction mixture was prepared on ice in 0.2-m1 PCR tubes as 
follows: 1 
.d of 
l OX Ligation Buffer, 2 µl of pCR2.1 vector (50 ng) or 1 µl of pCR- 
Blunt vector (25 ng), 1 gl of T4 DNA Ligase, PCR product to give a 1: 1 (pCR2.1) or 
1: 10 (pCR-Blunt) molar ratio of vector: insert and molecular biology grade water to a 
final volume of 10 µl. The components were mixed by inversion and centrifuged 
briefly before being incubated overnight at 14°C (pCR2.1) or for one hour at 16°C 
(pCR-Blunt). After incubation, reactions were stopped by incubation for 10 minutes at 
70°C then returned to ice before transformation into a-select E. coli by electroporation 
(section 2.10.2). Transformants were selected on LB agar plates containing 100 mg/L 
ampicillin (pCR2.1) or 50 mg/L kanamycin (pCR-Blunt), 0.1 mM isopropyl-ß-D- 
thiogalactopyranoside (IPTG) and 40 mg/L 5-bromo-4-chloro-3-indolyl-ß-D- 
galactopyranoside (X-Gal). 
2.17. Ligation of DNA fragments using T4 DNA ligase (Promega) 
After digestion with the appropriate restriction enzyme, vector DNA was 
dephosphorylated using lU shrimp alkaline phosphatase (SAP) (Promega) and the 
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appropriate volume of lOX Dephosphorylation Buffer followed by incubation at 37°C 
for 10 minutes (cohesive ends) or one hour (blunt ends). Dephosphorylated vector 
DNA was then purified as described in section 2.13 and combined with the relevant 
insert DNA using either a 1: 3 (cohesive-end cloning) or 1: 10 (blunt-end cloning) 
molar ratio of vector: insert. The ligation reaction components were assembled on ice 
in 0.2 ml PCR tubes as follows: insert and vector DNA, 1 µl of Ligase Buffer, 1U T4 
DNA ligase and molecular biology grade water to a final volume of 10 µl. After 
mixing by inversion, the components were centrifuged briefly before incubation at 
room temperature for 3h (cohesive-end cloning) or at 15°C overnight (blunt-end 
cloning). The ligase enzyme was then inactivated by incubation at 70°C for 10 
minutes before the ligation mix was transformed into the appropriate strain of 
electrocompetent E. coli (section 2.10). 
2.18. Laboratory-selection of tigecycline-resistant mutants 
An overnight Iso-Sensitest broth culture of the parent strain was subjected to serial 
exposure to tigecycline or tetracycline, beginning at half the MIC and then doubling 
this concentration every 24 h until there was no further growth. MICs were monitored 
daily by Etest (section 2.5). PFGE was used to confirm parentage (section 2.4.1). 
2.19. A. baumannii-specific methods 
2.19.1. Sequencing of the adeR and adeS genes 
DNA fragments containing the adeR (1342 bp) and adeS (1641 bp) genes were 
amplified by PCR with Pfu DNA polymerase from A. baumannii genomic DNA (-10 
ng) using primers adeS segl R and ade reg segl F, and adeS TR and adeR seq F 
(Table 8), an annealing temperature of 55°C and an extension time of 100 seconds. 
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Nucleotide sequences of the resulting fragments were then determined (section 2.14) 
using primers adeR segl R, adeRr, adeRf, adeS seq3, adeS segl F, adeS KO F, adeSf 
and adeSr (Table 8) in addition to the above. 
Table 8. Oligonucleotide primers used in this study with A. baumannii 
Primer name 
ade reg segl F 
adeB CR 
adeB KO LF 
adeB(quan)f 
adeB(quan)r 
adeR LC f 
adeR LC r 
adeR seq F 
adeR segl r 
adeRf 
adeRr 
adeS KO F 
adeS KO R 
adeS segl f 
adeS seq 1r 
adeS seq3 
adeS TR 
adeSf 
adeSr 
OXA-51-likeF 
OXA-51-likeR 
rpoB Acin F 
rpoB Acin R 
S-am 
S-av 
Sequence (5' to 3') 
CCGATTGCGGTTGAATGCTT 
GAAAGAATGAGTCCACGAGA 
GATGTGGAAATGGCTCAGGT 
AACGGACGACCATCTTTGAGTATT 
CAGTTGTTCCATTTCACGCATT 
AGCCAACCCATCGATTTAAT 
TGATCACGGGAGTCTGAGCT 
GATACCGACACTCATAGCGT 
ATCTTGATCTAGCGCCGTCA 
ATGTTTGATCATTCTTTTTCTTTTG 
TTAATTAACATTTGAAATATG 
CGATTGAAAAAGGCTGGATT 
ATCGTCTTGGAACTCGGTTG 
TTGCAACCGAGTTCCAAGAC 
GCTGCTTCGGCTAAGAAGTT 
TTAGTCACGGCGACCTCTCT 
AGCGTCTCCCGATTTACCAA 
ATGAAAAGTAAGTTAGGAATTAGTAAG 
TTAGTTATTCATAGAAATTTTTATG 
TAATGCTTTGATCGGCCTTG 
TGGATTGCACTTCATCTTGG 
GAGTCTAATGGCGGTGGTTC 
ATTGCTTCATCTGCTGGTTG 
TTCAACAAGAAGATTGGACC 
CTTGCTCAATACGACGG 
Tm Source 
69 this study 
59 this study 
64 this study 
66 (197) 
66 (197) 
62 this study 
65 this study 
59 this study 
65 this study 
61 (197) 
49 (197) 
63 this study 
64 this study 
65 this study 
63 this study 
64 this study 
66 this study 
56 (197) 
53 (197) 
65 (277) 
64 (277) 
63 this study 
63 this study 
59 (164) 
58 (164) 
2.19.2. Gene expression analysis in A. baumannii 
Expression of the adeABC and adeRS operons was investigated using real-time RT- 
PCR as outlined in section 15 using primers adeB(quan)f and adeB(quan)r; adeR LC f 
and adeR LC r (Table 8), to amplify products of 84 bp and 102 bp, respectively. In 
both cases, expression was quantified relative to the RNA polymerase 0 subunit gene, 
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rpoB, which was assayed using primers rpoB Acin F and rpoB Acin R (Table 8) to 
amplify a 109 bp product. 
2.19.3. Insertional inactivation of A. baumannii genes 
2.1 9.3.1. Insertional inactivation of adeB in clinical isolate AB211 
The adeB gene was disrupted by the insertion of the suicide plasmid pBK-5 as 
follows: 
2.19.3.1.1. Construction of suicide plasmid pBK-5 
An internal 2219-bp fragment of adeB was PCR-amplified from genomic DNA (-10 
ng) of A baumannii isolate AB211 using primers adeB KO LF and adeB(quan)r 
(Table 8) as outlined in section 11.2, with an annealing temperature of 60°C and an 
extension time of 150 seconds. The resulting PCR product was cloned into pCR2.1 as 
described in section 16. Single white colonies were grown overnight with shaking 
(225 rpm) in LB broth containing 100 mg/L ampicillin. Plasmid extractions were then 
performed (section 2.6) and the resulting preparations were analysed for the presence 
of the adeB fragment by agarose gel electrophoresis after digestion with 5U of EcoRI 
for 4h at 37°C. The plasmid containing the desired fragment was designated pBK-5 
(Figure 13). 
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Figure 13. Map of pBK-5. 
Legend: 
adeB: internal fragment of adeB 
P: lac promoter/operator 
lacZ: lacZa gene 
Fl ori: origin of replication 
KanR: kanamycin resistance gene 
AmpR: ampicillin resistance gene 
pUC ori: origin of replication 
2.19.3.1.2. Interruption of adeB with pBK-5 
Cells of isolate AB21 1 were made electrocompetent (section 2.10.1) and the suicide 
plasmid pBK-5 was introduced by electroporation (section 2.10.2). Transformants 
were selected on Iso-Sensitest agar containing 50 mg/L kanamycin. Chromosomal 
integration of pBK-5 was confirmed by PCR (section 2.11.1) using primers M 13 F 
and adeB CR (Tables 7 and 8), an annealing temperature of 55°C, an extension time 
of four minutes, and 5 µl of a crude DNA extract (section 2.3.2) to amplify a 3040-bp 
product. The identity of this fragment was confirmed by nucleotide sequencing 
(section 2.14). 
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2.19.3.2. Insertional inactivation of adeS in clinical isolate AB211 
The adeS gene was disrupted by the insertion of suicide plasmids pSK-1 and pSK-2 as 
follows: 
2.19.3.2.1. Construction of suicide plasmids pSK-1 and pSK-2 
Two internal fragments of adeS were PCR-amplified (section 2.11.2) from AB211 
genomic DNA (-'10 ng). The first, a 794-bp fragment, was amplified using primers 
adeS KO F and adeS KO R (Table 8), an annealing temperature of 60°C and an 
extension time of one minute. The second, a 620-bp fragment, was amplified using 
primers S-am and S-av (Table 8), an annealing temperature of 55°C and the same 
extension time. Both fragments were cloned separately into pCR2.1 as outlined in 
section 2.16. Individual white colonies were examined by PCR for the presence of 
insert DNA of the correct size, as described in section 2.11.1, using primers M 13 F 
and M13 R (Table 7), an annealing temperature of 50°C and an extension time of one 
minute. The template was 5 µl of a crude DNA extract, prepared as in section 2.3.2. 
Single colonies that were positive for the correct insert DNA were grown overnight 
with shaking (225 rpm) in LB broth containing 100 mg/L ampicillin, after which 
plasmid extractions were performed as outlined in section 2.6. The resulting plasmids 
were designated pSK-1, containing the 794 bp fragment of adeS and pSK-2, 
containing the 620 bp fragment (Figures 14a and 14b). 
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Figure 14a. Map of pSK-1. 
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adeS: internal fragment of adeS 
P: lac promoter/operator 
lacZ: lacZa gene 
Fl ori: Fl origin of replication 
KanR: kanamycin resistance gene 
AmpR: ampicillin resistance gene 
pUC ori: origin of replication 
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2.19.3.2.2. Interruption of adeS with pSK-1 and pSK-2 
Plasmids pSK-1 and pSK-2 were introduced separately into electrocompetent AB211 
cells (section 2.10). Transformants were selected on Iso-Sensitest agar plates 
containing 50 mg/L kanamycin. Chromosomal integration of pSK-1 and pSK-2 was 
confirmed by PCR (section 2.11.1) using primers M13 R and adeS TR (Tables 7 and 
8), an annealing temperature of 50°C, an extension time of two minutes and 5 µ1 of a 
crude DNA extract (section 2.3.2) to amplify products of 1292 bp and 1118 bp, 
respectively. The nucleotide sequences of these fragments were then determined 
(section 2.14). 
2.20. E. cloacae-specific methods 
2.20.1. Gene expression analysis in E. cloacae 
Expression of ramA and the acrAB operon was investigated using real-time RT-PCR 
as outlined in section 2.15, using primers ramA seqLC F and ramA seqLC R; acrB 
Fex and acrB Rex (Table 9) to amplify products of 185 bp and 92 bp, respectively. In 
both cases, expression was quantified relative to the RNA polymerase ß subunit gene, 
rpoB, using primers rpoB Fex and rpoB Rex (Table 9) to amplify a 147-bp product. 
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Table 9. Oligonucleotide primers used in this study with E. cloacae 
Primer name 
acrB Fex 
acrB KOF 
acrB KOR 
acrB KOT R 
acrB Rex 
EBGH3 
EBGNHe-5 
Full ramA F 
Gm F 
GmR 
Km2. lF 
Km2.1 R 
pBADseq F1 
pBADseq Rl 
pBADseq R2 
ramA CDS R 
ramA CDS RH 
ramA seqCDS F 
ramA seqLC F 
ramA seqLC R 
rpoB Fex 
rpoB Rex 
Sequence (5' to 3) 
CGATAACCTGATGTACATGTCC 
AGTGAAAGGCCAGCAGCTTA 
CATCCAGCACTTTCTGCGTA 
GAGAAACGAAGGCGATACCA 
CCGACAACCATCAGGAAGCT 
GGGAAGCTTATTATCGTGAGGATGCGTCA 
CCCGCTAGCGAAAAGATGTTTCGTGAAGC 
CTGGCAAAACACACCTGGAA 
TGGCGGCGTTGTGACAATTTAC 
TGGACGCACACCGTGGAAACGG 
GCTTACATGGCGATAGCTAGACT 
AGTTCGATGTAACCCACTCGTGC 
TCAGACATTGCCGTCACTGCG 
TCAGACCGCTTCTGCGTTCTG 
TCGACGGCGCTATTCAGATCCT 
TCAGTGCGTCCGACTATGGT'I"TTC 
TGAAGCTTTCAGTGCGTCCGACTATGGTTTTC 
ATGACGATTTCCGCTCAGGTC 
CCGTTACGCATCGAAGAGAT 
CCCAGACTTTCGCCTTTGTA 
AAGGCGAATCCAGCTTGTTCAGC 
TGACGTTGCATGTTCGCACCCATCA 
2.20.2. Insertional inactivation of E. cloacae genes 
Tm Source 
61 (72) 
64 this study 
64 this study 
64 this study 
66 (72) 
74 (41) 
77 (41) 
66 this study 
71 this study 
78 this study 
63 this study 
68 this study 
72 this study 
70 this study 
71 this study 
70 this study 
77 this study 
68 this study 
64 this study 
64 this study 
71 (72) 
79 (72) 
2.20.2.1. Disruption of acrB in the clinical isolate E. cloacae TGC-R 
The acrB gene was inactivated by the insertion of a linear DNA fragment containing a 
gentamicin resistance cassette as outlined below, using methods described previously 
by Perez et al. (200) with some modifications: 
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2.20.2.1.1. Preparation of electrocompetent cells of isolate E. cloacae TGC-R 
harbouring pKOBEG 
The helper plasmid pKOBEG (41) (Figure 15) was introduced into electrocompetent 
TGC-R cells by electroporation (section 2.10), and transformants were selected on LB 
agar plates containing 100 mg/L chloramphenicol during overnight incubation at 
30°C. Individual colonies were analysed by PCR for the presence of pKOBEG as 
outlined in section 2.11.1, using primers EBGNhe-5 and EBGh3 (Table 9), an 
annealing temperature of 60°C and an extension time of two minutes to amplify a 
1960-bp product. Plasmid DNA was used as a positive control, while 5 µl of a crude 
DNA extract (section 2.3.2) was used as template. 
Figure 15. Map of pKOBEG [adapted from Chaveroche et al. (41)]. 
Legend: 
cat: chloramphenicol resistance gene 
araC: regulatory gene (araBAD promoter) 
pBAD: araBAD promoter region 
gam, bet, exo: phage X Red functions 
repA 101 ts: temperature-sensitive replication 
oriR101: origin of replication 
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A single transformant was made electrocompetent as follows: 20 ml of 
modified LB broth (without NaCl) containing 100 mg/L chloramphenicol was seeded 
with 200 gl of an overnight culture of TGC-R harbouring pKOBEG and incubated at 
30°C with shaking (225 rpm). When the OD60o reached 0.2, the phage a. Red genes 
encoded by pKOBEG were induced by the addition of L-arabinose to a final 
concentration of 0.2% w/v. When the OD60o reached 1.0 the culture was centrifuged at 
4000 xg at 4°C for 10 minutes, the supernatant removed and the pellet re-suspended 
in 40 ml of cold sterile water and re-centrifuged as before. The final pellet was 
suspended in 90 gl of 15% sterile glycerol. 
2.20.2.1.2. Construction of pCRBK-2 
An internal 1558-bp fragment of the acrB gene was amplified by the Expand High 
Fidelity Plus PCR system (section 2.11.2) from TGC-R genomic DNA (-10 ng) using 
primers acrB Fex and acrB KOR (Table 9), an annealing temperature of 55°C and an 
extension time of 95 seconds. The resulting fragment was cloned into pCR2.1 (section 
2.16). Individual white colonies were analysed by PCR (section 2.11.1) for the 
presence of the acrB fragment using primers M13 F and M13 R (Table 7), an 
annealing temperature of 50°C, an extension time of 100 seconds, and 5 µl of a crude 
DNA extract (section 2.3.2). A single colony that was PCR-positive for the acrB 
fragment was grown overnight with shaking (225 rpm) at 37°C in LB broth containing 
100 mg/L ampicillin. Plasmid extractions were then performed as described in section 
2.6. The resulting plasmid was designated pCRBK-1 (Figure 16a). 
The gentamicin resistance cassette from cloning vector pBBR1MCS-5 was 
amplified by PCR using Pfu DNA polymerase (section 2.11.3), primers Gm F and Gm 
R (Table 9), an annealing temperature of 60°C and an extension time of two minutes. 
94 
The resulting 854-bp fragment was cloned into Nrul-digested pCRBK-1 (within the 
acrB fragment) to generate pCRBK-2 (Figure 16b). Briefly, pCRBK-1 was digested 
with 5U of Nrul for 4h at 37°C, treated with SAP for one hour at 37°C and ligated 
overnight at 15°C with the above fragment using T4 DNA ligase and a 1: 10 molar 
ratio of vector: insert DNA (section 2.17). The ligation was introduced into 
electrocompetent a-select E. coli (section 2.10.2) and transformants were selected on 
LB agar plates containing 10 mg/L gentamicin. Individual colonies were grown 
overnight with shaking (225 rpm) in LB broth containing 10 mg/L gentamicin. 
Plasmid extractions were then performed (section 2.6) and the plasmid preparations 
were examined for the presence of the gentamicin resistance cassette by agarose gel 
electrophoresis after digestion with EcoRI (5 U for 4h at 37°C). 
2.20.2.1.3. Inactivation of acrB with a linear DNA fragment 
The 2412-bp linear DNA fragment employed to interrupt acrB was amplified from 
pCRBK-2 using the internal acrB fragment primers detailed above, the Expand High 
Fidelity Plus PCR system (section 2.10.2), an annealing temperature of 55°C and an 
extension time of 150 seconds. The resulting PCR product was introduced into 
electrocompetent TGC-R:: pKOBEG cells (section 2.10) and transformants were 
selected on LB agar plates containing 10 mg/L gentamicin. Chromosomal integration 
of the gentamicin resistance cassette was confirmed by PCR (section 2.11.1) using 
primers Gm F and acrB KOT R (Table 9), an annealing temperature of 60°C, an 
extension time of 120 seconds and 5 . tl of a crude DNA extract (section 2.3.2) to 
amplify a 1405-bp product, the nucleotide sequence of which was then determined 
(section 2.14). 
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Figure 16a. Map of pCRBK-l. 
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Figure 16b. Map of pCRBK-2. 
Legend: 
acrB: internal fragment of acrB 
P: lac promoter/operator 
lacZ: lacZa gene 
Fl ori: Fl origin of replication 
KanR: kanamycin resistance gene 
AmpR: ampicillin resistance gene 
pUC ori: origin of replication 
GenR: gentamicin resistance gene 
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2.20.2.2. Disruption of acrB in clinical isolate E. cloacae EC391 
The acrB gene was inactivated by the insertion of the suicide plasmid, pRSACRB. 
2.20.2.2.1. Construction of pRSACRB 
An internal 1102-bp fragment of acrB was amplified from EC391 genomic DNA (-10 
ng) by PCR with Pfu DNA polymerase (section 2.11.3) using primers acrB KOF and 
acrB KOR (Table 9), an annealing temperature of 60°C and an extension time of 70 
seconds. Plasmid pSMY-2 (Figure 19b) was digested for 4h at 37°C with Xbal to 
yield two fragments, which were separated by agarose gel electrophoresis. The 2263- 
bp fragment was gel-purified (section 2.13) and end filled to create a blunt fragment 
by treatment with Pfu DNA polymerase for 10 minutes at 72°C. The fragment was 
then dephosphorylated by SAP treatment for 1h and then ligated with the acrB 
fragment using T4 DNA ligase at 15°C overnight and a 1: 10 molar ratio of vector: 
insert DNA (section 2.17). The ligation was introduced into electrocompetent pir+ E. 
coli as described in section 2.10.2. Transformants were selected on LB agar plates 
containing 50 mg/L kanamycin. Individual colonies were examined for the presence 
of the acrB fragment by PCR (section 2.11.1) using primers M 13 F and acrB KOR 
(Tables 7 and 9), an annealing temperature of 55°C, an extension time of 80 seconds, 
and 5 µl of a crude DNA extract (section 2.3.2). A single colony that was positive for 
the acrB fragment by PCR was grown overnight with shaking (225 rpm) in LB broth 
containing 50 mg/L kanamycin at 37°C. Plasmid extraction was performed as 
described in section 2.6. The resulting plasmid was designated pRSACRB (Figure 
17). 
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Figure 17. Map of pRSACRB. 
Legend: 
acrB: internal fragment of acrB 
IacZ: IacZa gene 
ccdB: lethal gene 
KanR: kanamycin resistance gene 
R6Ky ori: origin of replication 
2.20.2.2.2. Interruption of acrB with pRSACRB 
The suicide plasmid pRSACRB was introduced into electrocompetent E. cloacae 
EC391 cells (section 2.10) and transformants were selected on LB agar plates 
containing 25 mg/L kanamycin. Chromosomal integration of pRSACRB was 
confirmed by PCR (section 2.11.1) using primers MODS on R and acrB KOT R 
(Tables 7 and 9), an annealing temperature of 58°C, an extension time of 90 seconds, 
and 5 µl of a crude DNA extract (section 2.3.2) to amplify a 1540-bp product, the 
identity of which was confirmed by nucleotide sequencing (section 2.14). 
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2.20.3. Overexpression of ramA in clinical isolate E. cloacae TGC-S 
2.20.3.1. Cloning and sequencing of ramA and GenBank accession numbers 
A DNA fragment containing the ramA gene was amplified by PCR with Pfu DNA 
polymerase (section 2.11.3) from E. cloacae TGC-S, TGC-R and TGC-S7 genomic 
DNA (-10 ng) using primers Full ramA F and ramA CDS R (Table 9), an annealing 
temperature of 60°C and extension time of one minute to amplify a 517-bp product. 
The resulting products were cloned into pCR-Blunt (section 2.16). Individual white 
colonies were analysed for the presence of insert DNA by PCR (section 2.11.1) using 
primers M13 F and M13 R (Table 7), an annealing temperature of 50°C, an extension 
time of 45 seconds and 5 µl of a crude DNA extract (section 2.3.2). Single colonies 
that were positive for insert DNA of the correct size by PCR were grown overnight 
with shaking (225 rpm) in LB broth containing 50 mg/L at 37°C. Plasmid extractions 
were then performed (section 2.6) and the nucleotide sequences of the inserts were 
determined using the above primers and plasmid DNA as template (section 2.14). The 
nucleotide sequence data were deposited with GenBank with accession numbers 
GU180677 (TGC-S) and GU180678 (TGC-R). 
2.20.3.2. Construction of pBADKM and pBADKM-R 
The kanamycin resistance cassette from pCR2.1 was amplified by PCR with Pfu 
DNA polymerase (section 2.11.3) using primers Km2.1 F and Km2.1 R (Table 9), an 
annealing temperature of 60°C and an extension time of 150 seconds. The resulting 
1138-bp product was cloned into a modified version of the expression vector, pBAD 
(Invitrogen), in which the unique Ncol restriction site had been replaced with a unique 
SmaI site, yielding plasmid pBADS (Figure 18a). Plasmid pBADS was digested with 
5U of EcoRV for 4h at 37°C followed by SAP treatment for Ih at 37°C. Ligation 
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with the above PCR product was then performed using T4 DNA ligase overnight at 
15°C and a 1: 10 molar ratio of vector: insert DNA (section 2.17). The ligation was 
introduced into electrocompetent a-select E. coli (section 2.10) and transformants 
were selected on LB agar plates containing 50 mg/L kanamycin. Individual colonies 
were grown overnight with shaking (225 rpm) in LB broth at 37°C. Plasmid 
extractions were performed (section 2.6) and preparations were analysed for the 
presence of insert DNA by agarose gel electrophoresis after digestion with Smal (5 U) 
for 4h at 25°C. The resulting plasmid was designated pBADKM (Figure 18b). 
The ramA gene was amplified by PCR from TGC-R genomic DNA (-10 ng) 
with Pfu DNA polymerase (section 2.11.3) using primers ramA seqCDS F and ramA 
CDS RH (Table 9), an annealing temperature of 60°C and an extension time of one 
minute. The resulting 350 bp product was digested with Hindill for 4h at 37°C then 
purified as described in section 2.13. Plasmid pBADKM was also digested with 
Hindill as above, followed by a further digestion with Smal for 4h at 25°C. The 
above HindIlI-digested PCR product was then directionally cloned into HindIIIISmaI- 
digested pBADKM. Ligation was performed using T4 DNA ligase for 3h at room 
temperature and a 1: 3 molar ratio of vector: insert DNA (section 2.17). The ligation 
was introduced into a-select E. coli, and transformants were selected on LB agar 
plates containing 50 mg/L kanamycin. Individual colonies were screened by PCR 
(section 2.11.1) for the presence of the ramA insert using primers ramA seqCDS F and 
pBADseq R2 (Table 9), an annealing temperature of 60°C, an extension time of 30 
seconds and 5 µl of a crude DNA extract (section 2.3.2). A single colony that was 
positive for the ramA insert was grown overnight in LB broth containing 50 mg/L 
kanamycin. Plasmid extraction was then performed as outlined in section 2.6. The 
resulting plasmid, pBADKM-R (Figure 18c), was used to overexpress ramA in 
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clinical isolate E. cloacae TGC-S (section 2.20.3.3); vector pBADKM was used as a 
negative control. 
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Figure 18c. Map of pBADKM-R. 
Legend: 
ramA: global regulatory gene 
AmpR: ampicillin resistance gene 
pBR322 ori: origin of replication 
araC: regulatory gene (araBAD promoter) 
Kan R: kanamycin resistance gene 
PBAD: araBAD promoter region 
2.20.3.3. Overexpression of ramA in TGC-S using pBADKM-R 
Plasmids pBADKM and pBADKM-R were introduced separately into 
electrocompetent E. cloacae TGC-S cells, as outlined in section 2.10.2. 
Transformants were selected on LB agar plates containing 50 mg/L kanamycin. 
Individual colonies were screened for the presence of pBADKM or pBADKM-R, as 
appropriate, by PCR (section 2.11.1) using primers pBADseq FI and pBADseq RI 
(Table 9), an annealing temperature of 60°C, an extension time of one minute and 5 µl 
of a crude DNA extract (section 2.3.2) to amplify products of 486 bp and 833 bp, 
respectively. Single colonies that were positive for either pBADKM or pBADKM-R 
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were grown overnight with shaking (225 rpm) in LB broth containing 50 mg/L 
kanamycin. 
LB broth (10 ml) containing 50 mg/L kanamycin was then seeded with 100 µl 
of the overnight culture of TGC-S harbouring either pBADKM or pBADKM-R and 
incubated with shaking (225 rpm) at 37°C to mid-log phase (OD600 = 0.5). Expression 
of ramA was induced for 4h by the addition of L-arabinose to final concentrations of 
0.2,0.02,2 x 10"3, and 2x 10-4 % w/v. RNA extractions were then performed (section 
2.8) and expression of acrAB was monitored by real-time RT-PCR (section 2.19.1). 
2.21. S. marcescens-specific methods 
2.21.1. Gene expression analysis in S. marcescens 
Expression of the sdeAB, sdeCDE, and sdeXY efflux pump-encoding operons was 
monitored by real-time RT-PCR (section 2.15) using primers sdeB LC F and sdeB LC 
R; sdeD LC F and sdeD LC R; sdeY LC F and sdeY LC R (Table 10) to amplify 
products of 158 bp, 153 bp, 168 bp and 137 bp, respectively. Expression was 
quantified relative to the RNA polymerase ß subunit gene, rpoB, using primers Sma 
rpoB F and Sma rpoB R (Table 10) to amplify a 137 bp fragment. 
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Table 10. 
Primer name 
hasF check F 
hasF KOF 
hasF KOR 
sdeB LC F 
sdeB LC R 
sdeD LC F 
sdeD LC R 
sdeY KOR 
sdeY LC F 
sdeY LC R 
Sma rpoB F 
Sma rpoB R 
XYCDSR 
2.21.2. 
2.21.2.1. 
Oligonucleotide primers used in this study with S. marcescens 
Sequence (5' to 3') Tm 
GCAATGAGCCAGGCAGAGAA 68 
CATGTCGAAATGGCGCCAAC 71 
TTGTAGGCGTTGATGCTGCT 66 
AGATGGCCGATAAGCTGTTG 64 
CAGCGTCCAGCTTTCATACA 64 
AGCTTCATTCATCCGGTCAC 64 
CATGATGGCGTTCTTCTTCA 64 
CTGGTTACGCGCTTCGGTCAG 70 
TCCATCAACGAAGTGGTGAA 64 
GTTTATCGAGAAGCCGAACG 64 
CTAACGAGTATGGCTTCCTG 59 
CTTCTTCATCCAGGTTGGAG 61 
TCACTGAGCGATCAGTGG 61 
Insertional inactivation of S. marcescens genes 
Source 
this study 
this study 
this study 
this study 
this study 
this study 
this study 
this study 
this study 
this study 
this study 
this study 
this study 
Disruption of sdeY in the laboratory mutant 10211-10 
The sdeY gene was inactivated by the insertion of the suicide plasmid, pSMY2 as 
detailed below: 
2.21.2.1.1. Construction of the suicide plasmid pSMY2 
An internal 1095-bp fragment of sdeY was amplified by PCR with Pfu DNA 
polymerase (section 2.11.3) from mutant 10211-10 genomic DNA (-10 ng) using 
primers sdeY LC F and sdeY KOR, an annealing temperature of 60°C and an 
extension time of 120 seconds. The resulting fragment was cloned into pCR-Blunt 
(section 2.16). Individual white colonies were analysed by PCR (section 2.11.1) for 
the presence of insert DNA, using primers M13 F and M13 R (Table 7), an annealing 
temperature of 50°C, an extension time of 70 seconds and 5 µl of a crude DNA extract 
(section 2.3.2). A single colony that was positive for insert DNA by PCR was grown 
overnight with shaking (225 rpm) at 37°C in LB broth containing 50 mg/L 
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kanamycin. Plasmid extraction was then performed as outlined in section 2.6. The 
new plasmid was designated pSMY1 (Figure 19a). 
A 388-bp DNA fragment containing the R6Ky origin of replication and 
multiple cloning site (containing a unique Xbal site) from plasmid pMOD-5 (Cambio) 
was amplified by PCR with Pfu DNA polymerase (section 2.11.3), primers MODS on 
F and MODS on R (Table 7), an annealing temperature of 58°C, an extension time of 
one minute and -10 ng of extracted plasmid DNA. Plasmid pSMY-1 was sequentially 
digested (5 U for 4 h) with Smal (25°C) and SacI (37°C). The 3124-bp fragment 
resulting from Smal/Sacl digestion of pSMYI (containing the sdeY fragment and the 
kanamycin resistance cassette from pCR-Blunt, but not the pUC origin) was isolated 
by agarose gel electrophoresis and purified as described in section 2.13. This DNA 
fragment was then treated with Pfu DNA polymerase (section 2.20.2.2.1) to yield a 
blunt-ended fragment and ligated to the above PCR product using T4 DNA ligase; 
overnight incubation at 15°C and a 1: 10 molar ratio of vector: insert DNA (section 
2.17). The ligation was introduced into electrocompetent pir+ E. coli (section 2.10.2) 
and transformants were selected on LB agar plates containing 50 mg/L kanamycin. 
Individual colonies were screened for the correct orientation of the R6Ky origin of 
replication / multiple cloning site by PCR (section 2.11.1) using primers M 13 F and 
MODS on R (Table 7), an annealing temperature of 55°C, an extension time of 90 
seconds and 5µl of a crude DNA extract (section 2.3.2). A single colony with the 
correct R6Kyori orientation was grown overnight at 37°C in LB broth containing 50 
mg/L kanamycin. The new plasmid, pSMY2 (Figure 19b) was extracted as described 
in section 2.6. 
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Figure 19b. Map of pSMY2. 
Legend: 
sdcY: internal fragment of sdeY 
lacZ: lacZa gene 
ccdB: lethal gene 
KanR: kanamycin resistance gene 
R6Ky ori: origin of replication 
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2.21.2.1.2. Interruption of sdeY with pSMY2 
The suicide plasmid pSMY2 was introduced into electrocompetent 10211-10 (section 
2.10) and transformants were selected on LB agar plates containing 25 mg/L 
kanamycin. Chromosomal integration of pSMY2 was confirmed by PCR (section 
2.11.1) using primers M13 F and XY CDS R (Tables 6 and 9), an annealing 
temperature of 55°C, an extension time of 140 seconds and 5 µd of a crude DNA 
extract (section 2.3.2). The identity of the resulting 2260 bp product was confirmed by 
nucleotide sequencing (section 2.14). 
2.21.2.2. Disruption of hasF in the laboratory mutant S. marcescens 10211- 
10 
The hasF gene was interrupted by a suicide plasmid pHASF. 
2.21.2.2.1. Construction of the suicide plasmid pHASF 
An internal 803-bp fragment of hasF was amplified from S. marcescens 10211-10 
genomic DNA (410 ng) by PCR with Pfu DNA polymerase (section 2.11.3), using 
primers hasF KOF and hasF KOR (Table 10), an annealing temperature of 60°C and 
an extension time of two minutes. The sdeY fragment of plasmid pSMY-2 (Figure 
19b) was then replaced with the fragment of hasF, as described in section 2.19.2.2.1. 
Individual colonies were screened by PCR (section 2.11.1) for the presence of hasF 
using primers hasF KOF and MODS on R (Tables 10 and 7), an annealing 
temperature of 58°C, an extension time of 70 seconds and 5 µl of a crude DNA extract 
(section 2.3.2). A single colony that was positive by PCR for the hasF insert was 
grown overnight with shaking (225 rpm) at 37°C in LB broth containing 50 mg/L 
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kanamycin. Plasmid pHASF (Figure 20) was then extracted as described in section 
2.6. 
dý 
ý 
f) 
ý n ý 
kann 
"I/ 
Figure 20. Map of pHASF. 
Legend: 
hasF: internal fragment of hasF 
lacZ: lacZa gene 
ccdB: lethal gene 
KanR: kanamycin resistance gene 
R6Ky ori: origin of replication 
2.21.2.2.2. Interruption of hasF with pHASF 
The suicide plasmid pHASF was introduced into electrocompetent S. marcescens 
10211-10 cells (section 2.10) and transformants were selected on LB agar plates 
containing 25 mg/L kanamycin. Chromosomal integration of pHASF was confirmed 
by PCR (section 2.11.1) using primers hasF check F and MODS on R (Tables 10 and 
7), an annealing temperature of 58°C, an extension time of 80 seconds and 5 µl of a 
crude DNA extract (section 2.3.2). The identity of the resulting 1372-bp product was 
confirmed by nucleotide sequencing (section 2.14). 
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2.22. Software packages used to analyse data and prepare figures 
2.22.1. Analysis of DNA and protein sequence data 
DNA and protein sequence data were analysed using BioEdit version 7.0.5.3 
(http: //www. mbio. ncsu. edu/BioEdit/page2. html). In some instances, primers were 
designed using Primer3 version 0.4.0 (http: //frodo. wi. mit. edu/primer3/). 
2.22.2. Figure preparation and statistical analysis 
Plasmid maps and other drawings were prepared using Carbon Outlines version 1.1 
(Go Figure Solutions, Bootle, UK). Sequence alignment figures were prepared using 
GeneDoc version 2.7.0 (http: //www. nrbsc. org/gfx/genedoc/). All graphs were 
prepared and statistical analyses performed using GraphPad Prism version 5.0 
(GraphPad Software, La Jolla, Ca., USA). 
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3. Results 
3.1. A. baumannii 
Clinical isolates of A. baumannii displaying reduced susceptibility or resistance to 
tigecycline were being referred to the HPA's ARMRL as early as 2004, two years 
before a marketing authorisation was granted by the EMA in 2006. 
Many of the A. baumannii clinical isolates in ARMRL's collection are 
members of two prevalent European clone II lineages, namely OXA-23 clone 1 (49) 
and the SE clone (259). In the United States, a carbapenem-resistant A. baumannii 
clone, ACB20 has caused a multicity outbreak since 2005 largely in the state of 
Illinois (154). These clones were of particular interest for two reasons. Firstly, apart 
from polymyxins, tigecycline is usually one of the only therapeutic options available 
for treating infections caused by carbapenem-resistant A. baumannii. Secondly, 
although the three clones differ in their modal tigecycline MICs; the molecular basis 
of this variation was unclear. In order to study this latter observation, multiple 
representatives of the two UK clones, referred from numerous centres between 2004 
and 2008, were selected from ARMRL's collection (these were selected as having the 
typical [modal] MICs for the clones) and representatives of the ACB20 clone were 
provided by Dr John Quinn (Table 2). 
The mechanisms of tigecycline resistance also were investigated in two 
instances where resistance emerged during tigecycline therapy in representatives of 
OXA-23 clone 1. The emergence of tigecycline resistance in this lineage during 
therapy was, and indeed remains, an issue of considerable public health importance 
that justifies further investigation. Details of the two clinical cases are outlined below. 
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3.1.1. Clinical case reports 
3.1.1.1. Case 1 
MDR A. baumannii (MDRAB; designated AB210), susceptible (by the hospital's own 
testing and confirmed by ARMRL) only to colistin and tigecycline, was isolated from 
abdominal drain fluid from a patient admitted to a London hospital ICU in 2005. The 
patient had a complicated stay, having developed an intra-abdominal infection 
following a cholecystectomy, requiring several courses of antibiotics, based on 
microbiology and clinical status. Tigecycline-susceptible MDRAB was repeatedly 
isolated from abdominal fluid so, when the patient became septic again, tigecycline 
was commenced at the standard regimen; a loading dose of 100 mg, followed by 50 
mg twice daily. As intra-abdominal infection this constituted on-label use. After one 
week of therapy, a tigecycline-resistant A. baumannii isolate (designated AB211) was 
recovered from the same site. Despite the microbiological failure of tigecycline 
therapy, the patient subsequently went on to make a full recovery. 
3.1.1.2. Case 2 
A patient presented to a London hospital with an infected femoral haematoma. Tissue 
samples grew mixed `coliforms' and anaerobes and the patient was treated 
empirically with amoxicillin / clavulanic acid. Three weeks following admission the 
patient developed profound sepsis and multi-organ failure; antibiotics were changed 
to meropenem. Following a period of apparent recovery, the patient then developed 
acute necrotic pancreatitis and a further episode of severe sepsis. Despite receiving 
five days of intravenous vancomycin, ciprofloxacin and amikacin an intra-abdominal 
collection developed and tigecycline-susceptible MDRAB (designated W6976) was 
isolated from a line tip. The patient was treated with amikacin (W6976 was resistant 
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to this agent) and tigecycline (50 mg twice daily following a loading dose of 100 mg) 
and pus drained from the collection yielded a pure growth of MDRAB. This and a 
further isolate (designated W7282) obtained six days later at a second drainage 
procedure were tigecycline-resistant. Tigecycline was replaced with intravenous 
colistin and therapy was continued for a further two weeks. The patient made a slow 
recovery and was eventually discharged home four months after initial admission. 
3.1.2. Isolate characterisation and antibiotic susceptibilities 
All isolates were identified as the A. calcoaceticus-A. baumannii complex by 
API20NE and were positive by PCR for the blaoxA-5I-uke gene, confirming them as A. 
baumannii (261). Isolates were identified as representatives of either the SE clone, 
OXA-23 clone 1 or the USA clone ACB20 by PFGE, which was also used to confirm 
the parentage of mutants selected in vitro (Figure 21). 
3.1.2.1. OXA-23 clone 1, SE clone and ACB20 clone representatives 
Tigecycline MICs for nine representative isolates of OXA-23 clone 1 and eight of the 
SE clone were 0.25 and I mg/L, respectively, representing the mode (± 1 two-fold 
dilution) for these lineages (49; 259); those for five representatives of the USA clone 
ACB20 were 2 mg/L (three isolates) or 4 mg/L (two isolates) (Table 11). 
3.1.2.2. Case study isolates 
Laboratory mutants with elevated tigecycline MICs were selected for by exposing 
susceptible isolates to tigecycline in vitro, in a step-wise fashion, until no further 
growth was observed (Materials and Methods section 2.18). This then allowed for 
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comparative investigations of efflux resistance mechanisms in the laboratory-selected 
and wild-type tigecycline-resistant mutants. 
The post-therapy clinical isolate from case 1, AB211 (tigecycline MIC, 16 mg/L) and 
the final laboratory mutant AB210-6 (tigecycline MIC, 64 mg/L) showed 32- and 
128-fold increases in tigecycline MIC, respectively, compared with the pre-therapy 
parent isolate AB210 (MIC, 0.5 mg/L). Similarly, there was a 16-fold increase in MIC 
for the post-therapy isolate W7282, from case 2 (MIC, 8 mg/L) compared with the 
pre-therapy isolate W6976 (MIC, 0.5 mg/L; Table 11) from the same patient. PFGE 
profiles were consistent within each of the two clinical series (Figure 21 a and 21 b), as 
were the profiles of the laboratory mutant, AB210-6 and its parent clinical isolate, 
AB210 (Figure 21c). 
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a. 
b. 
C. 
Figure 21. PFGE profiles of A. baumannii clinical isolates and mutants: (a) 
clinical isolates AB210 and AB211; (b) clinical isolates W7282 and W6976; (c) 
AB210 and mutant AB210-6. 
Interestingly, AB211 (though not the laboratory mutant, AB210-6) displayed a 
> 16-fold reduction in the MICs of tobramycin and amikacin and at least a four-fold 
reduction in the MIC of gentamicin compared with AB210 (Table 11). Further 
characterisation of this clinical pair by ARMRL and the Laboratory of HealthCare 
Associated Infection (LHCAI) revealed that isolate AB211 was negative by PCR for 
two distinct aminoglycoside resistance determinants, both of which were present in 
isolate AB210 (Turton, J. and Woodford, N., personal communication). The first of 
these, an aminoglycoside acetyltransferase gene, aacA4, which is located on a class I 
integron associated with the OXA-23 clone I lineage, is known to confer resistance to 
amikacin and tobramycin (258). The second, a 16S rRNA methylase gene, armA, 
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confers high-level resistance to all three tested aminoglycosides, as well as all other 
4,6-disubstituted deoxystreptamines (92). These observations probably explain the 
differences in aminoglycoside resistance phenotypes of the two isolates. 
There were also reductions of at least eight-fold in carbapenem MICs and a 
four-fold reduction in ceftazidime MIC for mutant AB210-6 compared with AB210 
(Table 11). Both the mutant and parent were positive for blaoxA_23 by PCR (Turton, J., 
personal communication) and the reasons for the difference in their MICs warrant 
further investigation; there were no similar MIC reductions within the two clinical 
pairs. 
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3.1.3. Analysis of expression of the efflux pump-encoding operon adeABC and 
the regulatory operon adeRS using real-time RT-PCR 
Reduced susceptibility and resistance to tigecycline in A. baumannii clinical isolates 
has to date been associated with up-regulation of the chromosomally-encoded RND- 
type efflux system AdeABC (197; 223), which is regulated by the two-component 
signal transduction system AdeRS (164). 
3.1.3.1. Analysis of adeABC expression in OXA-23 clone 1, SE clone and 
ACB20 clone representatives 
To investigate whether differential expression of the RND-type efflux pump-encoding 
operon adeABC correlated with differences in the modal tigecycline MICs for the 
three A. baumannii clones, expression of this operon was monitored in multiple 
representatives of each lineage. Real-time RT-PCR (Materials and Methods sections 
2.15 and 2.19.2) identified a mean six-fold higher level of adeABC expression in 
isolates of the SE clone than those belonging to OXA-23 clone 1 (Figure 22; p= 
<0.001). Comparison to the ACB20 clone was more complicated owing to differences 
in tigecycline MIC among individual isolates; however, when the isolates were 
analysed separately, there was an association between a higher MIC and elevated 
adeABC expression (Figure 23). 
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0.08, 
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0.04ý 
0.02-1 
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Or. OXA-23 clone 1 SE 
Clone 
0.25 1 
Modal TGC MIC (mg/L) 
Figure 22. Expression of adeABC relative to that of rpoB (means ± standard 
deviations) in multiple isolates of two epidemic clones. OXA-23 clone 1: nine 
isolates; range = 0.006 - 0.012. SE clone: eight isolates; range = 0.015 - 0.082. Modal 
tigecycline (TGC) MICs are shown. Mann-Whitney test; p= <0.001. 
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Figure 23. Expression of adeABC relative to that of rpoB (means ± standard 
deviations) in five isolates of the ACB20 clone. Tigecycline (TGC) MICs are shown. 
3.1.3.2. Analysis of adeABC expression in mutants selected in vivo and in 
vitro 
Overexpression of adeABC was also evident in both post-therapy isolates, and in the 
laboratory mutant compared with the pre-therapy isolates. There were mean 50- and 
407-fold increases in AB211 and AB210-6, respectively, compared with AB210 
(Figure 24), and a mean nine-fold increase in W7282 compared with W6976 (Figure 
25). No difference in expression of the regulatory operon, adeRS was seen between 
AB210 and AB211 (Figure 26). 
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Figure 24. Expression of adeABC relative to that of rpoB (means I standard 
deviations) in the pre- and post-therapy clinical isolates AB210 and AB211, the 
laboratory-selected mutant AB210-6. Tigecycline (TGC) MICs are shown. 
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Figure 25. Expression of adeABC relative to that of rpoB (means + standard 
deviations) in the pre- and post-therapy clinical isolates W6976 and W7282. 
Tigecycline (TGC) MICs are shown. 
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Figure 26. Expression of adeRS relative to that of rpoB (means + standard 
deviations) in the pre- and post-therapy clinical isolates AB210 and AB211. 
Tigecycline (TGC) MICs are shown. 
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3.1.4. Effect of varying concentrations of MnSO4 on adeABC expression and 
tigecycline MICs in the clinical isolates AB210 and AB211 
Manganese levels in Mueller-Hinton (MH) agar produced by different manufacturers 
can vary dramatically (82). This variation is known to affect tigecycline MICs for A. 
baumannii and other bacterial species where, in general, higher levels of manganese 
correlate with increased MICs (82; 250). It is, however, unclear exactly how 
manganese influences tigecycline activity in vitro. To investigate the effects of 
manganese concentration on adeABC expression, clinical isolates AB210 and AB211 
were grown in Iso-Sensitest broth supplemented with varying concentrations of 
MnSO4. Addition of 1 mg/ml MnSO4 resulted in elevated (four-fold) tigecycline 
MICs and increased expression (two-fold) of adeABC in both clinical isolates. 
However, further increases in supplemental MnSO4 (to a final concentration of 2 
mg/ml; approximately 0.72 mg/ml free Mn2+) did not result in further increases in 
MIC or adeABC expression in isolate AB210, and led to reduced expression of 
adeABC in isolate AB211 without a concurrent reduction in tigecycline MIC (Figure 
27). 
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3.1.5. Nucleotide sequencing of the adeRS operon 
Nucleotide sequence analysis of the regulatory operon adeRS in three representatives 
each of the SE clone and OXA-23 clone 1 revealed a difference at amino acid 62 of 
the sensor histidine kinase, AdeS, with methionine at this position in OXA-23 clone 
1 
and isoleucine in the SE clone (Figure 28). 
Isoleucine is present at this position in all AdeS sequences available in 
GenBank (accession numbers: ADM92606; ADM92604; ABX83930; ABX83928; 
ABX83924; ABX83922; ABX83920; ADP20500; ADP20498; ADP20496; 
ADP20494; ADP20492; ADP20490; ADP20488; ADP20486; ADP20484; 
ADP20482; ADP20480; ADP20478; ADP20476; ADP20474; ADP20472; 
ADP20470; ADP20468; ACM50741; ABQ57261; ABQ57260; ABQ57259; 
ABQ57258; CAJ77841; ABX83926; ACJ41457; AAR14190; YP 002319440; 
ACJ57418; YP_002325608; ABO12181; ZP_05827208; EEX04826; ZP_04661879; 
ZP07240373; ZP_07235152; ZP 07225668; ZP 06797232; ZP 06781464; 
AAL14443; CAM86703; YP_001713700). 
There were no differences in the amino acid sequences of the response 
regulator, AdeR. 
The adeRS operon was also sequenced in both clinical pairs and the 
mutant AB210-6. An Ala-94-*Val substitution in AdeS was found in the resistant 
clinical isolate AB211 compared with its parent AB210 (Figure 28). Two amino acid 
substitutions were detected in the laboratory mutant AB210-6: Gly-103--*Asp in 
AdeS (Figure 16) and Ala-91-*Val in AdeR (Figure 29). It is notable that the G--*A 
mutation responsible for the latter change was located immediately up-stream of the 
putative -10 promoter sequence of the adeABC operon, located within the adeR 
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coding region (164). A single substitution in AdeS, Ser-8-+Arg, was detected in 
W7282 compared with W6976 though no differences were detected in the response 
regulator, AdeR. 
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* 20 * 40 * 60 
AB210 MKSKLGISKQLFIALTIVNLSVTLFSVVLGYVIYNYAIEKGWISLSSFQQEDWTSFHFVD 
AB211 ............................................................ 
AB210-6 ............................................................ 
SE ............................................................ 
* 80 * 100 * 120 
AB210 : WMWLA'TVIFCGCIISLVIGMRLAKRFIVPINFLAEAAKKISHGDLSAR. AYDNRIHSAEMS 
Aß211 ................................. V.......................... 
AB210-6 .......................................... D ................. 
SE . .I.......................................................... 
* 140 * 160 * 180 
AB210 ELLYNFNDMAQKLEVSVKNAQVWNAAIAHELRTPITILQGRLQGIIDGVFKPDEVLFKSL 
AB211 ............................................................ 
AB210-6 . ............................................................ 
SE ............................................................ 
* 200 * 220 * 240 
AB210 LNQVEVLSHLVEDLRTLSLVENQQLRLNYELFDFKAVVEKVLKAFEDRLDQAKLVPELDL 
AB211 ............................................................ 
AB210-6 : ..................................................... 
SE : ............................................................ 
* 260 * 280 * 300 
AB210 : TSTPVYCDRRRIEQVLIALIDNAIRYSHAGKLKISSEVVSQNWILKIEDEGPGIATEFQD 
AB211 ............................................................ 
AB210-6 ............................................................ 
SE ............................................................ 
* 320 * 340 * 
AB210 : DLFKPFFRLEESRNKEFGGTGLGLAVVHAIIVALKGTIQYSNQGSKSIFTIKISMNN 
AB211 ......................................................... 
AB210-6 ......................................................... 
SE . ......................................................... 
Figure 28. Amino acid sequence alignment of the sensor histidine kinase, AdeS in 
AB210, AB211, AB210-6 (OXA-23 clone 1) and all SE clone isolates (n=3). 
Transmembrane helical regions are underlined. The conserved histidine residue that is 
the site of autophosphorylation is shown emboldened in red. 
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* 20 * 40 * 60 
AB210 : MFDHSFSFDCQDKVILVVEDDYDIGDIIENYLKREGMSVIRAMNGKQAIELHASQPIDLI 
AB210-6 
* 80 * 100 * 120 
AB210 : LLDIKLPELNGWEVLNKIRQKAQTPVIMLTALDQDIDKVMALRIGADDFVVKPFNPNEVI 
AB210-6 .............................. 
V............................. 
* 140 * 160 * 180 
AB210 : ARVQAVLRRTQFANKVTNKNKLYKNIEIDTDTHSVYIHSENKKILLNLTLTEYKIISFMI 
AB210-6 ............................................................ 
* 200 * 220 * 240 
AB210 : DQPHKVFTRGELMNHCMNDSDALERTVDSHVSKLRKKLEEQGIFQMLINVRGVGYRLDNP 
AB210-6 ............................................................ 
AB210 : LAVKDDA 
AB210-6 ....... 
Figure 29. Amino acid sequence alignment of the response regulator, AdeR in 
AB210 and AB210-6. The conserved aspartic acid residue (phosphorylation site) is 
shown emboldened in red. 
3.1.6. Interruption of genes in A. baumannii 
A. baumannii genes were disrupted by the targeted integration via homologous 
recombination of suicide plasmids containing internal fragments of the target genes 
(Materials and Methods section 2.19.3). Previous studies employed suicide vectors 
containing the pUC origin of replication to inactivate genes in this species 
(160; 164; 223). An overview of the strategy used here is shown in Figure 30. 
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Internal fragment of target gene PCR- 
amplified and cloned into pCR2.1 
L--ºI Introduced into AB211 by electroporation 
Transformants selected on Iso-Sensitest agar plates 
containing kanamycin 
Chromosomal integration confirmed by PCR and sequencing 
Figure 30. Overview of strategy used to interrupt genes in the clinical isolate 
AB211. 
3.1.6.1. adeB 
The RND efflux pump gene adeB was targeted for inactivation in the post-therapy 
clinical isolate, AB211 using suicide plasmid, pBK-5 (Figure 13), to assess fully the 
role of the AdeABC efflux system in the emergence of tigecycline resistance. 
Aminoglycoside susceptibility in AB211 (kanamycin MIC, 4 mg/L) - most likely due 
to the loss of armA - allowed the kanamycin resistance cassette encoded by pBK-5 to 
be used as the selectable marker. The integration of pBK-5 into the chromosome was 
confirmed by PCR followed by sequencing across the site of insertion (Figure 31). 
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Figure 31. Confirmation of the chromosomal insertion of pBK-5: (a) schematic of 
pBK-5 insertion displaying the primers used to perform PCR across the insertion site; 
(b) agarose gel electrophoresis displaying a 1-Kb DNA ladder in lane I and the 3040- 
bp PCR product in lane 2. 
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Interruption of adeB in the resistant clinical isolate, AB211 with plasmid pBK- 
5 restored full susceptibility to tigecycline (MIC, 0.5 mg/L; Table 12 and Figure 32). 
The PFGE profiles of AB21 I and AB21 I AadeB were consistent (Figure 33). 
Figure 32. Tigecycline Etest performed on clinical isolate AB211 and mutant 
AB2110adeB. 
AB211 AadeB I It %-ý 1x 1A 1I 1, 
AB211 ý IN W 
.. s t" ttS 
Figure 33. PFGE profiles of A. baumannii clinical isolate AB21 1 and derivative 
AB2110adeB. 
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3.1.6.2. adeS 
The regulation of adeABC was investigated in clinical isolate AB211 by the targeted 
disruption of the sensor histidine kinase gene, adeS with the suicide plasmids pSK-1 
(Figure 14a) and pSK-2 (Figure 14b). These plasmids were introduced separately into 
electrocompetent AB211 cells. As with the pBK-5 insertion described above, 
chromosomal integration of pSK-1 and pSK-2 was confirmed by PCR, followed by 
sequencing across the site of insertion (Figure 34). 
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Figure 34. Confirmation of the chromosomal insertion of pSK-1 and pSK-2: (a) 
schematic of pSK-1/2 insertion displaying the primers used to perform PCR across the 
insertion site; (b) agarose gel electrophoresis displaying a 1-Kb DNA ladder in lane I 
and the 1292-bp PCR product in lane 2 (pSK-1); (c) agarose gel electrophoresis 
displaying a 1-Kb DNA ladder in lane 2 and the 1118-bp PCR product in lane I (pSK- 
2). 
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Surprisingly, inactivation of adeS in the tigecycline-resistant isolate, AB211 
with either pSK-1 or pSK-2 did not affect tigecycline MICs. Previous work has 
suggested that this gene is essential for the expression of adeABC (164) and hence 
tigecycline resistance. Though chromosomal integration of these plasmids within 
adeS was confirmed by PCR and sequencing, it was still possible to PCR-amplify the 
entire, intact adeRS operon from both derivatives. Single colonies were positive both 
for plasmid integration and intact adeS, making interpretation of the phenotypic 
observations difficult. The reasons for this are unclear. It may be that the 
chromosomal insertions were unstable. Since the organisms were maintained under 
selective pressure, this would imply that such cells retained the plasmid extra- 
chromosomally. 
Unsuccessful attempts were made to generate a more stable adeS insertion 
derivative where only the selectable marker gene was integrated, a process that 
required a double homologous recombination event. Initially, theses attempts were 
made using the phage A. Red recombination system encoded by pKOBEG, which was 
used successfully to inactivate acrB in the E. cloacae clinical isolate TGC-R (section 
3.2.5.1). For this purpose, attempts were made to clone the phage A. Red genes into the 
E. coli / A. baumannii shuttle vector pAT-RA (63). However, the insertion proved 
problematic and after efforts to optimise the cloning experiments failed, the strategy 
was abandoned. 
Secondly, attempts were made to construct suicide plasmids using the pUC 19 
cloning vector containing a kanamycin resistance cassette flanked by regions 
complementary to adeS and the negative selectable marker gene, ccdB, which 
encodes a toxin that interferes with DNA gyrase activity, leading to cell death (26). 
Cloning of the ccdB gene failed despite using a CcdB-resistant commercial strain of 
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E. coli. Attempts to clone a second selectable marker gene, sacB from Bacillus 
subtilis were successful. The sacB gene encodes levansucrase, a fructosyltransferase 
that utilises sucrose to catalyse the synthesis of levan (a fructose polymer) and is 
involved in sucrose metabolism in B. subtilis, but which is lethal to E. coli in the 
presence of 5% sucrose (93). This was considered to be a better negative marker 
candidate since, unlike ccdB, the sacB gene product is not lethal unless the growth 
medium is supplemented with sucrose. Initial investigations demonstrated that the 
sacB gene was fit for purpose as it was lethal to clinical isolate, AB211 only in the 
presence of 5% sucrose. Unfortunately, time constraints meant that this strategy could 
not be developed further. 
3.2. E. cloacae 
The HPA's ARMRL has been receiving isolates of E. cloacae displaying reduced 
susceptibility and resistance (MICs ?2 mg/L) to tigecycline since 2005. Again, these 
included instances where resistance emerged during therapy and / or where pairs of 
clonally related isolates displayed a susceptible / resistant phenotype. Two such cases 
are described below. The molecular basis of tigecycline resistance was investigated 
using these clinical pairs and laboratory-selected mutants. 
3.2.1. Clinical case reports 
3.2.1.1. Case 3 
In 2006, a patient presented to a London hospital with a ten-day history of 
progressively increasing back pain, high fever (40°C) and swelling over the spine. The 
patient had undergone two previous operations for stabilisation of a lumbar spinal 
fracture, 20 months, followed by a revision 16 months, prior to this event. An 
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aspirate revealed two colony variants of E. cloacae, which varied 
in their antibiotic 
susceptibility patterns. Both appeared sensitive to ciprofloxacin, and an initial 
empirical regimen was changed to ciprofloxacin (400 mg every 12 h intravenous) on 
day four after admission. A definitive surgical procedure was performed three days 
later and one litre of pus and all the metalwork (eight screws and plates) were 
removed. The same organisms were isolated again but they now showed changes in 
antibiotic resistance patterns, with one variant now resistant to ciprofloxacin 
(designated TGC-R) and the other remaining susceptible (designated TGC-S). This 
pair of isolates was referred to the HPA's ARMRL, where the ciprofloxacin-resistant 
isolate was found also to be resistant also to tigecycline. Ciprofloxacin was 
subsequently replaced with meropenem after eight days and the patient slowly 
recovered after several months of carbapenem therapy. The original source of the 
infection was not established. 
3.2.1.2. Case 4 
A patient presented to a hospital in North-West England in 2009 with a three-day 
history of upper abdominal pain. Acute cholecystitis was diagnosed and was managed 
with intravenous piperacillin / tazobactam. The patient was admitted for an elective 
laparoscopy 16 days after initial presentation following an ultrasound, which revealed 
dilatation of the biliary tree and a gallstone impacted at the neck of the gall bladder. 
At laparoscopy, a pneumoperitoneum was seen and the surgery was modified to an 
open cholecystectomy. This was complicated by malrotation of the gut but drains 
were placed and the patient made a good post-operative recovery. However, two days 
after surgery the patient became septic and complained of abdominal pain and so 
underwent a laparotomy where a bowel leak was discovered. An endoscopic 
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retrograde cholangiopancreatography was performed the next day with large 
sphincterotomy. Spiking pyrexia led to the piperacillin / tazobactam therapy being 
restarted but as the organism cultured from drain fluid was resistant, and the patient 
was switched to ciprofloxacin and metronidazole. On day 10 post-surgery the patient 
developed severe Clostridium difficile infection and was commenced on oral 
vancomycin. Despite this management they continued to have spiking pyrexia and a 
CT scan revealed a large psoas collection which was drained percutaneously. Further 
collections could not be drained and the patient was transferred to another hospital 33 
days after admission for CT-guided drainage. This took place two days later and two 
variants of E. cloacae (designated EC390 and EC391) were isolated from drain fluid. 
Tigecycline therapy was started the next day, but was discontinued amid concerns of 
resistance. The pair of E. cloacae isolates was referred to the HPA's ARMRL, where 
tigecycline resistance was confirmed in one of them (EC391), whereas the other 
(EC390) was tigecycline-susceptible. The patient then received a combination of 
teicoplanin and ertapenem and their condition slowly improved until they were 
eventually discharged nearly four months after initial presentation. The patient 
subsequently went on to make a good recovery. 
3.2.2. Isolate characterisation and antibiotic susceptibilities 
All clinical isolates were identified as E. cloacae by API20E. MICs of ciprofloxacin 
and tigecycline were eight-fold higher for the clinical isolate, TGC-R (4 mg/L for 
both compounds) than for TGC-S (both 0.5 mg/L; Table 13). Although this clinical 
pair did not have identical PFGE profiles, analysis of the intermediate laboratory- 
selected mutants derived from TGC-S (Materials and Methods section 2.18) showed 
an analogous transition from the tigecycline-susceptible to the tigecycline-resistant 
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profile; moreover, the PFGE profile of the final laboratory-selected mutant TGC-S7 
(ciprofloxacin MIC, 4 mg/L; tigecycline MIC, 32 mg/L) was indistinguishable from 
that of clinical isolate, TGC-R (Figure 35a). MICs of chloramphenicol, minocycline, 
and tetracycline also were raised for TGC-R and TGC-S7 relative to TGC-S, whereas 
those of ß-lactams were unaffected, although that of cefpirome was high already (8 
mg/L), possibly reflecting AmpC-activity, as based on interpretive reading of wider 
antibiogram data (Table 13). Interestingly, the laboratory mutant, TGC-S7 displayed a 
four-, eight- and 16-fold reduction in the MICs of ceftazidime, aztreonam and 
cefotaxime, respectively, when compared with the parent clinical isolate, TGC-S 
(Table 13). The reasons for these reductions in the MICs are unknown though it is 
striking that similar reductions were observed for the laboratory-selected A. 
baumannii mutant AB210-6 (section 3.1.2.2. ). 
Tigecycline and minocycline MICs were increased 16- and eight-fold, 
respectively, in clinical isolate, EC391 when compared with isolate, EC390 (Table 
13). In contrast with the isolates described above, there was only a two-fold increase 
in the MIC of ciprofloxacin between EC390 and EC391. The PFGE profiles of the 
two clinical isolates were identical (Figure 35b). 
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Figure 35. PFGE profiles of E. cloacae clinical isolates and mutants: (a) TGC-S, 
TGC-R and all laboratory-selected mutants; (b) EC390 and EC391. 
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3.2.3. Analysis of expression of the efflux pump-encoding operon acrAB and the 
global regulatory gene ramA in clinical isolates and a laboratory mutant 
using real-time RT-PCR 
To date, tigecycline resistance in E. cloacae has been associated with up-regulation of 
the RND efflux system AcrAB and the global regulator, RamA (127). Expression of 
acrAB and ramA was analysed by real-time RT-PCR (Materials and Methods sections 
2.15 and 2.20.1). 
Relative to the tigecycline-susceptible isolate, TGC-S, expression of acrAB 
and ramA was increased four- and 276-fold, respectively, in isolate TGC-R and nine- 
and 407-fold, respectively, in the laboratory mutant, TGC-S7 (Figures 36 and 37). 
Expression of acrAB was increased five-fold in the post-therapy clinical isolate 
EC391 when compared with its pre-therapy parent, EC390 (Figure 38). Expression of 
ramA in isolates EC390 and EC391 was not investigated. 
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15-1 
TGC-S TGC-R TGC-S7 
Isolate 
0.5 4 32 
TGC MIC (mg/L) 
Figure 36. Expression of acrAB relative to that of rpoB (means ± standard 
deviations) in the clinical isolates TGC-S and TGC-R, the laboratory mutant TGC-S7. 
Tigecycline (TGC) MICs are shown. 
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TGC-S TGC-R TGC-S7 
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i 
Figure 37. Expression of ramA relative to that of rpoB (means ± standard 
deviations) in the clinical isolates TGC-S and TGC-R, the laboratory mutant TGC-S7. 
Tigecycline (TGC) MICs are shown. 
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II 
EC390 EC391 
Isolate 
0.5 8 
TGC MIC (mg/L) 
Figure 38. Expression of acrAB relative to that of rpoB (means ± standard 
deviations) in the clinical isolates EC390 and EC391. Tigecycline (TGC) MICs are 
shown. 
3.2.4. Overexpression of ramA in the clinical isolate TGC-S 
Keeney et al. previously demonstrated an association between elevated tigecycline 
MICs and overexpression of acrAB and ramA in E. cloacae. However, no previous 
experimental evidence has placed acrAB definitively in the RamA regulon (127). 
To investigate this aspect, ramA from isolate TGC-R was overexpressed in 
isolate TGC-S using the pBAD expression vector (Materials and Methods section 
2.20.3). In order to achieve this, the gene first had to be PCR-amplified from E. 
cloacae genomic DNA. Primer design was problematic owing to the fact that there 
were no publicly-available genome sequence data for this species at the time 
although, more recently, the complete genome of the E. cloacae type strain ATCC 
13047 has been published (212). Initial attempts to amplify ramA using primers 
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designed on gene sequences from closely-related species (accession numbers: 
NC 009436; AJ404625; U19581) were unsuccessful. Nevertheless, although no E. 
cloacae ramA nucleotide sequences were available in GenBank, there was a RamA 
protein sequence (accession number: P55922) and the reverse primer ramA CDS R 
was designed by reverse-translating this protein sequence. Nucleotide sequence data 
reported by Komatsu et al. were used to design the forward primer, Full ramA F 
(Table 9) (133). The ramA gene was then cloned into the pBADS derivative, 
pBADKM (Figure 18b) generating plasmid pBADKM-R (Figure 18c). The addition 
of the kanamycin resistance gene to pBADS allowed the pBAD-based expression 
system to be used with clinical isolate TGC-S owing to the isolate's susceptibility to 
the aminoglycosides. This would otherwise not have been possible because isolate 
TGC-S was ampicillin-resistant (Table 13). 
Induction of ramA expression by increasing the L-arabinose concentration 
resulted in increased acrAB expression (Figure 39). When ramA was induced with a 
relatively high (0.2% w/v) concentration of L-arabinose, acrAB was expressed at a 
higher level than in isolate TGC-R, for which the tigecycline MIC was 4 mg/L 
[relative acrAB expression 7.75 (±1.43) vs. 4.43 (±1.63) for TGC-R]. 
Comparison of the nucleotide sequence of ramA (partial coding region) in 
isolates TGC-S and TGC-R revealed a His-95--+Arg substitution in TGC-R (Figure 
40), although this was not selected in TGC-S7, and its significance is therefore 
uncertain. 
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10-, 
8H 
6H 
4-1 
2-1 
0 0.0002 0.0002 0.002 0.002 0.02 0.02 0.2 0.2 
L-arabinose (% w/v) 
Figure 39. Expression relative to that of rpoB (means ± standard deviations) of 
acrAB in TGC-S harbouring either control plasmid, pBADKM (Figure 18b), shown in 
white or pBADKM-R with cloned ramA (Figure 18c) shown in black, in the presence 
of varying concentrations of L-arabinose. 
* 20 * 40 * 60 
TGC-S MTISAQVIDTIVEWIDDNLHQPLRIEEIARHAGYSKWHLQRLFMQYKGESLGRYIRERKL 
TGC-R ............................................................ 
* 80 * 100 
TGC-S : LMAARDLRESDERVYDICLRYGFDSQQTFTRIFTHTFNQPPGAYRK 
TGC-R .................................. R........... 
Figure 40. Amino acid sequence alignment of the global regulator, RamA in 
clinical isolates TGC-S and TGC-R. 
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3.2.5. Interruption of genes in E. cloacae 
3.2.5.1. Insertional inactivation of acrB in clinical isolate TGC-R 
The acrB gene in isolate TGC-R was disrupted by insertional inactivation using the 
helper plasmid pKOBEG (Figure 15) and a linear DNA fragment containing a 
gentamicin resistance cassette flanked by regions complementary to the target gene 
(Materials and Methods section 2.20.2.1). An overview of the strategy used is 
outlined in Figure 41. The susceptibility of TGC-R to the aminoglycosides (Table 13) 
allowed for the use of gentamicin as the selective agent. The chromosomal insertion 
of the gentamicin resistance cassette within the acrB gene was confirmed by PCR and 
sequencing across the insertion site (Figure 42). 
pKOBEG introduced into TGC-R by electroporation 
ý--fI 
Single transformant made electrocompetent, and 
phage A Red genes induced with L-arabinose 
Internal fragment of acrB amplified by PCR and cloned 
into pCR2.1, generating plasmid pCRBK-1 
Gentamicin resistance cassette PCR-amplified from 
pBBR1 MCS-5 and cloned into the acrB fragment of pCRBK-1, 
generating pCRBK-2 
Linear DNA fragment amplified by PCR from pCRBK-2 
and introduced into TGC-R:: pKOBEG by electroporation 
H Transformants selected on LB agar plates containing gentamicin 
Chromosomal integration confirmed by PCR and sequencing 
Figure 41. Overview of strategy used to interrupt acrB in the clinical isolate TGC- 
R. 
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Gml ade .ý 
12 
Figure 42. Confirmation of the chromosomal insertion of the gentamicin 
resistance cassette from pBBR 1 MCS-5: (a) schematic of gentamicin cassette insertion 
displaying the primers used to perform PCR across the insertion site; (b) agarose gel 
electrophoresis displaying a 1-Kb DNA ladder in lane I and the 1405-bp PCR product 
in lane 2. 
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Disruption of acrB in clinical isolate TGC-R restored full susceptibility to 
tigecycline (MIC, 0.125; Figure 43 and Table 14), ciprofloxacin, chloramphenicol, 
and resulted in a large reduction in the MICs of minocycline (? 64-fold) and 
tetracycline (16-fold) (Table 14). Isolate TGC-R and mutant TGC-RAacrB had 
identical PFGE profiles (Figure 44). 
Figure 43. Tigecycline Etest performed on clinical isolate TGC-R and derivative 
TGC-RAacrB. 
Figure 44. PFGE profiles of E. cloacae clinical isolate TGC-R and derivative 
TGC-RDacrB. 
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3.2.5.2. Insertional inactivation of acrB in clinical isolate EC391 
To confirm the role of AcrAB in tigecycline resistance in EC391, the acrB gene was 
inactivated by the targeted insertion of suicide plasmid, pRSACRB (Figure 17; 
Materials and Methods section 2.20.2.2). Although the phage X Red functions 
encoded by pKOBEG were employed successfully to inactivate acrB in clinical 
isolate TGC-R (section 3.2.5.1), a different approach was taken with isolate EC391. 
This was because the pKOBEG system proved somewhat cumbersome and 
inefficient. 
A suicide plasmid system based upon the R6Ky origin of replication (ori) was 
considered a better alternative (section 3.3.4) (132). Figure 45 shows an overview of 
the strategy used. Isolate EC391 remained susceptible to the aminoglycosides (Table 
13) which allowed for the use of kanamycin as the selective agent. Chromosomal 
integration of pRSACRB was confirmed by PCR and sequencing across the insertion 
site (Figure 46). 
Internal fragment of acrB amplified by PCR 
L--N Fragment of sdeY in pSMY2 replaced with acrB fragment to 
generate pRSACRB 
I pRSACRB introduced into EC391 by electroporation 
T aansforma tts selected nn LB agar plates containing kanamycin 
Chromosomal integration confirmed by PCR and sequencing 
Figure 45. Overview of strategy used to interrupt acrB in clinical isolate, EC391. 
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ýý 
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acrB 
Figure 46. Confirmation of the chromosomal insertion of suicide plasmid, 
pRSACRB: (a) schematic of gentamicin cassette insertion displaying the primers used 
to perform PCR across the insertion site; (b) agarose gel electrophoresis displaying a 
1-Kb DNA ladder in lane I and the 1540-bp PCR product in lane 2. 
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Disruption of acrB in clinical isolate, EC391 restored full susceptibility to 
tigecycline (MIC, 0.125; Figure 47). The PFGE profiles of EC391 and EC391AacrB 
were consistent (Figure 48). 
Figure 47. Tigecycline Etest performed on clinical isolate EC391 and derivative 
EC391 AacrB. 
.ý 
Figure 48. PFGE profiles of E. cloacae clinical isolate EC391 and derivative 
EC391 AacrB. 
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3.3. S. marcescens 
There were no tigecycline-resistant clinical isolates of S. marcescens available in 
ARMRL's collection until the isolate described in case 5 (section 3.3.1.1) was 
referred in 2009. Since the mechanisms of tigecycline resistance in this species were 
unknown, the molecular basis of such resistance was investigated using the clinical 
isolate described below and laboratory-selected mutants. 
3.3.1. Clinical case reports 
3.3.1.1. Case 5 
Clinical isolate SM346 was recovered from the urine of a patient hospitalised for 
assessment in North-East England in 2009. They received no antimicrobial therapy 
while in hospital. 
3.3.2. Isolate characterisation and antibiotic susceptibilities 
Isolate SM346 was identified as S. marcescens by API20E; MICs were 16 mg/L of 
tigecycline and 64 mg/L of tetracycline, compared with 0.25 mg/L and 16 mg/L for 
the type strain, NCTC 10211. Tigecycline resistance could be selected by serial 
passage of the latter strain (Materials and Methods section 2.18), and MICs of 
tigecycline and tetracycline for an intermediate mutant, 10211-6, and the ultimate 
mutant, 10211-10, were 8 and 64, and 256 and >256 mg/L, respectively. Mutant 
10211-10 also showed 16-fold increases in the MICs of ciprofloxacin (0.25 mg/L to 4 
mg/L) and cefpirome (0.5 mg/L to 8 mg/L). Similarly, a mutant selected from S. 
marcescens NCTC 10211 during exposure to tetracycline (10211-TC7) showed a 16- 
fold increase in tigecycline MIC when compared with the parent strain, though no 
increases in the MICs of ciprofloxacin or cefpirome were observed (Table 15). The 
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type strain 10211 and its laboratory mutant 10211-10 had identical PFGE profiles 
(Figure 49). 
a. 
Itli 
7E[i -R___ . _---------- 
ýýti 0 
b. 
Figure 49. PFGE profiles of the S. marcescens type strain and derivatives: (a) 
NCTC 10211, the laboratory-selected mutant 10211-10 and derivative 10211- 
1 OA sde Y; (b) 10211-10 and derivative 1021 1- l OAhasF. 
155 
vi 
ý 
ý 
.. ý 
ý F  
Ei 
U 
11 
F-ý 
a 
4) 
A 
0 
rA 
a ý a 
X 
O 
w 
U 
a 
a, 
U 
ia 
a. 
U 
U 
ý 
U 
N 
Q 
U 
U 
ý 
Er 
U 
U 
ý 
a 
U 
X 
O 
U 
> 
Q 
ý 
CU 
¢ 
U 
F- 
¢ 
ý 
ý 
Q 
Cl 
M 
N 
M 
I 
A 
N 
N 
N 
It 
ý, M 
N 
M 
ýc 
O 
O_ 
A 
Itt n 
00 
. -r 
't 
I 
I A 
ýo 
It 
ý 
rýý oc 
ý= 
. -e rý 
IIII 
Annn 
^I ry Q . -. 
ýh 
oýýö 
IV - It f-4 
ONýý 
M= `0 ýe 
00 ýý It 
-4 -Q- 
88Q C) 
Annn 
ýýa It 
N 00 Z 00 
-- NH 
-. t - ti) C; 
ýli1 
ýýýý 
NS 
O 
ýo 
pH 
U 
. 
-+ 
. 
=. 
.: H 
ZÖÖÖ 
U 
R 
[-r ý 
ý ro 
ýn 
O =c.., 
O 
ýO 
o a' .-U U 
U ý. 
u Z. 
ov 
X ro O _U 
ý--ý 
Q 
U=° 
UÜ 
In :b UN 
Q C1 
ºý 
U 
UÜ 
ý U 
. ti 
jz . - bý 
ý 0 
ý 
cý 0 
"Ü. Cr 
2jWV7 
co . ^. 
ld UU 
ý,,, ý º. 
rý 
N 
¢ ýä 
vN 
vy 
7-- UZ 
U 
w° v 
.. a 
ý 
.. U_ 
ý 
u 
ö 
ý ý 
U 
a 
O 
U 
s 
V) 
C. r 
.. ý ý. 
z ý ý 
F- 
w 
F- 
z 
w ý 
ý 
ý 
aq 
O 
F 
a 
ý U 
ý 
w 
ý 
w 
ý 
ý 
ý 
W 
ý 
ý 
¢ F- 
Q ua 
H 
z 
N 
M 
n 
M 
n 
ý 
N 
M 
A 
ý ý 
N 
M 
A 
fV 
N 
M 
A 
O 
06 
A 
C) ýo 0 
C5 
vi 
n Ö 
0 
N 
M A 
ýo 
, It M 
ý 
ý 
zzzz 
NNNN 
Annn 
NNNN 
nnnn 
NCýr 
ýNNN 
~Ann 
10 ýc ýý N ~nn 
00 *NN 
ýE 00 ýE 00 
N \p "O 
eh ý , -. 
ýý N ý.. ý ýN Öp 
W) N 
c; O0O 
0 V) NO IZ v) fV Ö ý 
O CI O vOl 
NNNN 
0000 
NNNN 
r') rn el ro) nnnn 
N 
O 
U 
E-U 
z 
ýo 
N 
O 
O 
O 
I- 
E- 
N 
2 
ý 
U 
t-. 
.D O 
w+ 
C6 0 Fý 
vö 
cp 
Üý 
aý"ý 
py ö 
u= q= 
ä >, 
Z 
aU 
QH 
Q .ý 
ýO 
N 
CLý 
.ý. 
W 
.ý 
Ü 
RS 
., 
.ý U U_ 
cý 
N 
ýz aýW 
ý... 
Äý 
ß 
3.3.3. Analysis of expression of the efflux pump-encoding operons sdeAB, 
sdeCDE and sdeXY in the type strain NCTC 10211 and laboratory 
mutant 10211-10 using real-time RT-PCR 
The mechanisms of tigecycline resistance in S. marcescens were unknown although 
resistance in other Enterobacteriaceae species had been associated with up-regulation 
of the RND efflux transporter, AcrAB (127; 128; 224). Three RND systems have been 
described to date in S. marcescens, namely SdeAB (135), SdeCDE (22) and SdeXY 
(42). When a BLAST search was performed of the assembled (but unpublished) 
genome sequence of S. marcescens Dbl1 (Sanger Institute S. marcescens BLAST 
Server available at http: //www. sanger. ac. uk/cgi-bin/blast/submitblast/s_marcescens) 
using an E. cloacae acrB sequence (accession number: AM287287) the results 
indicated that the sdeY gene was the most similar to this at the nucleotide level, with 
79% identity. 
The potential of efflux by RND-type transporters as a mechanism of 
tigecycline resistance in S. marcescens was investigated by analysis of expression of 
sdeAB, sdeCDE and sdeXY in type strain NCTC 10211 and laboratory mutant 10211- 
10. 
Compared with NCTC 10211, mutant 10211-10 overexpressed all of the three 
RND efflux systems studied, but the increase in expression of sdeXY was 
reproducibly higher (c. 11-fold) than the 2-3-fold increases for the sdeAB and sdeCDE 
pumps (Figures 50,51 and 52). Expression of sdeXY was also raised in clinical 
isolate, SM346 and intermediate mutant, 10211-6 (tigecycline MIC, 8 mg/L) as 
compared with NCTC 10211. Likewise, the mutant selected during exposure to 
tetracycline, 10211-TC7, showed a modest (c. two-fold) increase in sdeXY expression 
compared with NCTC 10211 (Figure 52). 
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Isolate 
0.25 64 
TGC MIC (mg/L) 
Figure 50. Expression of sdeAB relative to that of rpoB (means ± standard 
deviations) in the type strain NCTC 10211 and the laboratory mutant, 10211-10. 
Tigecycline (TGC) MICs are shown. 
0.05-1 
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0.02-1 
0.01 ý 
0.00 
10211 10211-10 
Isolate 
0.25 64 
TGC MIC (mg/L) 
Figure 51. Expression of sdeCDE relative to that of rpoB (means ± standard 
deviations) in the type strain NCTC 10211 and the laboratory mutant, 10211-10. 
Tigecycline (TGC) MICs are shown. 
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Figure 52. Expression of sdeXY relative to that of rpoB (means ± standard 
deviations) in the clinical isolate SM346, the type strain NCTC 10211 and derivatives. 
Tigecycline (TGC) MICs are shown. 
3.3.4. Interruption of genes in S. marcescens 
The efflux pump-encoding operon sdeXY and the to1C homologue, hasF were targeted 
for disruption in the final laboratory mutant, 10211-10 to investigate their 
involvement in tigecycline resistance. 
The hasF gene was targeted because previous work has indicated that HasF 
may be the only outer-membrane channel involved in energy-dependent efflux in S. 
marcescens (136). 
Initially, attempts were made to modify the phage X, Red recombination system 
for use in 10211-10 by cloning a kanamycin resistance marker into pKOBEG and 
generating a linear DNA fragment containing a gentamicin resistance cassette flanked 
by regions complementary to sdeY. Although pKOBEG replication was observed in 
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10211-10 under kanamycin pressure, multiple attempts to inactivate sdeY using this 
system were unsuccessful. 
A suicide plasmid system was then considered; however, pUC-derived 
plasmids, like those used to inactivate genes in A. baumannii (section 3.1.4) were not 
suitable, as they replicate in S. marcescens. The origin of replication of plasmid R6K 
was considered a viable alternative, as its function is dependent upon the replication 
initiator (Rep) protein, a, which is encoded by the pir gene (132). Plasmids containing 
this origin of replication do not replicate in bacteria that lack the pir gene, including S. 
marcescens. The R6K on was first used successfully in a suicide construct to 
inactivate the toxR gene of Vibrio cholerae (173), and has also been used to inactivate 
efflux pump genes in S. marcescens (22). The strategies employed to interrupt the 
sdeY and hasF genes of S. marcescens are shown in Figures 53 and 54, respectively. 
Chromosomal integration of pSMY-2 and pHASF was confirmed by PCR and 
sequencing across the insertion site (Figures 55 and 56). 
'--I' 
Internal fragment of sdeY amplified by PCR and cloned into 
pCR-Blunt to generate pSMY1 
R6Ky origin PCR-amplified from pMOD-5 and cloned into 
pSMY1, replacing the pUC origin, to generate pSMY2 
pSMY2 introduced into 10211-10 by electroporation A 
1ý Transformants selected on LB agar plates containing kanamycin 
Chromosomal integration confirmed by PCR and sequencing 
Figure 53. Overview of strategy used to disrupt sdeY in the laboratory mutant 
10211-10. 
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Internal fragment of hasF was amplified by PCR and cloned into 
pSMY2, replacing the sdeY fragment, to generate plasmid 
pHASF 
pHASF was introduced into 10211-10 by electroporation 
Transformants selected on LB agar plates containing kanamycin 
Chromosomal integration confirmed by PCR and sequencing 
Figure 54. Overview of strategy used to disrupt hasF in the laboratory mutant 
10211-10. 
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a. 
M13 F 
-. 4* 
XY CDS R 
sdeX - sdeY 
pSMY2 
Km' IacZ ccdB ý sdeY - 
b. 
123 
Figure 55. Confirmation of the chromosomal insertion of suicide plasmid, 
pSMY2: (a) schematic of pSMY2 insertion displaying the primers used to perform 
PCR across the insertion site; (b) agarose gel electrophoresis displaying a 1-Kb DNA 
ladder in lane 1 and the 2260-bp PCR product in lane 3. 
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a. 
hasF check F -ol* 
MOD5 on R 
- hasF 
b. 
Kmn IacZ ccdB 
pHASF 
1234 
hasF - 
Figure 56. Confirmation of the chromosomal insertion of suicide plasmid, 
pHASF: (a) schematic of pHASF insertion displaying the primers used to perform 
PCR across the insertion site; (b) agarose gel electrophoresis displaying a 1-Kb DNA 
ladder in lane I and the 1372-bp PCR product in lane 4. 
Interruption of either sde Y or hasF in the laboratory mutant 10211-10 restored 
full susceptibility to tigecycline (MIC, 0.125; Figures 57 and 58; Table 16). MICs of 
ciprofloxacin, cefpirome and tetracycline also were markedly reduced to below the 
values for the `wild-type' parent, NCTC 10211. MIC shifts were much less marked 
for meropenem, but followed the same general trend, being increased for mutant 
10211-10 but reduced by inactivation of sdeY or hasF. Compared with 10211-10 the 
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ceftazidime MIC was reduced eight- and 16-fold in derivatives 10211-1OAsdeY and 
10211-IOAhasF, respectively, whilst the MIC of cefotxime was reduced (eight-fold) 
for 10211-1OAhasF only. Interruption of hasF resulted in a reduction in the MICs of 
aztreonam, carbenicillin, cefoxitin, piperacillin and minocycline (Table 16). 
Figure 57. Tigecycline Etest performed on laboratory mutant 10211-10 and 
derivative 10211- l OAsde Y. 
Figure 58. Tigecycline Etest performed on laboratory mutant 10211-10 and 
mutant 10211-100hasF. 
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3.4. Screening of tigecycline-resistant isolates for the tet(X) gene by PCR 
Tigecycline-resistant (MIC, ?4 mg/L) clinical isolates of all species used in this 
thesis (n=5) were screened by PCR for the presence of tet(X) (281). Tet(X) is a flavin- 
dependent mono-oxygenase known to modify tigecycline (175). The tet(X) gene was 
not detected in any of the organisms tested, although the positive control strain gave a 
PCR product of the correct size (Figure 59). 
1234 
Figure 59. Agarose gel electrophoresis displaying a 123-bp DNA ladder in lane I 
and the results of tct(X) PCR performed on the E. coli positive control strain Em24 
pBSJ (275) (lane 2) and clinical isolates AB211 (lane 3) and W7282 (lane 4). 
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4. Discussion 
At the beginning of the studentship in the spring of 2007, tigecycline had been 
licensed in the US for less than two years and in Europe for only a year. It was the 
first new tetracycline derivative to be marketed in over three decades and was the 
first-in-class glycylcycline antimicrobial to be approved for clinical use. Around the 
time of its launch, on the basis of its in vitro activity and performance in clinical trials, 
there was expectation that it would find use in the treatment of infections caused by 
MDR pathogens, including many Gram-negative species (153). However, by 2006 
(the year tigecycline was licensed in Europe) there was already evidence that 
tigecycline is a substrate of chromosomally-encoded RND-type efflux systems of P. 
aeruginosa, M. morganii, P. mirabilis and K. pneumoniae (61; 222; 224; 267). There 
were also warning signs of the propensity of tigecycline to select for resistance, as 
evidenced by data from phase III trials that documented five instances of emerging 
tigecycline resistance in a number of Gram-negative species, namely, K. pneumoniae 
(two instances), M. morganii, E. cloacae and A. baumannii (153). 
In this study, isolates of Enterobacteriaceae (E. cloacae and S. marcescens) 
and A. baumannii referred to ARMRL that displayed resistance to tigecycline (>_ 4 
mg/L) were characterised, and efflux by RND systems was investigated as a possible 
mechanism. 
4.1. A. baumannii 
Reports of resistance to tigecycline in A. baumannii are worrying, given the MDR 
nature of the majority of clinical isolates of this species, in addition to its propensity 
to persist in the nosocomial environment. Of particular concern are reports of 
resistance in representatives of epidemic, carbapenem-resistant lineages where 
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tigecycline is usually one of the few agents to remain active in vitro, along with 
colistin, to which resistance has also been documented (59). It therefore was 
considered particularly important to investigate the emergence of tigecycline 
resistance during tigecycline therapy in representatives of one of the UK's most 
successful carbapenem-resistant lineages, OXA-23 clone 1. 
The first task was to confirm both the identity of the A. baumannii isolates 
described in Table 2 and their tigecycline MICs (Results sections 3.1.1.1 and 3.1.1.2; 
Tables 2 and 11). Identification to genus level was achieved using API20NE, although 
phenotypic tests such as this do not distinguish between members of the A. 
calcoaceticus-A. baumannii complex very well (94). A relatively simple method for 
confirming an isolate as A. baumannii is detection by PCR of the blaoX, a, _51_uke gene, 
which has been shown to be intrinsic to the species (261). This was chosen as a 
simpler and cheaper alternative to other molecular methods of species-level 
identification such as sequencing of the 16S - 23S rRNA gene spacer region (Results 
section 3.1.2) (40). However, since the completion of the practical element of this 
study, the blaoxA-51-tike gene has been detected in a clinical isolate of A. nosocomialis 
(formerly known as Acinetobacter genomic species 13TU) and so can no longer be 
considered an absolutely reliable species-specific marker (140; 183). All isolates were 
then assigned to OXA-23 clone 1, the SE clone or the ACB20 clone by analysis of 
their PFGE profiles (Results section 3.1.2). PFGE identification within these clusters 
also confirmed their species identity as A. baumannii. 
Susceptibility testing was performed by agar dilution or by Etest according to 
BSAC guidelines on Iso-Sensitest agar (Materials and Methods section 2.5). Care was 
taken to prepare media containing tigecycline on the day of use to avoid the potential 
for artificially high MICs resulting from the inactivation of tigecycline by oxidation in 
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aged media (112). There has been some controversy surrounding the methods for 
determining tigecycline susceptibility in vitro when using Mueller Hinton (MH) 
media (82; 250). Significantly different zone diameters were observed when 
tigecycline disc diffusion susceptibility testing was performed using MH agar 
supplied by different manufacturers (250). Subsequently, it was found that elevated 
tigecycline MICs correlated with higher concentrations of manganese in the medium 
(82). The reasons for this effect are unclear, though it was postulated that it may be 
due to induction of RND transporters by manganese (82). This aspect was 
investigated using clinical isolates AB210 and AB211 (Results section 3.1.4). 
Evidence that tigecycline is a substrate of the AdeABC efflux transporter was 
first published in 2007, less than a month after the beginning of the PhD studentship 
(197; 223). I therefore decided to focus on this mechanism when investigating the 
emergence of resistance in clinical isolates of A. baumannii. 
Since up-regulation of AdeABC had been linked with elevated tigecycline 
MICs in other studies (197; 223) the real-time RT-PCR assay described by Peleg et al. 
(197) was used to investigate expression of adeABC. However, problems with DNA 
contamination in the RT-negative controls were encountered when using the multi- 
copy 16S rRNA gene as the reference housekeeping gene according to the published 
assay (197). It was also observed that the 16S rRNA reactions had consistently low 
but variable CT values. As a result the assay was redesigned using the single copy- 
gene, rpoB as the reference housekeeping gene, using primers designed in highly 
conserved regions, as evidenced by multiple sequence alignment. An on-column 
DNase treatment step was introduced into the RNA extraction protocol (Materials and 
Methods section 2.8) to ensure the purity of RNA extracts. 
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The post-therapy, tigecycline-resistant clinical isolate, AB211 and its 
tigecycline-susceptible, pre-therapy counterpart, AB210 had been referred to ARMRL 
in 2005 (Results section 3.1.1.1). PFGE analysis confirmed them as OXA-23 clone 1 
representatives (Figure 21 a) and in vitro susceptibility testing confirmed tigecycline 
resistance and susceptibility in AB211 and AB210, respectively (Table 11). 
Using the modified assay described above, RT-PCR identified overexpression 
of this efflux system in the tigecycline-resistant clinical isolate, AB211 and the 
laboratory-selected, tigecycline-resistant mutant, AB210-6 compared with the pre- 
therapy, tigecycline-susceptible clinical isolate, AB210 (Results section 3.1.3). There 
was an association between increasing tigecycline MIC and elevated expression of 
adeABC (Figure 24). These data were in agreement with previous reports (197; 223) 
and suggested involvement of the AdeABC efflux system in the mutational 
emergence of tigecycline resistance, under tigecycline selection pressure, both in vitro 
and in vivo. 
Real-time RT-PCR data suggested that up-regulation of the RND transporter 
AdeABC was responsible for the tigecycline-resistant phenotype. To assess fully the 
role of this pump in the emergence of resistance in AB211 it was decided to attempt 
to silence the system by targeting the adeB for inactivation (Materials and Methods 
section 2.19.3.1.1). 
A number of strategies exist for the inactivation of genes in Gram-negative 
bacteria, though most of these have been developed for use in E. coli (17). At the time 
of choosing a strategy for the inactivation of adeB in 2008, all the studies that 
reported on the inactivation of A. baumannii genes described either: (i) the 
chromosomal integration of suicide plasmids encoding a selectable marker (antibiotic 
resistance) gene, mediated by a single homologous recombination event or (ii) 
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integration of the selectable marker gene only, which was similarly encoded on a 
suicide plasmid but which relied upon a double homologous recombination event 
(160; 164; 223). An alternative PCR-based method has since been described (14). 
The simplest of the suicide plasmid-based approaches is integration of an 
entire plasmid within the gene of interest, which disrupts the coding region and 
inactivates the gene. This was the approach adopted by Ruzin et al. to inactivate adeB 
(223) and, on this basis, the suicide vector pBK-5 was constructed (Materials and 
Methods section 2.19.3.1.1). Plasmid pBK-5 contains ampicillin and kanamycin 
resistance genes only (Figure 13) and so can only be used to inactivate adeB in 
isolates with relatively low MICs for one or both of these agents whereas isolates of 
OXA-23 clone 1 are usually resistant to ampicillin and the aminoglycosides (49). 
Fortuitously, the kanamycin MIC for post-therapy isolate AB211 was 4 mg/L, which 
allowed for selection of mutants using this agent (Results section 3.1.4.1). However, 
the laboratory mutant, AB210-6 was resistant to both agents and so was not amenable 
to such genetic manipulation (Table 11). Inactivation of adeB in AB211 resulted in a 
reduction in tigecycline MICs to the pre-therapy level (Table 12). This result 
suggested that up-regulation of AdeABC was the sole mechanism of tigecycline 
resistance in this case. 
By this time there was published evidence that tigecycline is also a substrate of 
the AdeIJK transporter of A. baumannii (56), but given the evidence above, efflux by 
this RND pump was not investigated as a possible mechanism of resistance. 
After establishing that up-regulation of AdeABC was the sole mechanism of 
tigecycline resistance in clinical isolate AB211 and most likely also in laboratory 
mutant AB210-6, the next question to be addressed was how the pump had come to be 
up-regulated. Expression of adeABC is controlled by the divergently co-transcribed, 
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two-component signal transduction system, AdeRS (164). Analysis of adeRS 
expression by real-time PCR revealed no 
differences in expression between AB210 
and AB211, indicating that differential expression of the regulatory operon was not 
responsible for AdeABC up-regulation 
(Figure 26). 
Specific amino acid substitutions in both the sensor histidine kinase, AdeS and 
its cognate response regulator, AdeR have been associated with constitutive 
expression of adeABC (51; 164). Nucleotide sequencing of adeRS 
in AB210, AB211 
and AB210-6 did not identify any of the previously reported mutations, 
but did 
predict the presence of an Ala-94--+Val substitution 
in AdeS in the tigecycline- 
resistant clinical isolate, AB211 compared with AB210. 
A Gly-103-Asp substitution 
in AdeS and an Ala-91-+Val change in AdeR were also identified in the tigecycline- 
resistant laboratory mutant, AB210-6 compared with its susceptible parent, AB210 
(Results section 3.1.5). The Ala/Val-91 and Gly/Asp-103 residues of AdeS are located 
in the RAMP (histidine kinase, adenylyl cyclase, methyl-accepting chemotaxis 
protein, and phosphatase) linker domain. This is potentially relevant, as the HAMP 
domain of the NarX sensor kinase of E. coli is thought to play an active part in 
transmembrane signal transduction (13) whilst mutations in the linker domain of the 
VanSB sensor histidine kinase have been associated with glycopeptide resistance in 
enterococci as a result of induction of the vanB gene cluster (64). The Ala/Val-91 
residue of AdeR is located in the signal receiver domain, one position downstream of 
a residue that appears to be important for the co-ordination of Mgt+, which is required 
for the phosphorylation of the conserved aspartic acid residue. The G--+A point 
mutation responsible for the Ala-91--+Val substitution in AdeR was located within the 
promoter region of the adeABC operon (Results section 3.1.5). These mutations may 
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explain the elevated level of adeABC transcript observed 
in AB211 and the even 
higher level of expression seen in AB210-6 compared with AB210. 
Previous work demonstrated that inactivation of adeRS results in susceptibility 
to known substrates of AdeABC in A. baumannii, including the aminoglycosides, 
suggesting that AdeR positively regulates adeABC expression (164). Therefore, it was 
attempted to explore further the role of AdeRS in the overexpression of adeABC 
observed in clinical isolate AB211 by taking advantage of the relatively low 
kanamycin MIC. Suicide plasmids, pSK-1 and pSK-2 (Figure 14) were used in an 
attempt to inactivate the adeRS operon. The strategy was the same as that used to 
inactivate adeB (Figure 30). Although previous work has shown that functional 
AdeRS is required for AdeABC activity (164), no change in tigecycline MIC was 
observed upon interruption of adeS (Results section 3.1.6.2). This result led to 
assessment of the integrity of the adeRS locus in the AadeS `mutant' by PCR; this 
appeared to be intact despite evidence that the pSK-1/2 insertion was successful 
(Figure 34). In a study describing a PCR-based method of gene interruption in A. 
baumannii, it was found that when an outer membrane protein gene was disrupted 
using a suicide plasmid, 40% of the population reverted to wild-type after 10 passages 
without selection pressure (14) and it seems likely that the chromosomal insertions of 
pSK-1/2 were similarly unstable even under selection pressure. Since further attempts 
to inactivate adeS had to be abandoned due to time constraints (Results section 
3.1.6.2), the nature of adeABC regulation by AdeRS was not investigated further in 
clinical isolate AB211. 
As noted earlier, it has been documented that increasing levels of manganese 
in the susceptibility testing medium can lead to increases in tigecycline MICs, and 
induction of RND transporters has been proposed as a possible mechanism (82). 
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Clinical isolates AB210 and AB211 displayed elevated tigecycline MICs when the 
medium was supplemented with MnSO4. AB211 was more affected than 
AB210 by 
higher levels of MnSO4 in terms of increases in tigecycline MIC (Figure 27). MnSO4 
supplementation appeared to affect adeABC expression 
in both isolates though not in 
a manner that could explain the observed tigecycline 
MICs (Figure 27). There was no 
correlation between level of adeABC expression and 
MIC in the case of AB211 
(Figure 27). The mechanism(s) by which manganese affects the in vitro activity of 
tigecycline versus A. baumannii therefore remains obscure. 
In 2009, ARMRL received a further pre- and post-treatment clinical pair of A. 
baumannii isolates where tigecycline resistance had been reported in the post-therapy 
isolate, W7282 while the pre-therapy isolate, W6976 was susceptible to this agent 
(Results section 3.1.1.2; Table 11). Further in vitro susceptibility testing of these two 
isolates confirmed the tigecycline MICs, and PFGE analysis identified both as 
representatives of OXA-23 clone I (Figure 21b). 
Given the body of evidence available at that time that suggested that up- 
regulation of AdeABC was the major tigecycline resistance mechanism in A. 
baumannii, the expression of adeABC in W6976 and W7282 was assessed. Real-time 
RT-PCR identified overexpression of adeABC in the post-therapy isolate, W7282 
suggesting that AdeABC activity was responsible for the tigecycline-resistant 
phenotype (Figure 25). 
Unlike clinical isolate AB211, isolate W7282 retained resistance to the 
aminoglycosides (Table 11). This meant that it was not possible to use pBK-5 or any 
other pCR2.1 derivative encoding only ampicillin and kanamycin resistance genes for 
the inactivation of adeB. Non-antibiotic selection markers were considered for use, 
including a potassium tellurite resistance cassette that was used successfully in other 
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Gram-negative species (227). However, since isolates W6976 and W7282 were not 
referred to ARMRL until 2009, the remaining time for laboratory work was limited, it 
was considered that construction of further suicide vectors for the inactivation of adeB 
was not a priority given that existing evidence from this and other studies suggested 
the observed adeABC overexpression was most likely responsible for tigecycline 
resistance in W7282. 
The mechanism of adeABC overexpression in W7282 relative to W6976 was 
investigated by analysis of the nucleotide sequence of adeRS in both isolates. Initially, 
no differences were detected between the two isolates, although subsequent whole- 
genome shotgun sequencing analysis (section 4.1.1) identified a Ser-8-+Arg 
substitution in AdeS in W7282 relative to W6976 (Results section 3.1.5). This residue 
is not located in any conserved domain and its biological significance remains 
uncertain. Nevertheless, since it was the only difference identified in the adeRS locus 
between the two isolates it could be that it was responsible for adeABC 
overexpression. 
In summary, the emergence of tigecycline resistance in two representative 
isolates of the epidemic, carbapenem-resistant lineage, OXA-23 clone 1 during 
tigecycline therapy was investigated. In both instances the tigecycline resistance 
phenotype was associated with up-regulation of AdeABC and, in the case of AB211, 
the role of this pump in the emergence of resistance was confirmed by insertional 
inactivation of adeB. These data are in agreement with previous reports that have also 
suggested that tigecycline is a substrate of AdeABC (197; 223). Taken together, it 
appears that up-regulation of this RND efflux system is currently the major 
mechanism of tigecycline resistance in this species. 
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OXA-23 clone 1 belongs to the internationally-disseminated European clone 
II. This is the first report of tigecycline resistance emerging during therapy in the 
widespread UK lineage, OXA-23 clone 1. Such resistance is concerning since the 
OXA-23 clone 1 lineage is already resistant to carbapenems and all other drugs except 
polymyxins. Moreover, both patients were being treated for intra-abdominal 
infections, which are a licensed indication for tigecycline, whereas previous reports of 
emerging tigecycline resistance have mostly concerned off-label use (11; 210). 
Distinct lineages of A. baumannii have different modal tigecycline MICs. 
Using multiple representatives of the OXA-23 clone 1, SE and ACB20 clones, it was 
demonstrated that an association exists between a higher modal tigecycline MIC and 
elevated expression of adeABC (Figures 22 and 23; Results section 3.1.3.1). These 
data support the hypothesis that differential expression of adeABC underlies not only 
intra-clone but also inter-clone variation in tigecycline MICs. 
Nucleotide sequence analysis of the adeRS operon in multiple representatives 
each of the SE clone and OXA-23 clone 1 revealed a difference at amino acid 62 of 
the sensor histidine kinase, AdeS, with methionine at this position in OXA-23 clone 1 
and isoleucine in the SE clone, as in all AdeS sequences available in GenBank 
(Results section 3.1.5). Met/Ile-62 is located in the second transmembrane helix of 
AdeS, of which the HAMP linker domain is an extension. The presence of Ile or Met- 
62 may therefore affect susceptibility to tigecycline and so could explain the observed 
difference in modal tigecycline MIC between these two lineages. 
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4.1.1. Whole-genome sequencing 
The recent availability of rapid and inexpensive whole-genome sequencing permits 
detailed investigation of genetic differences between pairs of bacterial isolates. In A. 
baumannii whole-genome studies have thus far focused either on comparing distinct 
antibiotic-susceptible and MDR strains (4,5), or related 
isolates from different patients 
(2). The results of these and other similar studies (7) point to a high degree of genome 
plasticity, the rapid emergence of antibiotic resistance, and significant genetic 
differences between closely-related isolates. 
Since the completion of the practical component of the studentship, the case 
study isolates AB210, AB211, W6976 and W7282 have been subjected to whole- 
genome sequencing as part of an on-going collaborative project investigating the 
genomics of Acinetobacter sp. 
Eighteen putative single nucleotide polymorphisms (SNPs) were detected 
between AB210 and AB211. Of these, nine were non-synonymous including one 
missense mutation. Several of these were located within genes predicted to be 
involved in core biological functions, including translation, nucleic acid biosynthesis, 
a-ketoglutarate and arabinose transport, environmental sensing (the signal 
transduction histidine kinase gene, adeS which had been previously identified), and 
signalling. 
Three contigs in AB210 were not covered by reads in AB211. One of these 
putative deletions disrupted the coding sequence of the DNA mismatch repair gene, 
mutS. The deleted regions comprised of genes encoding for transcriptional regulators, 
ion channels and transporters, a class A ß-lactamase enzyme, components of a type VI 
secretion system (degenerate in both isolates) and an EAL domain-containing protein 
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among others. One of the regions 
included a class 1 integron containing the 
aminoglycoside resistance genes, aac(6D-Ib, aadA and armA (previously confirmed as 
absent from AB211 by PCR), the absence of which is consistent with the change in 
aminoglycoside resistance between AB210 and AB21 1, with MICs of tobramycin, 
amikacin and gentamicin reduced at least eight-fold in AB211 (Table 11). 
In contrast to the AB210/AB211 pair, there were relatively few genetic 
differences between W6976 and W7282. No large structural changes were identified, 
though a total of six putative SNPs were detected between the two isolates, of which 
two were non-synonymous, with one located in a gene of unknown function and the 
other resulting in the Ser-8-*Arg substitution in AdeS (Results section 3.1.5). This 
mutation was not detected by Sanger sequencing when the nucleotide sequence of 
adeRS was originally investigated in this thesis. However, in the light of the whole- 
genome sequence data the nucleotide sequence of adeS was investigated a second 
time and the SNP was subsequently confirmed by Sanger sequencing of PCR 
amplicons. The reasons for the original error remain unclear. However, analysis of the 
repeat sequencing chromatograms identified a double peak at the SNP position 
(Figure 60). It could be that there was a mixed population of bacterial cells, with a 
proportion harbouring the wild-type allele. 
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Figure 60. Alignment of forward and reverse chromatograms displaying part of 
adeS from W7282. The SNP responsible for the Ser-8-*Arg substitution is boxed in 
red. 
Whole-genome sequencing gave insight into the nature of genetic changes 
between isolates under selection pressure through antibiotic therapy and a hostile host 
environment. This work demonstrated significant differences between AB210 and 
AB211 but relatively few between W6976 and W7282 suggesting that other factors, 
in addition to tigecycline pressure, played a role in selecting for the differences 
observed between the Case I isolates. The PFGE profiles of the two pairs were not 
identical (Figure 21, page XX) and therefore suggested the existence of genetic 
differences between the isolates. However, it is clear from the whole-genome 
sequencing data that standard molecular typing methods cannot be relied upon to 
predict the wider phenotypic characteristics of A. baumannii clinical isolates. 
4.2. E. cloacae 
The emergence of tigecycline resistance in E. cloacae was investigated using the two 
pairs of clinical isolates described in Results section 3.2.1. In contrast to the A. 
baumannii clinical pairs, neither patient had received tigecycline prior to the recovery 
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of the tigecycline-resistant isolates (Results section 3.2.1.1 and 3.2.1.2). This suggests 
that selection pressure other than tigecycline therapy can select for a tigecycline 
resistant phenotype in this species. 
Clinical isolates TGC-S (tigecycline-susceptible) and TGC-R (tigecycline- 
resistant) had been referred to ARMRL in 2006. Initial characterisation of these two 
isolates confirmed their identity and tigecycline MICs (Results section 3.2.2; Table 
13). Some differences were observed in their PFGE profiles, which led to there being 
some debate over whether or not they were representatives of the same strain (Results 
section 3.2.2). However, analysis of the profiles of the laboratory-selected mutants 
that were derived from TGC-S demonstrated that in vitro tigecycline exposure could 
select for the genetic events responsible for the changes in PFGE profile from TGC-S 
to TGC-R (Figure 35). 
Evidence that tigecycline is a substrate of the E. cloacae AcrAB efflux 
transporter was published in the spring of 2007, just prior to the beginning of the 
studentship (127; 200). Therefore, expression of acrAB was investigated in clinical 
isolates TGC-S and TGC-R using the real-time RT-PCR assay developed by Doumith 
et al. (72). Both TGC-R (the post-therapy isolate) and the tigecycline-resistant 
laboratory mutant, TGC-S7 overexpressed acrAB compared with TGC-S (Results 
section 3.2.3). Indeed there was a stepwise association between increasing tigecycline 
MIC and elevated expression of acrAB (Figure 36). 
The acrB gene of TGC-R was targeted for inactivation in order to confirm 
involvement of AcrAB in tigecycline resistance. The strategy of integrating pCR2.1- 
based suicide plasmids into the chromosome that was employed to inactivate genes in 
A. baumannii (section 4.1) was not suitable for use in E. cloacae due to plasmid 
replication. Instead, acrB was interrupted using a linear DNA fragment containing a 
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gentamicin resistance cassette flanked by regions complementary to the target using 
the helper plasmid pKOBEG (Figure 15), which encodes the bacteriophage ? Red 
functions (41; 203), using a modified version of the methods described by Perez et al. 
(200) (Figure 41). The acrB gene was disrupted in TGC-R using this approach and 
tigecycline susceptibility was restored (Table 14; Figure 43), confirming the role of 
AcrAB up-regulation in the emergence of resistance in this isolate and providing 
further evidence that tigecycline is a substrate of the AcrAB transporter of E. cloacae. 
In addition to restoring susceptibility to tigecycline, inactivation of AcrAB in 
isolate TGC-R affected the MICs of other agents demonstrating that ciprofloxacin, 
tetracycline, chloramphenicol and minocycline are also substrates of this efflux 
system (section 3.2.5.1; Table 14). These data are in agreement with published reports 
where AcrAB has been inactivated in clinical isolates of E. cloacae (127; 200). The 
eight-fold increase in gentamicin MIC observed for mutant TGC-RAacrB relative to 
its parent clinical isolate, TGC-R, is most likely the result of the chromosomal 
integration of the gentamicin resistance cassette used to select for insertion mutants 
(Figure 42; Table 14). 
Keeney et al. previously demonstrated an association between up-regulated 
AcrAB and overexpression of the AraC-type transcriptional regulator, RamA in E. 
cloacae (127). In this study, real-time RT-PCR identified a similar relationship 
between acrAB and ramA expression, with the latter being overexpressed in TGC-R 
and TGC-S7 compared with TGC-S (Results section 3.2.3; Figure 37). 
In K. pneumoniae and S. enterica serovar Typhimurium, RamA has been 
shown to positively regulate expression of acrAB, as demonstrated by transposon 
mutagenesis and targeted gene knockout studies (16; 224). However, no previous 
experimental evidence has placed acrAB definitively in the RamA regulon in E. 
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cloacae. To investigate this possibility, ramA was overexpressed in clinical isolate 
TGC-S using the pBAD expression vector which, under certain induction conditions, 
resulted in increased acrAB expression at levels sufficient to confer tigecycline 
resistance (Results section 3.2.4; Figure 39). These data confirm that up-regulation of 
AcrAB, mediated by RamA activation, was the factor conferring tigecycline 
resistance in TGC-R. The mechanism(s) of ramA overexpression in TGC-R and TGC- 
S7 was not investigated due to time constraints, but in K. pneumoniae and S. enterica 
serovar Hadar, genetic events that result in non-functional RamR have been 
implicated (101; 102). 
The significance of the His-95-->Arg substitution in RamA detected in TGC-R 
relative to TGC-S remains unclear (Results section 3.2.4). However, it was not 
selected for in the tigecycline-resistant mutant, TGC-S7, which overexpressed ramA 
(Figure 37), nor is His/Arg-95 located in a conserved domain. Taken together, these 
data indicate that the His-95--+Arg substitution was not responsible for ramA 
overexpression in TGC-R. 
The further tigecycline-susceptible clinical isolate, E. cloacae EC390 and its 
tigecycline-resistant counterpart, EC391, recovered from the same patient, were 
referred to ARMRL in 2009. Characterisation of these isolates confirmed their 
identity, tigecycline MICs, and PFGE profiling established that both isolates belonged 
to the same strain (Results section 3.2.2; Table 13; Figure 35b). 
Since up-regulation of AcrAB was responsible for tigecycline resistance in 
clinical isolate TGC-R, efflux by this transporter was investigated as a possible 
mechanism of tigecycline resistance in clinical isolate EC391 by monitoring 
expression of acrAB using the same real-time RT-PCR assay (72). Overexpression of 
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the pump operon was identified in isolate EC391 compared with EC390 
(Figure 38), 
once again implicating AcrAB 
in tigecycline resistance in E. cloacae. 
As with isolate TGC-R, susceptibility to the aminoglycosides allowed for 
selection of AacrB mutants of EC391 (Table 13). However, in the case of EC391, a 
suicide plasmid-based approach was used to 
inactivate acrB due to the inefficiency of 
the pKOBEG-based method (Results section 3.2.5.2; Figure 34). The suicide plasmid 
pRSACRB (Figure 17) contained a kanamycin resistance cassette (which allowed for 
the selection of mutants using this agent) and the conditional origin of replication, 
R6Ky (Results section 3.3.4). Interruption of acrB in EC391 with pRSACRB restored 
susceptibility to tigecycline and confirmed the role of AcrAB in resistance. This result 
is consistent with that of TGC-R as well as previous studies, which report that 
tigecycline is a substrate of this efflux system (127; 200). To my knowledge, this is the 
first report of an E. cloacae gene being interrupted using this method. 
The mechanism of AcrAB up-regulation in isolate EC391 was not 
investigated due to time constraints. 
In summary, the in vivo emergence of tigecycline resistance in two isolates of 
E. cloacae was investigated. In both cases, up-regulation of the RND transporter 
AcrAB was responsible for the resistance. RamA was implicated in the up-regulation 
of AcrAB in one case though was not investigated in the other. In contrast to the A. 
baumannii cases, neither patient received tigecycline before the resistant isolates were 
recovered (Results section 3.2.1). Thus, factors other than tigecycline pressure can 
select for resistance to this agent in E. cloacae. The emergence of tigecycline 
resistance described in case 3 was associated with ciprofloxacin therapy. This is the 
first report of emergence of resistance to tigecycline associated with ciprofloxacin 
therapy, rather than tigecycline therapy. Ciprofloxacin is known to be a substrate of 
183 
AcrAB in E. cloacae (200) and it is possible that exposure to this agent selected for 
AcrAB up-regulation, which resulted in cross-resistance to tigecycline. The potential 
to select cross-resistance to relatively new antimicrobials such as tigecycline through 
the use of established front-line therapies is of concern in the clinic. Ciprofloxacin 
therapy may also have contributed to the emergence of resistance described in case 4 
though the situation is less clear given that the patient received other drugs and that 
the organism was isolated only once, in contrast to case 3. In addition, the 
ciprofloxacin MIC for the tigecycline-resistant isolate, EC391 was not elevated 
compared with EC390 (Table 13) despite the overexpression of acrAB observed in the 
former and in contrast to the case 3 isolates. The reasons for this remain unclear. It 
could be that mutations in acrB, which altered the substrate specificity of the pump, 
were responsible though this would require experimental determination. Importantly, 
it is assumed that EC390 is the parent of EC391 although the possibility that the 
patient was concurrently infected with two variants of the same PFGE-defined strain 
cannot be excluded. 
4.3. S. marcescens 
Clinical isolate SM346 was referred to ARMRL in 2009 and was the only tigecycline- 
resistant clinical isolate of this species available for study. Characterisation of this 
isolate confirmed its identification and tigecycline-resistant phenotype (Results 
section 3.2; Table 15). 
The mechanism(s) of tigecycline resistance in S. marcescens have not been 
described although, since up-regulation of RND transporters had been implicated in 
such resistance in other Enterobacteriaceae (127; 128; 224), this mechanism was 
investigated. 
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Real-time RT-PCR assays were designed to target the RND component gene 
of the three characterised RND systems of 
S. marcescens, namely SdeAB, SdeCDE 
and SdeXY (22; 42; 135). Expression of these genes was monitored in the tigecycline- 
susceptible type strain, S. marcescens NCTC 10211 and 
its final laboratory-selected, 
tigecycline-resistant derivative, 10211-10 (Materials and Methods section 2.21). 
Mutant 10211-10 overexpressed all of the three RND efflux systems studied 
compared with NCTC 10211, but the increase in expression of sdeXY was 
reproducibly higher than the modest increases 
for sdeAB and sdeCDE (Figures 50- 
52). Expression of sdeXY was also monitored in clinical isolate SM346, the 
intermediate mutant, 10211-6 and the tetracycline-selected, tigecycline-resistant 
derivative of NCTC 10211,1021 1-TC7. These investigations identified an association 
between increasing tigecycline MIC and elevated expression of sdeXY (Results 
section 3.3.3; Figure 52), suggesting that tigecycline is a substrate of the SdeXY 
transporter, and pointing to a role for this efflux system in tigecycline resistance. 
It was not possible to use clinical isolate SM346 in sdeY knockout studies due 
to its resistance to the aminoglycosides used to select for mutants (Table 15). 
Therefore, to confirm the role of SdeXY in tigecycline resistance, the sdeY gene was 
targeted for inactivation in the laboratory mutant, 10211-10 (Figure 53). Interruption 
of sdeY in 10211-10 by suicide plasmid pSMY2 restored susceptibility to tigecycline, 
confirming the role of SdeXY in tigecycline resistance in this mutant (Results section 
3.3.3; Table 16; Figure 57). 
The outer membrane channel(s) are poorly defined in S. marcescens, though 
the To1C homologue HasF is implicated as one exit portal in energy-dependent efflux 
(136). On this basis, the potential of HasF to act as the outer membrane channel in a 
functioning tripartite complex with SdeX and SdeY was investigated by insertional 
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inactivation of hasF in the laboratory mutant 10211-10 using the suicide plasmid 
pHASF and the same strategy employed to 
inactivate sdeY (Figure 54). Interruption of 
either sdeY or hasF reduced the MICs of tigecycline, ciprofloxacin, cefpirome, and 
tetracycline markedly, to below the values for the `wild-type' parent (Tables 15 and 
16). These data strongly suggest that up-regulated SdeXY-HasF efflux was 
responsible for tigecycline resistance in S. marcescens, and that 
intrinsic efflux pump 
activity is responsible for the lower susceptibility of the species to ciprofloxacin 
(modal MIC 0.125 mg/L compared with 0.016 mg/L for E. coli; EUCAST). 
4.4. Tigecycline: six years in the clinic 
Since its introduction into clinical use in 2005 there have been a number of 
concerning reports on the emergence of tigecycline resistance and non-susceptibility 
during therapy in Gram-negative (55; 199; 210) and, more rarely, Gram-positive 
species (113; 275). Even before these there were the reports of emerging resistance 
observed during phase III trials (section 4). 
Besides those described in this thesis, there have been two reports of resistance 
emerging during tigecycline therapy in A. baumannii (199; 210). The first details two 
cases where patients developed bacteraemia while receiving tigecycline: (i) as empiric 
monotherapy after developing a fever following a lumbar laminectomy and (ii) for a 
wound infection and where tigecycline-resistant isolates of A. baumannii were 
recovered from blood cultures in both instances (MICs, 4 and 16 mg/L, respectively) 
(199). The authors observed potentiation of tigecycline activity in the presence of the 
EPI, PA(N, suggesting efflux as a mechanism of resistance (199). This report 
highlights the potential of tigecycline to select for resistant organisms in the 
bloodstream due to its relatively low C. Of note, both tigecycline-resistant isolates 
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were susceptible to imipenem. This is in contrast with the cases of emerging 
resistance in A. baumannii described 
in this thesis, where resistance emerged in a 
lineage resistant to carbapenems owing to production of an OXA carbapenemase 
(Table 11), and where both patients received tigecycline for an approved indication 
(Results section 3.1.1). The second literature report of emerging resistance in A. 
baumannii described a patient with HAP (not an approved indication) who was 
treated with tigecycline (210). A. baumannii was recovered from sputum and 
tigecycline MICs for the pre- and post-therapy isolates were 2 and 24 mg/L, 
respectively. Tigecycline MIC rises (0.75 to 2 mg/L) during tigecycline therapy were 
also noted in the case of a patient who received the drug for HAP and empyema 
caused by a KPC carbapenemase-producing strain of K. pneumoniae (55). In the UK, 
the non-susceptibility rate for tigecycline in Klebsiella spp. is high (17.7%) relative to 
other Enterobacteriaceae (111) and although the reason(s) for the MIC increase was 
not investigated, other reports have implicated up-regulation of AcrAB in Klebsiella 
as well as in the genera studied here (220; 224). 
Tigecycline is licensed for the treatment of cSSSI, cIAI and of CAP in the US. 
However, clinicians are tempted to use tigecycline for other, often severe infections 
because of its broad-spectrum activity and also because of the lack of therapeutic 
options, especially in the case of infections caused by MDR Gram-negative 
pathogens. Indeed, data from a recent South American study indicate that the majority 
of tigecycline prescriptions are for off-label indications (68.5%) in that region and that 
the most frequent off-label use was for VAP (53). 
There are mixed reports on the clinical efficacy of tigecycline in the off-label 
treatment of severe infection, including HAP and VAP. In a retrospective study of 
tigecycline monotherapy for infections caused by MDR A. baumannii and K. 
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pneumoniae in Greece, overall successful clinical outcome was observed 
in 81.8% of 
cases and 90.5% in the HAPNAP group 
(204). Another retrospective study of 
patients treated with tigecycline 
for A. baumannii infection demonstrated positive 
clinical outcome in 68% of cases, though the authors noted that three patients 
developed bacteraemia while receiving tigecycline which, in one case, was caused by 
K. pneumoniae (97). In 2010, the US FDA issued a Drug Safety Communication 
warning that there was an increased mortality risk associated with the use of 
tigecycline in the treatment of various serious infections compared to that of other 
drugs (262), further fuelling the debate on the efficacy of tigecycline in the treatment 
of such infections. 
It is clear that there are legitimate concerns over the use of tigecycline for the 
treatment of serious infections caused by MDR pathogens and in some respects the 
drug has already proved to be a disappointment in this regard. There is hope that new 
tetracycline analogues, such as the fluorocycline, TP-434 (Tetraphase), which is 
currently entering phase II clinical trials, will be prove to be more efficacious. In a 
recent study, this compound displayed greater in vitro activity versus MDR Gram- 
negative organisms than tigecycline (90) and there is evidence that it has oral 
bioavailability in humans (141). However, there are currently no data on whether or 
not TP-434 is vulnerable to efflux by RND transporters. 
4.5. Further work 
Time constraints meant that detailed investigations of a number of interesting aspects 
were not possible. Although the molecular mechanism of tigecycline resistance was 
elucidated in each isolate studied, some important questions remain. Lines of enquiry 
that should be pursued if further funding were to become available are detailed below. 
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Although evidence exists that the two-component regulatory system, AdeRS 
controls expression of adeABC in A. baumannii (164), the data presented here 
(Results section 3.1.5) and elsewhere indicate that other regulatory mechanisms 
remain to be found (197). Evidence from studies of E. coli and other Gram-negative 
species suggests that the regulation of RND efflux systems is complex, often 
involving multiple regulatory elements (98). In addition to investigating the 
possibility of involvement of other regulatory systems, the precise mechanism of 
transcriptional control by AdeRS remains to be fully elucidated. For instance, it is 
unclear which specific ligand(s) activate AdeS and how amino acid substitutions that 
have been associated with constitutive adeABC expression actually affect the 
biological activity of the sensor kinase. 
Comparative genomic analysis demonstrated considerable genetic differences 
between clinical isolates AB210 and AB211 (section 4.1.1). It seems likely that these 
differences will have phenotypic effects that extend beyond the antibiogram and that 
raise questions concerning the relative fitness of these isolates. It would be interesting 
to assess the in vivo performance of susceptible and resistant isolates using an animal 
model of A. baumannii infection such as that described by Peleg et al. (198). Analysis 
of the whole-genome sequence of AB211 revealed that the mutS gene was interrupted, 
suggesting that this isolate may display a hypermutator phenotype (section 4.1.1). 
This hypothesis should be experimentally investigated to assess the possible 
implications for the emergence of antibiotic resistance. 
This study provided evidence that demonstrated, for the first time that, acrAB 
is part of the RamA regulon in E. cloacae (Results section 3.2.4). However, the 
mechanism(s) of RamA up-regulation remains to be elucidated and this should be 
investigated to gain a fuller understanding of the molecular events that can lead to 
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acrAB overexpression and hence tigecycline resistance. Such increased knowledge of 
global regulatory elements may also shed light on the reasons for the reduction in the 
MICs of some ß-lactams observed for the laboratory-selected mutant, TGC-S7 (Table 
13). This phenomenon was also observed for the A. baumannii laboratory-selected 
mutant, AB210-6 (Table 11) and is evidence for changes in global regulatory 
networks in the species. 
Efflux as a mechanism of resistance to tigecycline in S. marcescens was 
investigated here and it was shown for the first time that the SdeXY-HasF complex 
was responsible for such resistance in a laboratory-selected mutant (Results section 
3.3). Although real-time RT-PCR data indicated that this mechanism may also be 
responsible for resistance in a clinical isolate, this remains to be confirmed with 
knockout mutagenesis studies using tigecycline-resistant clinical isolates. In addition, 
the mechanism(s) of sdeXY overexpression remain obscure. 
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4.6. Conclusions 
Tigecycline retains good in vitro activity against many problematic nosocomial Gram- 
negative pathogens. Despite concerns over its efficacy in the treatment of severe 
infections it is an important addition to the antimicrobial arsenal given the small 
number of new agents with any Gram-negative coverage entering clinical use. 
However, data presented here, as well as literature evidence, indicate that it is 
vulnerable to efflux by RND-type transporters, and that this mechanism often 
underlies mutational resistance in Enterobacteriaceae (127; 128; 220) and A. baumannii 
(197; 223), as well as the intrinsic resistance of P. aeruginosa and P. mirabilis 
(61; 267). In contrast to the acquired tetracycline resistance mechanisms described, 
there is no literature evidence of horizontal transfer of tigecycline resistance. The 
results of this study support the hypothesis that tigecycline resistance in clinical 
isolates of Gram-negative bacteria arises as a result of the up-regulated activity of 
intrinsic efflux systems. Thus, there exists the potential for any strain to develop 
resistance that possess a functioning RND efflux system of which tigecycline is a 
substrate. Despite this, tigecycline-resistant isolates of some species, notably E. coil, 
are encountered only rarely in the clinic. Further studies are necessary to gain a fuller 
understanding of the factors responsible for the emergence of efflux-mediated 
tigecycline resistance. 
RND-type transporters are ubiquitous in Gram-negative species and their up- 
regulation can result in resistance to multiple antimicrobial agents, as demonstrated 
here. Since agents other than tigecycline can select for up-regulated efflux, limiting 
the use of tigecycline alone may not prevent further cases of resistance emerging. 
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